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The immune system is responsible for mediating protection of its host from foreign pathogens, and 
its ability to do so efficiently is vital to the maintenance of health. Recognition of pathogens relies 
on a keen ability to discriminate self from non- self in order to minimize detrimental 
immunopathology against host- tissues. However, under certain circumstances, self- reactive T 
cells become activated and drive autoimmune targeting of host tissues, like that exhibited in Type 
1 Diabetes (T1D). T1D occurs when insulin secreting β cells residing in the pancreas are 
mistakenly recognized as foreign and targeted for destruction. While various immune cells work 
cooperatively to mediate β cell death, autoreactive CD4+ T cells are considered the primary 
contributors to disease pathology. Recent interest in the field of immunometabolism has 
demonstrated the importance of cellular metabolic programs in the activation and differentiation 
of immune cells, especially T cells. Specifically upon antigen encounter, T cells become activated 
and rely on the less efficient aerobic glycolysis to support rapid growth, clonal expansion, and 
effector functions. Based on the importance of glycolysis in promoting T cell activation and 
effector function, use of glycolytic inhibitors to suppress autoreactive T cell responses in Systemic 
Lupus Erythematosus (SLE), Multiple Sclerosis (MS), and Rheumatoid Arthritis (RA) have 
proven beneficial in alleviating autoimmunity. However, the ability to modulate T cell metabolism 
in the context of T1D has remained unexplored. Here, we assessed the ability of the small molecule 
PFK15, a competitive inhibitor of a rate- limiting enzyme in the glycolysis pathway PFKFB3, to 
v 
suppress autoimmunity during T1D. Our results demonstrated that inhibiting glycolysis reduced 
diabetogenic T cell responses in vitro, and significantly delayed the onset of T1D in adoptive 
transfer models. The protective benefits associated with PFK15 treatment were due to induction 
of terminal CD4+ T cell exhaustion. This phenotype was due to a direct effect on autoreactive T 
cells, as antigen presenting cell (APC) function was unaltered by PFK15. Collectively, our data 
support modulating cellular metabolism as a novel approach to controlling aberrant T cell 
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1.0 INTRODUCTION 
A portion of this section was adapted from the author’s version of a review paper. The definitive 
version of this work was published in Immunometabolism. 
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1.1 IMMUNITY DEPENDS ON AN ABILITY TO DESCRIMINATE BETWEEN SELF 
AND NON- SELF 
The immune system is tasked with the vital role of protecting the host from foreign invaders, and 
acts as a critical barrier from infectious agents and pathogens [1]. This relies on an ability to 
distinguish self from non- self, and acts as a safeguard against the onset of autoimmunity (i.e. 
targeting of self- tissues) [1, 2]. Broadly speaking, the immune system has two arms: the innate 
and the adaptive immune systems. While the innate immune system relies on non- specific 
recognition of pathogen- associated molecular patterns (PAMP’s) by macrophages, dendritic cells 
(DCs), and neutrophils;  the adaptive immune system is comprised of initiating T and B cell 
responses to specific antigens and establishing memory phenotypes that mediate lifelong 
protection [2]. Ultimately, the interplay and cooperation between these two systems is instrumental 
to the development of an effective immune response that clears the invading pathogen.   
Importantly, while a hallmark of immunity is recognition of foreign antigens, this specialized 
sensing relies on a keen ability for host immune cells to differentiate between self and non- self-
tissues. Innate immune cells rely on pattern recognition receptors (PRRs) that sense the presence 
of microorganisms to provide initial discrimination between self and non-self [1]. PRRs of 
macrophages and DCs allow for the simple recognition of evolutionarily conserved structures 
common to many pathogens that are no present on the body’s own cells (i.e. peptidoglycans, 
lipopolysaccharides, mannose- rich oligosaccharides, etc.), leading to non- specific recognition 
[2]. Pattern recognition and detection of foreign antigens triggers an initial adaptive immune 
response characterized by engulfment of the pathogen by macrophages and DCs, and the 
processing and presentation of peptides on the cell surface via MHC-I and MHC-II molecules that 
are recognized by naïve T cells to activate adaptive immunity [1, 2].  
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Presentation of antigens by APCs to naïve T cells in secondary lymphoid organs (i.e., draining 
lymph nodes) leads to the commencement of an adaptive immune response that brings the 
specificity lacking from the innate arm of the immune system. Activation of CD4+ T cells requires 
three distinct signals, including 1) recognition and binding of the T cell receptor (TCR) with 
peptide: MHC complexes, 2) co- stimulation provided by triggering of CD28 on T cells by CD80 
and CD86 on APCs, and 3) cytokine micromilieu and reactive oxygen species (ROS) that directs 
the polarization and differentiation of unique T helper subsets (Figure 1) [1-5]. Activation of T 
cells results in the clonal expansion of antigen- specific effector T cells that mediate adaptive 
immunity via secretion of cytokines that promote inflammation via immune cell recruitment, and 
maturation of other immune cells, like CD8+ T cells, that can mediate direct lysis of infected host 
cells [2]. Specificity of the T cell response relies on a principle known as clonal selection, which 
occurs during T cell development in the thymus, leading to a diverse repertoire of T cells bearing 
diverse T cell receptors and specificities [1]. This selection process is vital for maintaining 













Figure 1. Three signals are required for the activation and differentiation of CD4+ T cell subsets. 
Naïve CD4+ T cells require three signals for proper T cell activation and function. Signal 1 consists of binding of the 
TCR to peptides bound to MHC molecules on APCs and subsequent downstream signaling. Signal 2, or costimulation, 
is provided by the binding of costimulatory molecules CD80/CD86 to CD28 co- receptor on T cells, which amplifies 
intracellular processes associated with T cell activation. Cytokines and the presence of ROS in the local micromilieu 
to skew the differentiation of various T helper cell subsets, including Th1, Th2, Th17, and Treg populations. These 3 
signals are required to produce a productive immune response against invading pathogens and to maintain tolerance 




1.1.1 Development of the T cell repertoire occurs in the thymus  
T cell precursors originating in the bone marrow migrate to the thymus where development into 
mature T cell populations occurs. Here, immature T cell progenitors undergo a rigorous selection 
process that ultimately shapes the mature repertoire of T cells [1]. Upon the formation of antigen 
receptors, T cells are required to undergo testing to select for useful antigen receptors that are able 
to recognize pathogens and do not react against an individual’s host cells and occurs in 2 stages: 
positive and negative selection [1, 2]. These two processes aim to eliminate T cell clones 
expressing self- reactive as well as nonfunctional TCRs from the host, and are vital for the proper 
function of the adaptive immune response.  
During positive selection, developing thymocytes whose receptors are able to interact weakly 
with self- antigen receive survival signals. The ability of thymocytes to interact with self-peptide- 
MHC complexes is particularly crucial, as it ensures that an individual’s T cells can respond to 
antigens bound to their own MHC molecules to initiate immune responses in the periphery [1, 2]. 
Successful interaction of developing thymocytes with peptide- MHC complexes triggers a survival 
signal, while cells unable to bind self- peptide complexes leads to the induction of cell death by 
neglect [1, 2]. However, why selection on self- peptide:MHC complexes benefits the production 
of a competent T cell repertoire able to respond to unknown foreign antigens the host will 
encounter in the future has not been clearly resolved. One study by Mandl et al. demonstrated that 
positive selection uses the strength of self- peptide:MHC binding to optimize recognition to foreign 
antigens, where the strength of self- reactivity correlates directly with the strength of TCR binding 
to foreign peptides [6]. Specifically, it was determined that T cells with receptors that interacted 
strongly to self-antigens predominate in responses to diverse pathogens, thus selecting for high 
affinity T cell clones that are effective at clearing potential threats. Ultimately, positive selection 
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is crucial in ensuring the preferential maturation of T cells with the greatest capacity to respond to 
foreign antigen [6]. Further, prior to positive selection, thymocytes bear both the CD4 and CD8 
co- receptors. Positive selection via MHC-I or MHC-II dictates expression of the corresponding 
CD8 or CD4 co- receptor respectively, that will be retained by thymocytes upon maturation, and 
therefore is important for lineage commitment of developing T cells [1].  
As previously mentioned, positive selection ensures that TCRs expressed by thymocytes are 
capable of interacting with host MHC complexes, however the risk of selecting for self- reactive 
thymocytes remains. To mitigate this risk, developing T cells undergo a process termed  negative 
selection, whereby lymphocytes that bind too strongly to self- reactive TCRs are eliminated from 
the repertoire [1]. This occurs when self- antigens are displayed by MHC molecules on the surface 
of thymic epithelial cells or resident DCs and macrophages. The self- antigens presented within 
the thymus encompass a wide range of both tissue specific (i.e. insulin) and ubiquitously expressed 
antigens, whose expression is mediated by the autoimmune regulator (AIRE) [1, 2]. Mutations in 
AIRE in mice and humans can lead to the development of autoimmune disorders [1]. 
Consequently, the collection of self-antigens expressed in the thymus have a direct impact on 
ability for the host to delete autoreactive T cell clones, thereby influencing the occurrence of 
autoimmunity. The deletion of self- reactive T cell clones during this process is vital to the 
establishment of central tolerance, and prevents their potentially pathogenic activation later should 
they encounter self- peptides after maturation. 
1.1.2 Maintenance of self- tolerance relies on specific checkpoints in the periphery 
Although developing T cells undergo robust testing and selection in the thymus to 1) produce a 
diverse T cell repertoire capable of mounting immune responses against a plethora of pathogens 
7 
and foreign invaders and 2) protect against the onset of autoimmune diseases, this process is not 
perfect. In fact, some T cells do escape these processes in healthy individuals, therefore allowing 
autoreactive T cell clones capable of mediating autoimmunity to migrate into the periphery [7]. 
Moreover, not all self- proteins, especially those that are tissue- restricted, are expressed in the 
thymus. Notably, many T cells with some underlying level of autoreactivity are able to mount 
immune responses to foreign antigens, therefore can play beneficial roles as the deletion of all 
weakly self- reactive T cells would leave a hole in the diversity of T cells an individual has to 
mediate life- long protection from disease [1, 7]. Luckily, there are a number of mechanisms in 
the periphery that exist to prevent the activation of autoreactive T cells as a means to achieve a 
state of self- tolerance. These checkpoints act synergistically to mediate protection against 
autoimmunity without inhibiting the ability of the immune system to remain effective at clearing 
invading pathogens. However, a failure in one or more of these tolerogenic mechanisms can lead 
to the onset of autoimmunity, like that of which occurs when pancreatic islet β cells are attacked 
during Type 1 Diabetes (T1D). These checkpoints, and how they fail in T1D will be discussed in 
more detail in the following sections.  
1.1.2.1 Checkpoint 1: Central Tolerance 
As discussed in great detail above, central tolerance mechanisms within the thymus are the first 
checkpoint of self- tolerance. It is here that immature thymocytes undergo rigorous testing via 
positive and negative selection mechanisms as a means to delete strongly self- reactive T cells [1, 
2, 7]. However, as not all potentially autoreactive T cells are removed from the T cell repertoire 
during their development, other mechanisms in the periphery must be in place as safeguards 
against the activation and expansion of autoreactive lymphocytes that escape negative selection 
processes.  
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1.1.2.2 Checkpoint 2: Peripheral Tolerance 
A number of mechanisms exist in the periphery to keep autoreactive T cells in check, which 
include 1) suppression by regulatory T cells (Tregs), 2) induction of anergy, 3) activation- induced 
cell death, and 4) immune suppression by immune inhibitory receptors (IRs). These 4 processes 
will be described in more detail herein.  
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1.1.2.2.1 Suppression by Regulatory T cells (Tregs) 
 
Regulatory T cells, or Tregs (defined simply as CD4+ CD25+ FoxP3+ T cells), are a subpopulation 
of T cells that can modulate the immune system by maintaining tolerance to self- antigens, and 
preventing autoimmune diseases. Tregs have immunosuppressive capabilities that can suppress or 
downregulate the proliferation and effector functions of effector T cells via a number of 
mechanisms [1, 2, 8, 9]. There are two types of Tregs: natural Tregs (nTreg) and induced (iTregs). 
nTregs develop in the thymus. Moderately autoreactive nTregs can escape deletion in the thymus 
similarly to autoreactive effector T cells, and when activated by self- antigen in the periphery, can 
inhibit the activation of other self- reactive T cells and prevent their subsequent differentiation and 
effector functions [1, 2, 8, 9]. iTregs on the other hand develop in peripheral tissues in the presence 
of TGF-β [1]. Although Tregs exist to mediate suppression of pathogenic T cells responsive to 
self- tissues, evidence in the literature suggests these cells are defective in a number of autoimmune 
diseases [8-12]. This is true in Type 1 Diabetes (T1D), where insulin- secreting β cells in the 
pancreas are targeted and destroyed by autoreactive T cells. Although Treg numbers remain 
unchanged in T1D, suppressive function is often dysfunctional. Further, in some instances, Tregs 
can adopt a proinflammatory phenotype characterized by the secretion of IFNγ, further 
potentiating autoimmune mediated damage [8-12].  
The potent suppressive nature of Treg cells have led to the development of Treg based therapies 
for the treatment of autoimmune diseases. Several approaches aiming to increase Treg numbers or 
support suppressive function have shown promise, however these approaches often times 
ultimately fail or lead to non-specific global immunosuppression and off- target effects [13, 14]. 
Regardless, Tregs are a promising therapeutic target for suppressing autoimmunity, especially in 
regard to restoring Treg function under circumstances where they become defective. Ultimately, 
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finding a balance or use of combinatorial therapies to induce antigen- specific Tregs are vital to 
the success of Treg mediated therapies for the treatment of autoimmune disorders, albeit without 




Anergy is defined as a state of hyporesponsiveness to antigen, ultimately leading to immunological 
ignorance. This phenotype occurs when autoreactive T cells are stimulated with antigen along with 
sub- optimal CD28 co- stimulation (signal 2), or high co-inhibition [1]. This results in low IL-2 
production and cell cycle arrest [1]. Ultimately, potent and lasting immunoregulatory signaling via 
lack of proper co-stimulation or engagement of IRs with their associated ligands (PD-1: PD-L1, 
LAG-3: MHC-II, CTLA-4: CD80/CD86) can lead to a hyporesponsive state resulting in long- 
lived T cells with reduced effector functions and tolerance to self-antigens [17].  Notably, anergic 
T cells maintain expression of the high affinity IL-2 receptor CD25, and therefore can be rescued 
via IL-2 stimulation, indicating that while anergy is a tolerogenic phenotype, it is not permanent 
and can lead to re- activation of potentially pathogenic T cells [18]. Regardless, induction of a 
hyporesponsive, anergic T cell phenotype in NOD mice and human T1D patients is associated 




1.1.2.2.3 Activation- Induced Cell Death (AICD) 
 
Deletion of autoreactive T cells not only occurs during negative selection in the thymus, but also 
can occur in the periphery. In peripheral T cells, those responding to self- antigens can be 
eliminated through activation- induced cell death (AICD), which is a form of apoptosis induced 
by repeated TCR stimulation [1, 21]. AICD results from the interaction between Fas and Fas ligand 
(FasL) on activated T cells. Ultimately, the ligation of Fas with FasL induces a signaling cascade 
that initiates apoptosis, thereby eliminating self- reactive T cells [21, 22]. However, defects in the 
AICD pathway exist and contribute to autoimmunity, especially in T1D. Interestingly, activated T 
cells from the non- obese diabetic (NOD) mouse model of T1D are more resistant to AICD than T 
cells from non- autoimmune prone control strains. Analysis of T cells from T1D patients and at- 
risk populations are highly defective in their surface expression of Fas, and are more resistant to 
cell death [23]. Cumulatively, these data indicate that dysregulated apoptosis pathways may be 
involved in the pathogenesis of T1D, and highlight the importance of peripheral tolerance 
mechanisms in maintaining quiescence of autoreactive T cells.  
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1.1.2.2.4 Signaling via Immune Inhibitory Receptors act as a “brake” for T cell activation 
Immune inhibitory receptors (IRs), also termed checkpoint molecules, are important regulators of 
immunity, especially in the context of mediating protection against the onset of autoimmunity [24-
28]. While the interaction of co- stimulatory molecules (i.e. CD28:CD80/CD86) are important for 
directing T cell activation, differentiation, and expansion; the opposite is true for co- inhibitory 
receptors, which negatively regulate TCR driven signals and T cell activation [21]. A number of 
IRs have been identified and include cytotoxic T-lymphocyte- associated protein 4 (CTLA-4), 
programmed cell death protein- 1  (PD-1) , lymphocyte Activation Gene-3  (LAG-3), and T cell 
immunoglobulin and mucin- domain containing- 3 (TIM-3), and their expression is most often 
associated with a type of hyporesponsive phenotype termed T cell exhaustion during cancer and 
chronic infection [24-26]. However, the role of IRs goes beyond mediating T cell exhaustion, as 
these signaling molecules play a crucial role in regulation of T cell activation as well as Treg 
suppressive function. During activation, TCR signaling upregulates IR expression, where 
signaling with their associated ligands controls and contracts expanded T cell populations as a 
means to balance the immune response (Figure 2) [24-29]. This regulation is crucial to limiting 
autoimmunity and detrimental immunopathology. Evidence of this is in T1D specifically has been 
supported by studies where animals deficient in CTLA-4, PD-1 or LAG-3, or mice treated with 
antibody blockade demonstrate accelerated disease kinetics, further underscoring the importance 
of IRs in maintaining quiescence of autoreactive T cells [30-32].  
Although the expression of IRs and specifically T cell exhaustion is typically associated with 
detrimental outcomes in cancer and chronic infection, the opposite is true in autoimmunity. In one 
study by McKinney et al., it was demonstrated that levels of T cell exhaustion in patients across a 
variety of autoimmune diseases strongly correlated with their clinical outcomes, with a T cell 
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exhaustion signature predicting favorable clinical responses [29]. Therefore, based on these 
correlations, promoting T cell exhaustion could be a beneficial phenotype for inhibiting 
autoimmunity, especially in those individuals with defects in IR expression and signaling. These 






















Figure 2. Mechanisms of Immune Inhibitory Receptor (IR) Signaling 
Signaling of IRs such as CTLA-4, LAG-3, and PD-1, with their associated ligands are important in mediating tolerance to self- antigens 
in the periphery, and also play a role in tempering T cell responses to foreign antigens as a means to protect against aberrant 
immunopathology. During T cell activation, CTLA-4, LAG-3, and PD-1 expressed by T cells can interact and bind to their ligands 
CD80/CD86, MHC-II, and PD-L1/PD-L2, respectively. If ligand binding occurs, downstream signaling leads to a stop signal that 
inhibits T cell activation, proliferation, and cytokine production (left panel). In contrast, absence of IR:ligand binding results in 
fulminant T cell activation and associated effector functions (right panel). Diagram created using BioRender.com. 
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1.2 AUTOIMMUNE RESPONSES RESEMBLE NORMAL IMMUNE RESPONSES TO 
PATHOGENS 
Despite the checkpoints in place to prevent the activation of autoreactive T cells, a breakdown in 
one or more self- tolerance safeguards leads to the activation of autoreactive T cells that mediate 
the destruction of host tissues and the onset of autoimmune diseases, like Type 1 Diabetes (T1D) 
[33-35]. Notably, the activation of autoreactive T cells is no different than T cell activation to 
foreign pathogens. Unfortunately, the inability to effectively delete autoreactive T cells from the 
repertoire and control their activation in the periphery leads to autoimmunity, where self- reactive 
T cells mistakenly recognize host tissues as foreign. These concepts will be explored in more detail 
in the following sub- sections, with a specific focus on the pathogenesis of T1D, and the resulting 
attack of insulin- secreting β cells that occurs in affected patients.  
1.2.1 Immunopathology of Type 1 Diabetes 
Invasion of the pancreatic islets by immune cells (insulitis) is a hallmark of T1D pathogenesis that 
leads to progressive destruction of the  cell and precedes disease onset. This along with a break 
in tolerance to  cell antigens lead to the activation and clonal expansion of autoreactive CD4+ T 
cells that drive T1D. While the etiology of T1D is not completely understood, we do know that in 
those with a genetic predisposition to autoimmunity, a triggering event (i.e. chemical exposure, 
dysglycemia, endoplasmic reticulum (ER) stress, reactive oxygen species (ROS), or viral 
infection) affecting  cells in the pancreas leads to release of  cell antigens that are phagocytosed 
by antigen presenting cells (APCs), like macrophages and dendritic cells (DCs), and leads to their 
subsequent activation [36-41]. Activated APCs traffic to the pancreatic draining lymph node where 
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they present  cell self-antigens to autoreactive CD4+ T cells that become activated and travel back 
to the pancreas as effector CD4+ T cells. Effector CD4+ T cells coordinate the resulting 
autoimmune attack of the  cell via secretion of proinflammatory cytokines like IFN and tumor 
necrosis factor- (TNF) that can directly cause  cell death, provide help to activate CD8+ T cells 
and B cells, and provide an inflammatory milieu that favors continual APC activation [36, 39]. 
Ultimately, this perpetuates a cycle of autoimmune attack that when left unhindered, leads to the 
organ- specific autoimmunity and  cell destruction that culminates in hyperglycemia and T1D 
onset (Figure 3) [36, 39]. Orchestration of autoimmune responses by APCs, T cells, and B cells 
together leads to  cell death and hyperglycemia. The diversity of immune cells involved in 
autoimmune attack of the  cell provide a variety of potential therapeutic targets to control aberrant 
responses in T1D. Further, finding ways to alter the differentiation of immune cell subsets to more 
anti-inflammatory phenotypes or impeding activation of autoreactive T cells will allow for the 







Figure 3. Immune- mediated  cell killing leads to onset of T1D. 
In genetically predisposed individuals, an initial threat targeting the  cell triggers the release of  cell antigens in the 
pancreas. These autoantigens are phagocytosed and processed by islet- resident macrophages and DC that become 
activated and traffic to the pancreatic draining lymph node. It is here that naïve autoreactive CD4+ T cells specific for 
islet antigens become educated, leading to their subsequent activation and clonal expansion, supported in large part 
by dramatic changes in cellular metabolism. Once activated, effector CD4+ T cells travel back to the target organ 










































































1.2.2 CD4+ T cells Drive T1D Pathogenesis 
While a number of immune cells are involved in autoimmune destruction of the  cell, autoreactive 
CD4+ T cells are largely responsible for mediating and driving disease pathogenesis [33, 35-37, 
39-47]. This is also true for other autoimmune diseases like SLE, MS, and RA. CD4+ T cells are 
fundamental and required for T1D development, as studies in the non- obese diabetic (NOD) 
mouse have shown that depletion of CD4+ T cells or treatment with non- depleting anti- CD4 
antibodies prevents disease onset [42, 48-50]. Further, genetic predisposition to autoimmunity and 
T1D disease development has been linked to human leukocyte antigen (HLA) class II alleles DR4, 
DQ8, and DQ2, which confer the highest genetic risk of T1D in human patients. This suggests that 
HLA class II restricted CD4+ T cells play a key role in T1D [34, 42, 51]. While CD8+ T cell 
mediated  cell killing is a major mechanism of disease development, CD4+ T cells lead the way 
in orchestrating the attack against islet  cells [34, 40, 42, 43]. While their role includes providing 
help to activate CD8+ T cells, B cells, and antigen presenting cells, activation of CD4+ T cells and 
their subsequent secretion of proinflammatory cytokines, especially IFN,TNF, and interleukin- 
1 (IL-1), can directly induce  cell apoptosis [33, 34, 36, 40, 42, 43]. Without intervention, this 
results in a cycle of  cell killing, resulting in dysregulation of dynamic glucose sensing and 
subsequent insulin secretion [36]. Therefore, understanding the mechanisms governing CD4+ T 
cell effector function, and using this knowledge to find therapeutic targets to inhibit autoreactive 
T cell activation are of the utmost importance, as they are critical for disease prevention and future 
therapies. 
The ability of autoreactive T cell clones to escape deletion during development in the thymus 
leads to autoimmunity [40, 41, 45, 47, 52]. However, a failure in peripheral tolerance mechanisms 
to control these rogue T cells also plays a significant role. Tregs (simply defined as CD4+ CD25+ 
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Forkhead box P3+ (FoxP3; master regulator of Treg development and function)), are members of 
the CD4 compartment and are widely regarded as the primary mediators of peripheral tolerance 
[35, 41, 47]. However, in T1D and other autoimmune disorders, Tregs are known to be functionally 
defective. In T1D specifically, Tregs have an altered phenotype, most notably in terms of their 
stability, survival, and functionality [10, 12, 16, 40-42, 45, 47, 52]. While there appears to be no 
change in levels of circulating Tregs in mice or human patients with T1D, previous studies have 
shown a decline in intra- islet Treg frequencies that correlated with disease development in the 
NOD mouse [10, 12]. Moreover, a number of investigations have shown that FoxP3+ Treg function 
and suppressive capacity is defective in those with T1D, as Tregs from affected individuals were 
less able to control the proliferation of autologous T effectors when compared to healthy controls 
[10, 12, 16, 41] Further, Tregs in autoimmunity suffer from lineage instability, as emerging data 
suggests that functional Tregs can either convert to effector T cells or become Th1- like Treg cells 
associated with reduced or loss of FoxP3 expression and suppressive function, expression of the 
Th1 specific transcription factor T-box protein expressed in T cells (T-bet), and enhanced 
proinflammatory cytokine secretion, especially IFN [11, 53]. Further insight is needed to discern 
the causative reason behind impaired Treg stability and function in T1D, as reinvigorating Treg 
function may promote tolerance in those predisposed to autoimmunity.  
1.3 FUELING IMMUNITY: METABOLIC PROGRAMS DICTATE IMMUNE CELL 
FUNCTION 
1.3.1 Cellular Metabolism Governs CD4+ T cell Function 
Cellular metabolism dictates T cell fate and function. Consequently, cellular metabolism has the 
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ability to influence the final outcome of the innate and adaptive immune responses, further 
impacting health and disease outcome [54]. T cells undergo substantial metabolic reprogramming 
from oxidative phosphorylation (OXPHOS) to aerobic glycolysis during activation upon encounter 
with cognate antigen [54-62]. This section will briefly review the major metabolic pathways 
utilized by T cells during activation and quiescence, however this topic has been reviewed in more 
detail in reports cited here [58-61]. 
As T cells move through the various stages of their life cycle, their metabolic demands vary. 
Naïve CD4+ T cells are metabolically quiescent, as they utilize OXPHOS via the mitochondria to 
support basic cellular processes, maintain homeostasis, and to circulate the periphery surveying 
the body for foreign invaders [58, 59, 62]. In fact, 96% of the adenosine triphosphate (ATP) 
generated by naïve T cells comes from oxidative metabolism, with roughly 4% coming from 
glycolytic metabolism [61]. Upon recognition of foreign antigen, along with the necessary 
costimulatory signals, naïve T cells become activated and undergo metabolic reprogramming to 
support this change in function. During activation, T cells switch to a program of anabolic growth 
and biomass accumulation to generate daughter cells, requiring an increased demand for ATP and 
metabolic resources [54, 58-62]. This developmental program is characterized by an increase in 
rapid growth, proliferation, and acquisition of specialized effector functions [57-60, 62]. Activated 
T cells are more metabolically active, and engage primarily in aerobic glycolysis, marked by the 
conversion of glucose to lactate despite the presence or availability of oxygen [59, 60]. This 
phenomenon, known as the Warburg Effect, was characterized by Dr. Otto Warburg in the 1920’s, 
and is a hallmark of cancer metabolism [63, 64]. Although far less efficient than OXPHOS in terms 
of energy production, aerobic glycolysis allows for proliferating T cells to generate ATP quickly, 
and also allows for the generation of metabolic intermediates important for clonal expansion and 
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effector capabilities [54, 59]. After clearance of the initial threat, most effector T cells die, however 
a small population of long- lived antigen- specific memory T cells remain that mediate protection 
against re-challenge [65]. Memory T cells, much like naïve T cells, are quiescent and rely primarily 
on OXPHOS and fatty acid oxidation (FAO) for their development and long-term survival [58-60] 

























Figure 4. Distinct metabolic profiles dictate T cell fate and function. 
The metabolic needs of CD4+ T cells drastically change over the course of an immune response. Consequently, 
immunometabolism has the ability to dictate whether a pro- or anti- inflammatory response will ensue. While there is 
some layover in the metabolic programs of different T cell subsets, clear distinctions exist. Naïve T cells are quiescent 
and utilize OXPHOS to generate ATP to support antigenic surveillance. Upon encounter with antigen, naïve T cells 
become activated and undergo a metabolic to utilize aerobic glycolysis, which is vital for T cell proliferation and 
acquisition of effector functions. After clearance, a small subset of T cells become memory T cells and revert back to 
a program of FAO and OXPHOS, which promotes longevity and survival. Like memory T cells, Tregs too are thought 











































Tregs too have their own metabolic preferences that dictate their function and stability, however 
there have been conflicting reports in both mouse and human studies, as it appears Tregs utilize a 
number of metabolic programs depending on their environment and specific needs [11, 57-61, 66-
71]. Overall, Tregs are thought to preferentially rely on oxidative metabolism [57, 67] (Figure 4). 
This idea was supported in a paper by Angelin et al., where it was determined that FoxP3 induced 
OXPHOS and shut down glycolysis via binding to the myelocytomatosis oncogene (Myc) 
(transcription factor that drives glycolytic metabolism and metabolic reprogramming) gene 
promoter and suppressing Myc gene expression [72]. More specifically, Tregs rely on FAO, which 
feeds into the mitochondria to supply OXPHOS, and readily take up externally derived fatty acids 
to support high rates of FAO. Interestingly, treatment with etomoxir, an inhibitor of the enzyme 
Carnitine palmitoyltransferase I (CPT1), which converts acyl- CoAs to acylcarnitines allowing 
for entry of fatty acids into the mitochondria and FAO, abrogates Treg development and 
suppressive function suggesting that Tregs depend on the FAO pathway to differentiate and 
perform their effector functions [12, 57, 58, 69, 70]. On the other hand, Tanimine et al. and others 
have indicated that glycolysis controls the induction of functional FoxP3 during early activation 
and proliferation in Tregs isolated from human subjects [73]. Another study of human Tregs found 
that the glycolytic enzyme enolase-1 was required for Treg suppressive capacity via control of 
FoxP3 splice variants [74]. While the exact metabolic preferences of Tregs remain elusive, it’s 
clear that these cells display a mixed metabolism depending on nutrient availability and 
environmental cues. Further studies are desperately needed to fully understand the metabolic 
requirements of Tregs in order to have a better understanding of mechanisms driving Treg 
differentiation, stability, and functional capacity. All in all, while each phase of the T cell life cycle 
has distinct metabolic requirements, each program allows for T cells to function and respond to 
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various situations effectively during their life span. Moreover, as cellular metabolism is 
responsible for shaping immune responses, it’s clear that changes in immunometabolism drive 












































Figure 5. Changes in Immunometabolism drive β cell death in T1D. 
T1D pathogenesis is largely mediated by the activation of autoreactive CD4+ T cells that is fueled by metabolic 
reprogramming. Activation of CD4+ T cells is a metabolically demanding process accompanied by a metabolic switch 
to aerobic glycolysis, that although less efficient, is required for T cell clonal expansion and effector capabilities. Like 
CD4+ T cells, other immune cells undergo metabolic reprogramming to support immune function. CD4+ T cells are 
critical mediators of orchestrating  cell destruction, where proinflammatory cytokine production can lead to direct  
cell death and support the downstream activation of other immune cells like CD8+ CTLs, APCs, and B cells. The 
importance of metabolic reprogramming and immune cell activation therefore provide an opportunity to modulate 
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1.3.2 Immunometabolism of macrophages and dendritic cells 
Professional APCs, including macrophages and dendritic cells (DCs), are important in mediating 
innate and adaptive immune responses to both self and foreign antigens.  As is the case with all 
immune cells, a number of metabolic transitions occur over the course of the APC lifecycle, as 
reviewed in more detail in chapter 4 and in the following reviews [59, 75]. Similarly to the 
immunometabolism of CD4+ T cell lineages, metabolic differences exist between pro- and anti-
inflammatory subsets of APCs [75-78]. Proinflammatory DCs and classically activated M1 
macrophages switch from an oxidative metabolic profile to aerobic glycolysis upon activation, 
where glucose is preferentially fermented to lactate despite the availability of oxygen [59, 75, 76, 
78]. In contrast, tolerogenic DCs and alternatively activated M2 macrophages involved in wound 
healing and the resolution of inflammation rely on oxidative phosphorylation and the breakdown 
of fatty acids via β- oxidation [59, 75, 76, 78]. As T1D is associated with an aberrant 
proinflammatory phenotype of autoreactive T cells and APCs, this section will focus on this subset 
of APC metabolism.  
Reliance on aerobic glycolysis to fuel the energy needs of proinflammatory APCs have been 
demonstrated in a number of studies [59, 75, 76, 78]. Specifically, use of inhibitors of the 
glycolysis pathway, especially 2-DG, have demonstrated an ability to reduce APC activation, 
upregulation of costimulatory molecules required for antigen presentation, and effector cytokine 
production (i.e., TNFα, IL-1β, IL-6) [59, 75, 76, 78]. There is also evidence to support the idea 
that APCs are metabolically flexible, and can rely on other metabolic substrates to fuel energy 
needs during times of nutrient restriction [79, 80]. Due to their importance in the pathogenesis of 
T1D, further exploration of the metabolic programs used by islet infiltrating macrophages and DCs 
28 
warrant investigation to allow for the generation of combinatorial therapies that modulate both 
APC and T cell functions to control autoimmunity. 
1.4 METABOLIC DYSREGULATION AS A CONSEQUENCE AND TARGET IN 
AUTOIMMUNITY 
Studies investigating the mechanisms that dictate T cell activation and function have shed light on 
the importance of cellular metabolism in guiding these processes. While there is some layover in 
terms of the pathways that are vital for immune cell function, metabolic signatures exist between 
T cell subsets and are important in controlling T cell differentiation [56-60]. Further, different 
metabolic processes can influence the final outcome of an immune response and can govern 
whether a pro- or anti- inflammatory response will ensue. In the case of autoimmunity, recent work 
has highlighted that metabolic differences exist between immune cells in healthy individuals 
versus in patients with autoimmune disorders [55, 81, 82]. Due to the importance of metabolism 
in controlling cell fate and function, as well as the importance of CD4+ T cells that coordinate 
autoimmune attack of the  cell in T1D, understanding metabolic signatures of autoreactive CD4+ 
T cell subsets in autoimmunity are vital to providing new therapeutic targets to control these 
responses. The following section will review immunometabolism as a therapeutic target to control 
autoreactive T cell responses in SLE, MS, and RA. This will afford insight on the metabolic 
requirements of autoreactive T cells and provide evidence to support metabolic regulation as the 
future of immunotherapies in autoimmunity, especially in T1D.  
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1.4.1 Systemic Lupus Erythematosus 
Studies focused specifically on the role of immunometabolism in autoimmunity have indicated 
that autoreactive T cells display altered metabolic dependencies and programs [55, 81, 82]. 
Interestingly, self- reactive T cells from different autoimmune diseases studied thus far display 
distinct metabolic programs with little overlap, further indicating a role for the specific immune 
microenvironment in driving T cell differentiation and effector function. Due to the importance of 
effector T cells in orchestrating attack of the various tissues targeted in autoimmunity, inhibiting 
the activation of these CD4+ T cells is an ideal therapeutic target [61, 71, 83]. Generally speaking, 
autoreactive T cells are thought to have enhanced bioenergetics compared to healthy controls, 
although the metabolic demands of autoreactive T cells in T1D specifically remain largely 
unexplored. This was demonstrated in a lupus model by Yin et al., where it was determined that 
both glycolysis and mitochondrial oxidative metabolism, as well as mammalian target of 
rapamycin complex 1 (mTORC1) activity, are elevated in CD4+ T cells from lupus prone mice 
compared to non-autoimmune control animals [84]. The authors concluded that this metabolic 
dysregulation was a major contributor to the immunological abnormalities associated with lupus 
pathogenesis including T cell hyperactivation and increased IFN production [84]. The enhanced 
cellular metabolism of CD4+ T cells from lupus prone animals preceded onset of disease and 
increased as T cells became more activated throughout disease progression, indicating that 
metabolic differences may be able to be specifically manipulated to prevent onset of autoimmunity 
prior to CD4+ T cell hyperactivation [84]. In an effort to normalize autoreactive CD4+ T cell 
functions in vitro and in vivo, the authors utilized a combination treatment of the glycolysis 
inhibitor 2-DG and metformin, an inhibitor of mitochondrial metabolism (specifically Complex 1 
of the electron transport chain (ETC). In vitro, this treatment combination inhibited excessive IFN 
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production and promoted interleukin-2 (IL-2) production which is otherwise defective during 
lupus [84]. In vivo, targeting glucose and mitochondrial metabolism reversed disease and 
simultaneously led to significant decreases in glycolysis and OXPHOS in autoreactive T cells to 
levels similar to that of non- autoimmune prone controls, decreased the expression of activation 
and effector function markers, decreased autoantibody production, and improved production of 
IL-2 by autoreactive CD4+ T cells; ultimately leading to significant reductions in disease pathology 
[84]. This enhanced bioenergetic profile of lupus- prone CD4+ T cells was also seen in T cells from 
human SLE patients, and could be normalized via treatment with metformin [85]. While treatment 
with either 2-DG or metformin alone were sufficient to prevent disease, combination therapy was 
required for disease reversal. Moreover, a continuous treatment was required to maintain tolerance, 
as cessation of treatment lead to disease flare- ups [85].  
Recent work by Choi et al. confirmed that CD4+ T cells from lupus prone animals were 
glycolytic, and found that Inhibiting glucose metabolism selectively targeted autoreactive 
follicular helper T cells (Tfh), which are expanded in SLE and are required for production of high 
affinity autoantibodies [86]. This treatment was capable of preventing onset of disease in various 
mouse models of SLE. Use of CG-5, a glucose transporter inhibitor, was also capable of 
ameliorating autoimmune activation in lupus [87]. Tfh cells from lupus prone animals displayed 
increased mTORC1 activation compared to B6 controls, consistent with the findings by Yin et al., 
and had a pre- activation status indicated by higher mTORC1 activation in naïve CD44- negative 
CD4+ T cells in lupus- prone animals [84-86]. Moreover, CD4+ T cells from lupus animals 
displayed increased expression of the pro- survival factor B-cell lymphoma 2 (Bcl2), indicating a 
resistance of autoreactive T cells to apoptosis. Preventative treatment (animals were autoantibody 
positive without clinical disease) with 2-DG reduced autoantibody production as well as the 
31 
frequency and number of Tfh and germinal center B cells and reduced the number of total splenic 
CD4+ T cells in four lupus- prone mouse strains, but not in control B6 mice [86]. Interestingly, 
treatment with 2-DG had variable effects on CD4+ T cell activation, as activation and CD44+CD4+ 
T cell frequency were only decreased in a few of the lupus models tested, indicating that 
spontaneous lupus Tfh cells are uniformly sensitive to glycolysis inhibition compared to other T 
cell subsets that showed a variable response depending on strain. Finally, while proliferation and 
signal transducer and activator of transcription 3 (STAT3) signaling were similar between lupus- 
prone and B6 Tfh cells, these were increased in naïve TC CD4+ T cells in which glycolysis is also 
higher than in naïve B6 CD4+ T cells. This finding is interesting, in that it indicates that 
autoreactive CD4+ T cells display heightened bioenergetics that may contribute to the ability for 
autoreactive T cells to escape deletion and persist in the periphery. This heightened activation 
status of naïve CD4+ T cells in autoimmune prone animals also gives precedence for selectively 
targeting CD4+ T cell metabolism as a means to control autoimmunity [84-86].  
As was demonstrated in mouse models of SLE, CD4+ T cells from human patients also exhibit 
elevated cellular metabolism compared to CD4+ T cells from healthy control patients [84]. 
Enhanced bioenergetics correlated with increased production of IFN that could be normalized in 
vitro via treatment with Metformin [84]. These data corroborate earlier studies that demonstrated 
lupus T cells from human patients have increased mTOR activity, mitochondrial dysfunction, 
increased oxidative stress, and glutathione depletion [88-93]. Aberrant oxidative stress and ROS 
in SLE T cells was attributed to increased oxygen consumption and mitochondrial ETC complex 
I activity [89]. As ROS are important mediators in rewiring CD4+ T cell metabolism during 
activation, the phenotype exhibited by SLE T cells is indicative of enhanced bioenergetics, 
aberrant T cell activation, and overall T cell dysfunction that contributes to SLE immunopathology 
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[91]. Further, higher mTOR activity leads to expansion of pathogenic Th17 cells and reduction of 
functional Tregs, further contributing to autoimmunity [90]. Interestingly, treatment with 
rapamycin or the antioxidant N-acetylcysteine (NAC) were capable of reducing SLE disease 
activity by decreasing mTOR activity in effector T cells, expanding Tregs, and enhancing Treg 
suppressive functions [88-90, 92-94]. All in all, these studies in murine and human models of SLE 
disease indicate metabolic aberrations exist in the CD4+ T cell compartment compared to healthy 
counterparts, and that targeting metabolic pathways can reverse T cell dysfunction to correct 
known defects that contribute to SLE pathogenesis. 
1.4.2 Multiple Sclerosis 
The metabolic profile of CD4+ T cells from patients with multiple sclerosis (MS) also display 
altered bioenergetics compared to those of healthy patients, however the literature has had 
conflicting reports. As is the case in other autoimmune disorders, Th17 cells contribute to 
autoimmune disease pathogenesis and progression, where a metabolic switch to glycolysis 
accompanies T cell activation and drives effector functions [57, 59, 60, 95]. This finding that 
Th17s relied on glycolysis was confirmed in a study by Shi et al., where it was demonstrated that 
Th17 differentiation was dependent on hypoxia- inducible factor 1 (HIF1) dependent up- 
regulation of glycolytic activity, as CD4+ T cells deficient in HIF1 had diminished Th17 
differentiation due to a failure to upregulate the glycolytic enzymes required for metabolic 
reprogramming during activation [71]. Further, blocking glycolysis via 2-DG or the mammalian 
target of rapamycin (mTOR) inhibitor Rapamycin reduced Th17 differentiation of naïve T cells in 
vitro and reduced the ability of Th17 to cause experimental autoimmune encephalomyelitis (EAE), 
a murine model of MS, in vivo [71]. This was associated with reduced lymphocyte infiltration and 
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spinal cord inflammation [71]. Other work in EAE has demonstrated the importance of glutamine 
in driving autoreactive CD4+ T cell activation, differentiation, and effector functions, and is 
dependent on the amino acid glutamine transporter alanine-serine-cysteine transporter 2 (ASCT2) 
[96]. Indeed, genetic knockout of ASCT2 resulted in reduced Th1 and Th17 differentiation, 
cytokine production, reduced leukocyte infiltration into the central nervous system, and reduced 
EAE disease severity compared to wild type (WT) controls [96]. Interestingly, the importance of 
glutamine in mouse models of MS was also true in patients, where increased concentrations of 
glutamine and glutamate has been found in the cerebrospinal fluid and brain biopsies from affected 
individuals. Increases in these metabolites were also associated with disease severity and have 
been suggested to be potential biomarkers for MS [97, 98].  
In human patients, altered energy metabolism has been a common finding, however the exact 
metabolic phenotype of autoreactive CD4+ T cells remain elusive. Studies analyzing the gene- 
expression profile in brains from post- mortem MS subjects have showed evidence of an 
upregulation of genes involved in cellular metabolism like HIF1 and the protein kinase B (AKT) 
signaling pathways, which are involved in upregulating glycolysis [99]. Further, MS patients have 
significant changes in serum levels of different metabolites, including an increase in serum 
nicotinamide adenine dinucleotide (NADH) compared to healthy patients. Interestingly, increased 
concentrations of glutamine and glutamate has been found in the cerebrospinal fluid and brain 
biopsies from affected individuals. Increases in these metabolites were also associated with disease 
severity and have been suggested to be potential biomarkers for MS [97-99]. In MS lesions, 
mitochondrial changes have also been reported, including a loss of complex I and IV activity in 
the mitochondrial ETC, implicating a role for mitochondrial damage and oxidative stress in MS 
disease pathogenesis [100-105]. While a number of metabolic differences exist between MS 
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patients and healthy controls based on what has been reported in the current literature, these studies 
have not focused on the metabolic characteristics of CD4+ T, which similar to T1D and lupus, are 
the main effectors in driving autoimmunity in MS. In 2015, De Riccardis et al. set out to determine 
the metabolic phenotype of immune cells in the MS autoimmune response using CD4+ T cells 
isolated from peripheral blood mononuclear cells (PBMCs) of relapsing remitting MS patients 
[101]. They found that CD4+ T cells from these patients had impaired OXPHOS activity and 
decreased activity of mitochondrial complex 1 and IV compared to healthy subjects, confirming 
the findings from earlier studies [101, 102]. When analyzing glucose metabolism in CD4+ T cells 
from these patients, MS CD4+ T cells displayed increased glycolytic flux as measured by increased 
activities of two major rate limiting enzymes in the glycolysis pathway, hexokinase and 
phosphofructokinase [101]. During activation, CD4+ T cells switch to a program dominated by 
aerobic glycolysis, which is the conversion of glucose to lactate despite the presence or availability 
of oxygen. Because of this phenomenon, lactate secretion is a useful output to measure reliance on 
glycolytic metabolism in T cells. As expected, extracellular lactate release was enhanced in T cells 
from MS patients compared to control subjects [101]. This, along with the findings that CD4+ T 
cells from MS patients had reduced ratios of ATP from mitochondrial metabolism over glycolytic 
ATP, as well as increased glucose transporter 1 (Glut1) expression (the most important glucose 
transporter for T cells) compared to healthy controls indicates an increased reliance on glycolysis 
by autoreactive T cells in MS [101]. Interestingly, the enhanced reliance on glycolysis by 
circulating CD4+ T cells from MS patients supplies further evidence that autoreactive T cells have 
enhanced bioenergetics compared to T cells from healthy controls. However, there are limitations 
to this study, which included total CD4+ T cells. It would be interesting to note whether the 
enhanced glycolytic metabolic phenotype described was due to an increase in Teffectors in the 
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periphery in those with MS compared to healthy individuals, or whether metabolism was truly 
dysregulated in naïve, effector, and memory T cell populations between MS patients and healthy 
subjects, as performed in work described earlier in lupus [86, 101]. 
Contrary to the findings by De Riccardis et al., another study found that T cells from MS 
patients were in fact less glycolytic and had impaired engagement of mitochondrial respiration 
than their healthy counterparts, as indicated by a lower extracellular acidification rate (ECAR) and 
oxygen consumption rate (OCR) measured by Seahorse Extracellular Flux analysis [106]. These 
measurements are indicators of glycolysis and OXPHOS, respectively. This metabolic defect was 
confirmed by measuring the expression of key enzymes involved in both glycolysis and 
mitochondrial respiration. Reduced protein levels of key enzymes such as Glut1 and hexokinase, 
correlated with the seahorse analysis performed, further confirming a metabolic defect in CD4+ T 
cells from MS patients [106]. This finding is in conflict with the enhanced bioenergetic profile of 
T cells observed in MS patients from the study outlined above, and could be due to differences in 
the patient cohort, as the T cells in the De Riccardis study were from patients that had been treated 
in the past, albeit these patients had not been treated for at least 3 months [101]. On the contrary, 
samples from the patients in the La Rocca study were isolated from affected individuals who had 
not underwent treatment for their condition. This difference in treatment regimens between the 
two studies could account for these metabolic differences, as immunomodulatory agents have been 
shown to modulate cellular metabolism [106]. Moreover, the methods used to assess metabolism 
in both studies were vastly different, as the De Riccardis study relied on the evaluation of 
enzymatic activity and the La Rocca study utilized an approach that took the whole cell into 
consideration using a functional analysis like Seahorse extracellular flux. Regardless, the impaired 
metabolic profile of MS CD4+ T cells in the La Rocca study is an interesting finding, as glycolysis 
36 
is required not only for T cell differentiation but also for acquisition of specialized effector 
functions, like IFN secretion [107]. Further, this is different than the metabolic phenotype of 
autoreactive T cells from other autoimmune diseases in that instead of having enhanced 
bioenergetics, T cells from these patients had reduced glycolysis and OXPHOS. How these T cells 
are still able to become activated and perpetuate disease under a reduced bioenergetic state 
warrants investigation so as to obtain a full picture of the metabolic choices T cells have at their 
disposal. Further, the activation status of these T cells would also be important to investigate. It 
has been reported in the cancer literature and other autoimmune disorders that a chronic exposure 
to antigen and metabolic competition in the tumor microenvironment (TME) can lead to T cell 
exhaustion or anergy [108]. T cell exhaustion in particular is associated with increased expression 
of checkpoint molecules like programmed cell death protein 1 (PD-1) and lymphocyte activation 
gene-3 (LAG-3), which are capable of reprograming T cell metabolism themselves, and will be 
discussed in more detail below [109, 110]. Further characterization of the expression of key surface 
proteins and delineation of the molecules that regulate metabolism and cell fate decisions should 
be further explored, in addition to understanding the activation status. Finally, it is vital to our 
understanding of autoimmune disease pathogenesis to study metabolic profiles of T cells over the 
course of autoimmune destruction. These studies are important to better understand the metabolic 
dependencies of autoreactive T cells over the course of disease pathogenesis and will aid in the 
discovery of novel biomarkers and pathways that can be solicited to specifically target these 
pathogenic T cells therapeutically to prevent or reverse disease in affected individuals. 
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1.4.3 Rheumatoid Arthritis 
In RA, altered immune tolerance and metabolic defects contribute to chronic synovial 
inflammation and joint destruction, mediated in large part by CD4+ T cells [111, 112]. The first 
evidence that altered bioenergetics played a role in RA pathogenesis was found in early studies 
analyzing serum samples from RA patients, where aldolase A and -enolase, two enzymes of the 
glycolytic pathway, were identified as autoantigens [55, 113, 114]. Similarly to the results 
described above, CD4+ T cells from a spontaneous mouse model of RA were more metabolically 
active compared to controls. Further, glycolysis inhibition with 2-DG significantly reduced joint 
inflammation and activation of adaptive and innate immune cells, as well as autoantibody 
production [115].  
Contrary to the findings in animal studies, naïve CD4+ T cells isolated from the PBMCs of RA 
patients were found to be energy deprived and were unable to fully engage aerobic glycolysis 
[111]. This was indicated by reduced glucose utilization, lactate production, and generation of 
intracellular ATP 72 hours post in vitro stimulation, and correlated with increased apoptosis, which 
was 50% higher in RA T cells compared to controls [111]. To understand whether RA T cells were 
anergic thus leading to reduced glucose utilization, parameters of T cell responsiveness were 
monitored post stimulation. Interestingly, RA T cells responded as vigorously as their control 
counterparts, proliferated faster, and were able to produce IL-2 to the same extent as control T 
cells, indicating that naïve RA T cells were able to respond to environmental stimuli and undergo 
activation at a rate comparable or better than control T cells, however metabolically speaking RA 
T cells displayed abnormalities in the utilization of glucose, ATP production, and were more 
susceptible to undergo cell death in response to stimulation [111]. This metabolic phenotype was 
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found to be due to a defect in up regulating the rate limiting enzyme 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 3 (PFKFB3), a key regulator of glycolytic flux [111].  
The immune microenvironment plays a significant role in T cell differentiation and function, 
as evidenced by studies researching the impact the TME has on tumor- infiltrating lymphocyte 
(TIL) function.  In order to determine whether the failure to induce PFKFB3 expression in RA T 
cells was a consequence of the inflammation associated with RA disease progression, PFKFB3 
transcript levels in CD4+ T cells were correlated with a disease activity score, indicating disease 
severity. Contrary to what you would expect, patients with lower disease activity had no advantage 
over patients with more severe disease [111]. Further, a failure to induce PFKFB3 expression did 
correlate with diagnosis of RA, but not with the inflammatory milieu, indicating that reduced 
PFKFB3 expression by RA T cells is a defect in all RA patients regardless of disease clinical score 
or severity [111]. Nonetheless, it’s important to note that autoimmunity precedes the onset of 
clinical symptoms, and that exposure of CD4+ T cells to chronic stimulation in an inflammatory 
environment likely plays a key role in altering immune function and lymphocyte stability in the 
local micromilieu. For example, in the TME, a competition for nutrients, especially glucose 
between tumor cells and tumor infiltrating lymphocytes, is thought to drive T cell dysfunction and 
exhaustion thus leading to cancer persistence and tumorigenesis [108]. This too could be the case 
in RA, as the fibroblast- like synoviocytes (FLS) that play a major role in the initiation and 
development of synovial inflammation and joint destruction in patients display an activated 
phenotype characterized by enhanced glycolytic metabolism similarly to cancer cells [112, 116]. 
This enhanced metabolic profile allows RA FLSs to exhibit an abnormal capacity for migration, 
invasion, and proinflammatory cytokine production that contribute to disease pathology [112]. The 
proinflammatory nature of FLSs in RA most likely promotes a hostile immunosuppressive 
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environment that over time, renders autoreactive infiltrating T cells dysfunctional due to high 
lactate output and a lack of nutrients available to fuel proper T cell activation [72, 108]. Therefore, 
its plausible that the metabolic defects in CD4+ T cells from RA patients does not cause disease, 
rather it occurs as a consequence of the environment. Indeed, treatment of RA FLSs with the anti- 
glycolytic PFK15, a competitive inhibitor of the enzyme PFKFB3, lead to decreased expression 
of proinflammatory cytokines, migration, and proliferation [112]. Whether metabolic regulation 
of RA FLS lead to normalization of T cell metabolism and function remains unknown and should 
be investigated more thoroughly. Moreover, more studies are needed to fully dissect the metabolic 
features of CD4+ T cells in RA from disease onset through progression. This would allow for 
thorough examination of the metabolic defects plaguing autoreactive T cells in RA, and may 
provide new details that explain differences seen in mouse models and patient samples.  
1.5 EVIDENCE OF METABOLIC DYSREUGLATION IN T1D: OPPORTUNITIES FOR 
INTERVENTION? 
While metabolism as a therapeutic target has been exploited in many autoimmune diseases, such 
as the ones detailed in this review, it has been largely unexplored in T1D research. However, like 
CD4+ T cells in lupus, MS, and RA, there is growing evidence from our laboratory and others that 
 cell reactive T cells demonstrate enhanced bioenergetic demands and metabolic defects that drive 
autoimmune targeting of the pancreatic  cell. While most of this review has focused on utilization 
of glycolysis to fuel T cell activation, mitochondrial OXPHOS and ROS are also enhanced during 
activation, as mitochondrial derived ROS not only act as a third signal for efficient T cell 
activation, but also are essential for IL-2 production and proliferation upon antigenic stimulation 
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[4, 117]. T cell mitochondrial dysfunction is seen often in autoimmunity, and is attributed to 
increased mitochondrial inner- membrane hyperpolarization (MHP) [117]. Recently it has been 
identified that the production of ROS and synthesis of ATP are tightly regulated by maintenance 
of mitochondrial membrane potential. Further, mitochondrial dynamics and function are thought 
to drive T cell differentiation [118, 119]. More specifically, it has been demonstrated that increased 
mitochondrial membrane potential leads to an effector T cell phenotype characterized by increased 
glycolysis and ROS production [120]. Interestingly, T cells from patients with T1D display MHP 
and increased mitochondrial membrane potential, indicating a more activated phenotype compared 
to healthy control T cells [117]. This phenotype was seen in T cells in the CD4 and CD8 
compartment regardless of activation status, indicating that MHP is a general characteristic of T 
cells in patients with T1D. Moreover, enhanced MHP was linked to increased ROS production and 
IFN secretion, indicating that mitochondrial dysfunction promotes effector functions of 
autoreactive T cells due to an altered proinflammatory T cell effector response [117]. This finding 
that ROS drive T cell activation and effector capabilities correlate with data from our laboratory, 
where use of a manganaese metalloporphyrin (MnP) with ROS scavenging capabilities during T 
cell activation inhibited diabetogenic CD4+ T cell responses in vitro and delayed diabetes 
progression in an adoptive transfer model of T1D in vivo [37, 39, 121-123]. Work by Previte et al. 
demonstrated that redox modulation via MnP treatment during activation maintained AMP- 
activated protein kinase (AMPK) activation that resulted in decreased mTOR activation and a 
reduced ability to undergo metabolic reprogramming to aerobic glycolysis [123]. These data 
demonstrated that ROS are required for driving and sustaining T cell activation and promoting the 
metabolic switch to glycolysis [123]. Altogether, this data suggests that self- reactive CD4+ T cells 
have enhanced bioenergetic demands fueled by glycolysis, and that this increased reliance on the 
41 
glycolytic pathway long- term induces MHP, increases ROS production, and makes these T cells 
super- effectors that drive Th1 mediated  cell destruction. Moreover, the fact that T1D T cells 
secrete more IFN after activation is in itself indicative of an enhanced glycolytic profile, as 
aerobic glycolysis controls preferential translation of IFN mRNA and is required for acquisition 
of T cell effector functions [107]. Finally, data presented by Chen et al. indicating that naïve T 
cells had higher MHP supports the idea that autoreactive T cells are in a heightened activation 
state. This data, along with the potential for poor peptide binding due to dysfunctional antigen 
presentation, may provide further insight as to how and why autoreactive T cells are able to escape 
deletion in the thymus and go unabated in the periphery [117, 124]. It may also be a reason as to 
why effector T cells become resistant to Treg mediated control or explain why Treg function is 
defective in T1D, as enhanced glycolysis may lead to FoxP3 destabilization and subsequent loss 
of suppressive capabilities.  
1.5.1 Hyperglycemia and the immune microenvironment’s role in shaping  cell reactive T 
cell responses in T1D 
A common theme discussed thus far has been understanding the role of the immune 
microenvironment on T cell differentiation and function, and how that contributes to autoimmune 
disease progression and pathology. As glucose is the substrate of choice for T cells undergoing 
activation and is required for metabolic reprogramming to occur, it would be interesting to know 
whether hyperglycemia contributes to the heightened bioenergetic profile and metabolic defects 
of  cell reactive CD4+ T cells in T1D. One could postulate that autoreactive T cells in T1D, which 
appear to be more glycolytic compared to T cells from healthy controls, are able to utilize glucose 
more freely due to its abundant availability in the blood, thereby enforcing a proinflammatory 
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program that leads to a predominate effector T cell phenotype. This phenomenon has been 
previously described for CD8+ T cells, where in vitro simulated hyperglycemia increased IFN 
secretion [125, 126]. In human studies, Chen et al analyzed the impact of hyperglycemia on T cell 
mitochondrial membrane potential by measuring membrane potential in T cells from a cohort of 
patients with Type 2 Diabetes (T2D) and comparing it to the membrane potential of T cells from 
patients with T1D [117]. This comparison allowed for delineating whether the high glucose 
environment or immune abnormalities associated with autoimmune conditions lead to the 
metabolic defects in T cells from T1D patients. Intriguingly, it was found that T cells from T2D 
had membrane potential levels that were indistinguishable from controls. However, this was 
significantly lower than the membrane potential of T cells isolated from T1D patients. These data 
indicate that the mitochondrial defects seen in T cells from individuals affected by T1D is a 
consequence of autoimmunity, and not a consequence of the high blood glucose levels and loss of 
glucose control in these patients [117]. Whether T cells between T1D and T2D were more 
glycolytic in hyperglycemic environments remains unknown. It would be intriguing to follow 
metabolic and mitochondrial dysfunction in autoreactive T cells starting during development in 
the thymus through early initiation of autoimmunity, all the way to onset and progression of 
clinical symptoms and disease. While this would be difficult to do using patient samples, a large-
scale study following the course of disease could be more easily done using the NOD mouse, a 
spontaneous model of T1D that closely mimics key characteristics of human disease. While not a 
perfect system, it would allow for a better understanding of how T cells respond to various 
environmental stimuli encountered during development and in the periphery that could contribute 
to metabolic and immunologic dysfunctions.  
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Furthermore, defective Treg function is a common feature of autoimmune diseases [8, 12, 41]. 
Metabolism plays a key role in regulating the balance between Teffectors and Tregs [10, 11, 53, 
57, 66, 67, 71]. While Treg suppressive capabilities and FoxP3 stability are thought to be supported 
by use of FAO, glycolysis has been demonstrated to be required for Treg proliferation and 
circulation [57, 74]. Glycolysis, which is associated with Teffector activation, drives 
proinflammatory responses while OXPHOS and FAO are associated with Tregs, and drive an anti- 
inflammatory response. Modulating the glycolysis pathway has been shown to inhibit effector T 
cell responses while also promoting the induction of FoxP3+ Tregs [57, 59, 71, 72, 84-86, 115]. In 
SLE, Treg cells exhibit increased mTOR activity that correlated to their dysfunction and 
diminished suppressive capacities, which could be corrected with rapamycin treatment [94]. This 
provides evidence that Tregs in autoimmune conditions are more glycolytic, and could indicate 
why they fail to control autoreactive T cells in SLE, MS, RA, and T1D [94]. Notably, while 
rapamycin treatment is capable of expanding SLE Tregs and correcting functional defects, mixed 
results have been obtained with Treg expansion in T1D patients [88-90, 92-94, 127]. One study by 
Monti et al. investigating the effect of rapamycin on human Tregs in vivo demonstrated that 
treatment did not alter the frequency, proliferation, or cytokine production of circulating Tregs, 
but it enhanced their capability to suppress proliferation of effector T cells in T1D [127]. The 
varying effects of rapamycin on Treg expansion seen in SLE and T1D could be attributed to the 
type of pathogenic T cells that mediate autoimmune damage in both conditions. In SLE, patients 
have enhanced Th17 cell responses that correlate with disease activity [128]. On the other hand, 
T1D is a primarily Th1 mediated disease [37, 39, 40, 42, 121]. This difference in Th cell 
differentiation could indicate why Treg expansion is more easily accomplished in SLE patients. In 
particular, recent literature has indicated that T cell metabolism, namely the glycolysis pathway, 
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is an important checkpoint controlling the differentiation of Th17 and Treg cells, as blocking 
glycolysis has the ability to inhibit Th17 differentiation while promoting Treg cell generation [57, 
71]. Further research is needed to dissect the metabolic features of effector T cells and Tregs in 
autoimmune conditions, with particular attention to how T cells in various disease pathologies 
differ from one another. Specifically in T1D, it would be of interest to know whether high blood 
glucose levels and enhanced glycolysis leads to destabilization of the Treg lineage, and to further 
characterize whether Treg dysfunction in autoimmunity is a result of metabolic alterations, as 
appears to be the case in SLE [94].  
1.5.2 Enforcing T cell exhaustion: A foe in cancer, a friend in autoimmunity? 
Immune dysfunction in cancer is thought to occur as a result of T cell exhaustion and increased 
Tregs in the tumor microenvironment that limit anti-tumor immunity. T cell exhaustion, which is 
typically associated with CD8+ T cells but can occur in the CD4 compartment, is characterized by 
loss of effector functions, altered cytokine responses, overexpression of checkpoint inhibitory 
receptors (i.e. PD-1, CTLA-4, LAG-3, and TIM-3 and altered metabolic programs leading to T 
cell hyporesponsiveness and cancer progression [129]. Checkpoint blockade of inhibitory 
receptors, especially PD-1 have revolutionized cancer immunotherapy, as they have proven to be 
effective in reinvigorating exhausted T cells in the TME. Unfortunately, immunotherapy is known 
for a multitude of immune- related adverse effects, including onset of autoimmune disorders like 
PD-1 inhibitor induced T1D [130]. Specific work in T1D has revealed that PD-1/Programmed 
death- ligand 1 (PD-L1) deficiency and blockade or deletion of LAG-3 in NOD animals accelerates 
the onset of autoimmune diabetes, indicating an important role for checkpoint inhibitory receptors 
in regulating T cell responses in T1D [30, 131, 132].  
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Studies using mouse models and samples from human patients have revealed that the PD-
1/PD-L1 pathway is dysregulated in T1D [133-135]. Indeed, activated T cells from new- onset 
T1D patients fail to upregulate PD-1 compared to healthy subjects [134]. This was true too for 
CD4+ T cells in adults with long- standing T1D [136]. Interestingly, this phenotype was seen only 
in CD4+ T cells from T1D patients, whereas PD-1 expression was similar between T cells from 
SLE patients and healthy controls , indicating PD-1 dysregulation is specific to T1D onset and 
pathogenesis [136].  
LAG-3 is another checkpoint molecule that has been tied to immune cell dysfunction in T1D. 
This was confirmed in work by Bettini et al. where deletion of LAG-3 in autoimmune prone NOD 
animals resulted in accelerated diabetes with 100% incidence that corresponded to increased T cell 
islet infiltration, and not due to Treg dysfunction [30, 31]. This phenotype was exclusive to 
autoimmunity, as LAG-3 deletion in non- autoimmune prone C57BL/6 mice resulted in a minor 
phenotype with no development of spontaneous disease, similarly to the minimal 
immunopathologies associated with PD-1 knockout in non- autoimmune prone mice [137, 138]. 
Together, these data indicate a critical role for LAG-3 in controlling early expansion of 
autoreactive T cell clones. It would be important to study LAG-3 expression on T cells from 
healthy individuals and T1D patients to better understand whether LAG-3, like PD-1, is 
dysregulated during autoimmunity. Due to the synergistic nature of PD-1 and LAG-3, we would 
hypothesize that LAG-3 expression is decreased or signaling is dysfunctional in T cells from T1D 
patients. Moreover, it’s clear that checkpoint inhibitory receptors, including both PD-1 and LAG-
3, are important for maintaining self- tolerance and may be critical mediators that drive 
autoimmunity. 
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As one would expect, the state of T cell exhaustion is accompanied by distinct metabolic 
features [139]. Moreover, both PD-1 and LAG-3 have been implicated in reprogramming 
lymphocyte metabolism. For example, PD-1 signaling specifically promotes lipolysis and FAO 
and leaves T cells unable to engage in aerobic glycolysis via stabilization of phosphatase and tensin 
homolog (PTEN) [109]. As glycolysis is required for acquisition of T cell effector functions, this 
finding makes sense as exhausted T cells expressing PD-1 are dysfunctional in their ability to 
secrete proinflammatory cytokines and have limited effector capabilities [129]. This reliance on 
FAO is associated with T cell longevity and enhanced survival while exhausted and unable to 
utilize other key nutrients [109, 140]. A paper published this past year by our laboratory 
investigated the role of LAG-3 in maintaining metabolic quiescence in naïve CD4+ T cells [110]. 
Interestingly, it was determined that LAG-3 -/- CD4+ T cells demonstrated greater glycolytic 
capacity and enhanced proliferation and effector functions (i.e. IFN secretion) during activation, 
indicating a role for LAG-3 in regulating T cell activation and clonal expansion. This is an 
interesting finding and may provide evidence for enhanced metabolic phenotypes of T cells in 
autoimmune conditions, as inhibitory receptor expression is impaired in diabetogenic autoreactive 
T cells [134]. Impaired expression of PD-1 and LAG-3 could explain the hyperactivated phenotype 
and enhanced effector capabilities of autoreactive CD4+ T cells that are responsible for disease- 
inducing potential of these cells. Finally, altered bioenergetics and enhanced glycolysis in 
diabetogenic CD4+ T cells may confer resistance to Treg mediated suppression or lead to Treg 
dysfunction that is known to occur during T1D pathogenesis [10, 12, 40, 41, 45]. Based on these 
data, it would be interesting to know whether recapitulating an environment like the TME in cases 
of autoimmunity could prevent or reverse disease. As T cells in autoimmune prone individuals fail 
to upregulate these inhibitory receptors, enforcing the checkpoints and modulating T cell 
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metabolism to promote T cell exhaustion may lead to tolerance in affected individuals. In fact, a 
study by Tilstra et al. demonstrated that kidney- infiltrating T cells in a mouse model of lupus 
nephritis become metabolically and functionally exhausted after organ infiltration as a means to 
limit damage to self [141]. Therefore, enforcing this phenotype prior to disease onset via metabolic 
regulation may provide a new way to limit autoimmune disease associated pathologies [141]. 
Further investigation is needed to determine whether glycolysis inhibition or promotion of FAO 
leads to an exhausted state.  
1.6 METABOLIC INTERVENTION: A NEW OPPORTUNITY FOR T1D PREVENTION 
AND THE FUTURE OF IMMUNOTHERAPY  
Current therapeutic strategies for T1D have focused on 2 different approaches including 1) 
restoring or preserving endogenous  cell mass or 2) combatting autoreactivity and autoimmunity. 
While efforts to restore and preserve  cell mass have been interesting and shown promise in 
preclinical studies, these strategies ultimately fail due to a recurrence of autoimmunity [142, 143]. 
The first proof of principle study showing that immunotherapy is effective in human patients with 
T1D was published in 1984, and investigated the use of Cyclosporine in recent onset T1D patients 
[144, 145]. This has given precedence for finding ways to limit the autoimmune destruction of  
cells by the immune system. Two clinical trials have been published this year that investigated the 
use of low dose anti- thymocyte globulin (ATG) in new onset T1D patients and the anti- CD3 
antibody Teplizumab in relatives at risk for developing disease and found that both low- dose ATG 
preserved  cell mass while Teplizumab delayed disease onset [146, 147]. While disease was 
successfully delayed and  cell mass was preserved for a period of time, both treatments 
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consequently lead to lymphopenia in treated patients [146, 147]. Moreover, these new studies, 
while effective, have not addressed the broad immunosuppression associated with the treatment. 
This is a major hurdle to overcome especially in T1D, which affects juvenile patients, as wiping 
out the immune system could have broad implications for the ability to overcome potential 
infections and pathogens. Instead, they have used newer therapeutics that have the same 
lymphopenic affect that was demonstrated 35 years ago with Cyclosporine. Importantly though, 
these studies, along with the ability to predict onset of T1D based on the presence of one or more 
autoantibodies, has given precedence for manipulating T cell responses to prevent or delay disease 
onset in those predisposed to autoimmunity.  
As discussed in detail in this review, modulating CD4+ T cell metabolism has the ability to 
both prevent and reverse autoimmune conditions [71, 84-87, 115]. While not yet explored in T1D, 
the potential of metabolic intervention to be successful to control islet- antigen specific T cell 
responses exists and deserves further examination. At the time of diagnoses, patients with T1D 
have already experienced longstanding autoimmune onslaught to pancreatic  cells, and thus only 
have approximately 10-20%  cell mass still present [33-35, 40]. As in most autoimmune 
conditions, autoimmunity (specifically activation of autoreactive CD4+ T cells) precedes 
downstream damage, and is an important consideration to make when thinking about where and 
when metabolic intervention is best suited. Studies in T1D have shown that immunotherapy is 
successful in delaying and/ or preventing onset [144-147]. Based on the immunopathology of T1D, 
and due to the importance of CD4+ T cells in disease initiation and progression, we would 
hypothesize that use of metabolic inhibitors would be best suited as a prophylactic strategy, prior 
to diagnoses. Genetic predisposition and the presence of multiple autoantibodies can predict who 
will progress to have T1D [33, 35, 40, 146, 147]. Although not currently used in the clinic, testing 
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for the presence of autoantibodies to  cell antigens in children with a family history of T1D or in 
those at risk to developing autoimmunity could be used to determine whether metabolic 
intervention should be initiated. Moreover, the natural history of T1D takes place over a number 
of years, giving ample time for intervention prior to complete loss of dynamic glucose sensing and 
insulin secretion due to  cell loss [33]. This idea of disease prevention was outlined above. Studies 
in SLE have demonstrated the success of metabolic modulators in preventing autoimmunity (52-
54). Also, while it is possible that chronic administration may be necessary, inhibiting glycolysis 
has been shown to promote Treg differentiation while inhibiting effector T cell expansion (47, 52-
58,61-62). If metabolic intervention can restore the balance between effector T cells and Tregs, 
and improve suppressive function of dysfunctional Tregs in autoimmune diseases, a shorter 
treatment regimen may be successful in establishing durable tolerance to self- antigens. However, 
more work is needed to fully understand the ability of metabolic inhibitors to prevent or reverse 
disease, especially T1D, in order to determine length of treatment needed to establish tolerance. 
On the contrary to immune- targeted therapies that result in repression of global immunity, 
metabolic therapies have demonstrated great success in selective targeting of self- reactive T cells 
while leaving humoral immunity unscathed and intact [61, 84-87, 115]. This specific targeting of 
autoreactive T cells via use of anti- metabolites even when administered systemically is a 
phenomenon termed “cellular selectivity based on demand,” and was first described by Lee et al, 
in a study where targeting glucose and glutamine metabolism specifically prevented allograft 
rejection [148-150]. The idea behind this theory is that use of generic inhibitors of universal 
metabolic processes selectively affect cells with the greatest metabolic demand, without altering 
normal cellular homeostatic function [148-150]. While effector T cells alone have increased 
metabolic demands to support activation, proliferation, and effector functions, research in 
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autoimmunity has provided evidence that autoreactive T cells have altered bioenergetic programs 
that allow for their increased effector capabilities. These metabolic abnormalities could contribute 
to their persistence in the periphery and disease- promoting capabilities compared to T cells from 
healthy individuals. This makes metabolism an ideal target for autoimmunity, where enhanced 
metabolically demanding programs that self- reactive T cells rely on can be specifically modulated 
to promote tolerance. Moreover, as immune cells utilize distinct metabolic programs, inhibition of 
glycolysis for example should in theory have minimal effects on Tregs or established memory T 
cells to vaccines. When using metabolic inhibitors, like 2-DG, to alleviate autoimmune targeting 
by CD4+ T cells as described in detail above, the remainder of the immune system is otherwise 
unharmed and functionally able to respond appropriately to non- self-antigens (i.e. to 
immunization). However, it’s important to consider that metabolic intervention may also modulate 
immune cells other than CD4+ T cells. All immune cells, including macrophages, dendritic cells, 
B cells, and CD8+ T cells, undergo metabolic reprogramming to aerobic glycolysis upon activation 
[59, 75, 78]. Therefore, its plausible that use of inhibitors like 2-DG, metformin, or PFK15 could 
also alter APC, B cell, or CD8+ T cell function. In fact, treatment with glycolysis inhibitors like 2-
DG in mouse models of SLE and T1D resulted in reduced CD8+ T cell expansion and effector 
function and also lead to reduced autoantibody production by B cells [84, 86, 151]. All in all, 
current immunotherapeutic strategies to combat T1D have had harsh repercussions on the entire 
immune system. Moreover, there is evidence that autoreactive T cells do not play by the same 
rules metabolically and have altered metabolic demands and requirements compared to their non- 
autoimmune counterparts. Whether abnormal metabolism is a feature of other immune cell 
compartments in autoimmunity warrants further investigation. Moreover, further work is needed 
to determine the impact of metabolic modulators on CD8+ T cell, B cell, and APC function, as 
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most of the studies done thus far have focused on modulating CD4+ T cell metabolism. The 
importance of CD4+ T cells in autoimmunity and their distinct metabolic features provide a unique 
opportunity to move immunotherapy towards targeting metabolism, which has a proven track 
record of specifically controlling rogue self- reactive T cell responses without interfering with 
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ADMINISTRATION OF THE ANTI- GLYCOLYTIC PFK15 TO CONTROL 
ABERRANT T CELL ACTIVATION IN TYPE 1 DIABETES 
This chapter is an ongoing study and more experimentation is required before it can be 
considered for publication.  
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Although safeguards are in place to protect against the onset of autoimmunity, a breakdown in 
tolerance mechanisms can lead to the activation of autoreactive T cells that mediate 
immunopathology against self-tissues, like that which occurs during T1D. T1D is an autoimmune 
disease in which insulin-producing islet β cells are targeted and destroyed by the immune system, 
with CD4+ T cells largely mediating pathogenesis. Importantly, distinct metabolic programs 
dictate T cell differentiation and function over the course of the T cell lifecycle. Notably, CD4+ T 
cells undergo metabolic reprogramming to the less efficient aerobic glycolysis during activation 
to support clonal expansion and effector cytokine secretion. This is true too for diabetogenic CD4+ 
T cells, who upregulate the glycolysis pathway, including the rate- limiting enzyme PFKFB3,  
upon encounter with β cell antigen. Targeting the glycolysis pathway as a means to maintain 
tolerance has been investigated in a number of autoimmune disease models, including Lupus, 
Multiple Sclerosis, and Rheumatoid Arthritis, but remains a largely understudied therapeutic 
approach to control self- reactivity against islet β cells T1D. However, while other studies using 
immunomodulatory agents have been used successfully in the clinic to delay disease onset, their 
systemic delivery regimens often lead to global immune suppression, lymphopenia and/or a 
recurrence of autoimmunity. In this study, we utilized the small molecule PFK15, a competitive 
inhibitor of PFKFB3 that has shown efficacy in FDA clinical trials for advanced malignancies 
[152].  As a means to circumvent systemic administration of an anti- glycolytic, we formulated 
PFK15 into a microparticle (MP) in order to provide a sustained and constrained release of the 
drug to a targeted area to limit systemic exposure, thus allowing for selective control of β cell 
reactive T cells while keeping global immune function intact. Our results demonstrated that 
metabolic regulation of CD4+ T cell activation via PFK15 soluble and MP formulations inhibits 
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effector function in vitro and delays disease onset in vivo. These data support our hypothesis that 
the glycolysis pathway is a novel therapeutic target to combat rogue autoimmune responses in T1D 
without altering global immune function, as other studies have failed to address this consequence 
of current immunotherapeutic regimens. The work presented here are crucial in expanding our 
knowledge regarding the design of more effective and selective therapies for patients at risk for 



































The immune system is tasked with mediating protection of its host against various pathogens, 
where it relies on the ability to distinguish self from non- self to avoid detrimental 
immunopathology [1]. Under certain circumstances, a breakdown in tolerance leads to the 
activation of self- reactive T cells that can initiate autoimmunity, like that exhibited in T1D [33, 
34, 43]. A number of immune cells contribute to autoimmune destruction of insulin- secreting  
cells [33, 34, 43, 45]. However, CD4+ T cells are considered the primary mediators of disease 
pathology, and are crucial in perpetuating attack of insulin- secreting pancreatic islet  cells [33, 
34, 43, 45].  
Interest in the mechanisms governing the activation and effector capabilities of T cells have 
grown immensely, with a specific interest in understanding the role cellular metabolic programs 
play in mediating proper T cell function [15, 54-62, 71, 83, 95, 125, 148, 153-155]. Under 
homeostatic conditions, naïve CD4+ T cells are metabolically quiescent and rely on oxidative 
phosphorylation (OXPHOS) via the mitochondria to support basal processes [15, 58-60, 62, 71, 
95, 154]. Upon TCR mediated recognition of antigen, activated T cells adopt an anabolic 
metabolism characterized by a metabolic transition from OXPHOS to glycolysis. Costimulation 
and the presence of growth factors like IL-2 promotes metabolic reprogramming via induction of 
phosphoinositol 3- kinase (PI3K) – dependent activation of AKT [58-60, 95, 154]. Active AKT 
then acts as  a positive regulator of the mammalian target of rapamycin (mTOR), thereby 
stimulating glycolysis and cellular metabolism [60, 95, 154].  
Activated T cells preferentially ferment glucose into lactate, a process that occurs despite 
sufficient oxygen levels to support mitochondrial respiration [60, 95, 154]. This phenotype, known 
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as the Warburg effect, is a hallmark of highly proliferative cancer cells. Utilization of the 
glycolysis pathway is far less efficient than OXPHOS, with a net gain of 2 versus 36 molecules of 
ATP generated per one molecule of glucose, respectively [60, 95, 154]. However, lack of 
efficiency is secondary to the processes and intermediates glucose and the glycolysis pathway 
provide to highly proliferative cells. Not only is glycolysis required for proliferation and clonal 
expansion, but it’s also necessary to support the specialized effector functions of both CD4+ and 
CD8+ T cells [60, 95, 154]. Most notably, use of aerobic glycolysis is required for effector cytokine 
production (i.e. IFN synthesis), nucleotide and reducing equivalent generation via the pentose 
phosphate pathway (PPP) for producing biosynthetic precursors for cellular components necessary 
for proliferation, and for the production of the cytolytic effector molecules granzyme and perforin 
by CD8+ T cells [60, 95, 107, 154]. Evidence supporting the necessity of glycolysis for T cells 
comes from studies demonstrating that glucose deprivation inhibits IFN gene expression and 
cytolytic activity of CD8+ T cells [60, 95, 107, 154].  
An often-overlooked consequence of immunotherapy is the broad non- specific targeting of 
either non- autoreactive T cells or other cell types within the body, which ultimately may lead to 
global immunosuppression. Controlled drug delivery systems through use of micro (MP)- or nano- 
particle (NP) technologies have provided an effective way at delivering therapeutics locally to 
specific tissues to mitigate systemic delivery- induced toxic effects [156]. These approaches have 
proven beneficial in a number of disease settings, including a recent paper by our laboratory 
demonstrating use of MP technologies in preclinical models of RA [13].   
As T cells are critical contributors to the immunopathology of T1D, and due to the importance 
of a metabolic switch to glycolysis in fueling effector T cell functions, we hypothesized that 
inhibiting glycolysis would dampen CD4+ T cell activation and effector functions, that would 
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prevent autoimmune attack of pancreatic beta cells in a mouse model of T1D. Here we demonstrate 
the ability for systemic and local MP delivery of the glycolysis inhibitor PFK15 to dampen T cell 
responses in vitro, and delay T1D in vivo.  
2.3 MATERIALS AND METHODS 
2.3.1 Animals 
Non-obese diabetic (NOD), NOD.BDC2.5.TCR.Tg (BDC2.5) and NOD.scid mice were 
maintained under specific pathogen free conditions in the animal facility located at the Rangos 
Research Center within UPMC Children’s Hospital of Pittsburgh. All animal experiments were 
approved by the University of Pittsburgh’s Institutional Animal Care and Use Committee (IACUC; 
Assurance Number: D16-00118). Male and female mice aged 6-12 weeks old were used in all 
experiments.  
2.3.2 Splenocyte isolation and in vitro stimulation 
NOD animals were sacrificed, and spleens harvested and homogenized into single cell suspensions 
as described [123]. Red blood cells were lysed using RBC lysis buffer (Sigma Aldrich). For in 
vitro experiments, 2.5 x 106 splenocytes were plated per well in 24 well plates and stimulated with 
2.5 g/mL of ConA ± 2.5- 10 M PFK15 soluble drug (Selleck) for 48-72 hours. In some studies, 
PFK15 was administered via porous MP formulations, and were a generous gift formulated and 
provided by Dr Abhinav Acharya and Dr. Steven Little (University of Pittsburgh). The Little 
laboratory performed release kinetic studies and MP characterization and scanning electron 
microscopy as previously described [13, 157, 158]. MP experiments were performed in 24 well 
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Transwell plates (Corning).  Cells and culture supernatants were collected for downstream flow 
cytometry, ELISA, and lactate measurement analyses.  
2.3.3 Flow Cytometry 
5x105 – 1x106 cells were harvested at indicated timepoints and surface stained for flow cytometric 
analysis as described [123]. Briefly, cells were incubated with Fc block (CD16/CD32; BD 
Biosciences) for 15 minutes prior to staining for flow cytometry. Surface staining was performed 
at 4°C using antibodies against CD4, CD69, CD25, PD-1, CTLA-4, Vβ4, LAG-3 (BD 
Biosciences), or hen egg lysozyme (HEL) tetramers (NIH Tetramer Core Facility) in FACS buffer 
(1% BSA in PBS). For proliferation measurements, splenocytes were labeled with Cell 
Proliferation Dye Violet (BD Bioscience) per manufacturer’s instructions prior to stimulation. 
After indicated timepoints, cells were harvested, and surface stained as described above. In some 
instances, cells were fixed in 2% PFA for 15 minutes at 4°C (Thermo Fisher Scientific). Cells were 
stored at 4°C until time of analysis.  
To measure glucose uptake, splenocytes were incubated with 100 μM of the fluorescent 
glucose analog 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl) Amino)-2-Deoxyglucose (2-NBDG; 
Cayman Chemical) for 10 minutes at 37°C prior to harvest as described [110, 123]. Cells were 
washed with PBS and surface stained for CD4 expression and analyzed live by flow cytometry. 
To measure apoptosis, cells were stained with Annexin V and Propidium Iodide (PI) apoptosis 
detection kit per the manufacturer’s instructions (BD Biosciences), For all flow cytometry studies, 
fluorescence was measured using a FACS Aria II flow cytometer (BD Biosciences). All data were 
analyzed using FlowJo software (v10.5.3) and samples were gated on CD4+ cells. 
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2.3.4 Lactate and Cytokine Measurements 
Cell culture supernatants from in vitro experiments were harvested and used to measure IFNγ by 
ELISA. Antibody pairs for IFNγ were purchased from BD Biosciences. ELISAs were read on a 
SpectraMax M2 microplate reader (Molecular Devices) and data analyzed using SoftMax Pro 
version 7.0.2 software (Molecular Devices). Lactate, a byproduct of aerobic glycolysis, was 
measured using the Lactate Plus meter and test strips per manufacturer’s instructions (Novus 
Biologics).  
2.3.5 Nominal Antigen Immunization 
For immunization experiments, non- diabetic NOD mice were immunized with 100 µg HEL 
(Sigma Aldrich) emulsified in Complete Freund’s Adjuvant (CFA; Sigma Aldrich) at the base of 
the tail. Animals were treated with 2 mg of blank or PFK15 MPs as described above on each side 
near the inguinal lymph nodes. After 7 days, draining lymph nodes and spleens were harvested for 
downstream analyses. Specifically, cells from the dLNs and spleens were plated and stimulated 
with 25 µg HEL in an in vitro recall assay for 72 hours to measure activation and effector cytokine 
(IFNγ) production. 
2.3.6 Adoptive Transfer Model of T1D 
1 x 107 splenocytes from BDC2.5 mice were injected i.v. into NOD.scid recipients as described by 
our laboratory [123]. Recipient animals were split into three groups. One cohort of recipients 
received 25 mg/kg PFK15 (Selleck) dissolved in DMSO prepared fresh as described and used in 
previous literature [152, 159, 160]; the second cohort received blank MPs, and the third cohort 
received PFK15 MPs (5 mg/kg PFK15). The dose of PFK15 MPs administered was based on 
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preliminary in vitro studies. Animals were treated every third day for two weeks. Body weights 
and blood glucose (BG) levels were monitored over the course of the experiments. Animals were 
deemed diabetic after two consecutive BG readings  350 mg/dL. Diabetic animals were sacrificed 
at indicated timepoints and peripheral blood, pancreata, and spleens were harvested for 
downstream analyses. 
2.3.7 Tissue Collection and Histological Assessment 
Pancreatic tissue was collected and fixed in 4% paraformaldehyde (PFA; Thermo Fisher 
Scientific) overnight at 4 C. Fixed tissue was processed and embedded in paraffin by the 
Histology Core Laboratory located at UPMC Children’s Hospital of Pittsburgh’s Rangos Research 
Center [161].  Embedded tissue was sectioned at 4 μm thickness and stained with hematoxylin and 
eosin (H&E) for histological examination of immune infiltration in pancreatic islets. Samples were 
imaged using a Nikon Eclipse E800 microscope (Nikon) and associated software.  
2.3.8 Immunofluorescent Staining 
Immunofluorescent staining was performed on paraffin embedded samples prepared as described 
above. Antigen retrieval was performed in sodium citrate buffers followed by overnight incubation 
with primary antibodies against insulin (1:100; Santa Cruz), FoxP3 (1:100; Abcam), and TUNEL 
staining as previously described [162]; all co-stained with DAPI (1:3000; Thermo Fisher 
Scientific). The following day, slides were incubated with Alexa Fluor 488 or 594 conjugated 
donkey anti- rabbit or rat secondary antibodies (Invitrogen). Samples were imaged using a Leica 
DMi8 inverted microscope (Leica) and LAS X Navigator software (Leica).  
61 
2.3.9 Statistical Analyses 
All data are presented as mean values ± standard error of the mean (SEM), with n indicating the 
number of independent experiments or animals. Student’s t-test or One- way ANOVA were used 
where appropriate. For survival studies, Kaplan-Meier analysis was used to measure significance 
of diabetes incidence. A p-value of p < 0.05 was considered significant for all statistical analyses. 
Histology and immunofluorescent images were generated using Photoshop. All statistics and 
graphs were generated using GraphPad Prism software.  
2.4 RESULTS 
2.4.1 Soluble PFK15 treatment reduces T cell activation induced glucose uptake and lactate 
secretion in a dose dependent manner in vitro  
T cell activation is accompanied by a metabolic switch to glycolysis, marked by increased glucose 
uptake and the subsequent fermentation of glucose to lactate [155]. We first confirmed whether 
the glycolysis inhibitor PFK15, a competitive inhibitor of a rate limiting enzyme in the glycolysis 
pathway PFKFB3, inhibited T cell metabolic reprogramming during activation [155]. Briefly, 
splenocytes from non- diabetic NOD animals were stimulated with the lectin mitogen 
concanavalin A (ConA), a global T cell activator dependent on T cell:APC interaction  ± 2.5 – 10 
µM PFK15 in vitro [163, 164]. After 48- 72 hours, glucose uptake was measured via staining with 
the fluorescent glucose analog 2-NBDG, and lactate secretion was measured in cell culture 
supernatants as previously described [110, 123, 155]. As expected, we observed increased glucose 
uptake in ConA activated NOD splenocytes, compared to cells left in media alone 48 hours post 
stimulation. Further, PFK15 treatment reduced glucose uptake in a dose dependent manner, with 
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a significant reduction observed with 10 µM PFK15 treatment (Figure 6A-B). Coinciding with 
this, ConA stimulation led to significant increases in lactate secretion, with PFK15 treatment 






































Figure 6. PFK15 treatment reduces parameters of glycolysis in activated CD4+ T cells. 
NOD splenocytes were stimulated 2.5 ug/mL ConA  ± PFK15 for 24-72 hrs. A, B. Representative histogram and 
statistical analysis showing 2-NBDG fluorescence and MFI of CD4+ T cells, indicative of glucose uptake 48 hrs post 
stimulation (n = 3). C.  Lactate measurements in cell culture supernatants (n = 3). All data are presented as the mean 
















2.4.2 Inhibiting glycolysis reduces CD4+ T cell responses to ConA stimulation in vitro, with 
minimal toxicity  
Glucose restriction, as well as glycolysis inhibition, have been shown to reduce CD4+ T cell growth 
and IFNγ secretion during activation [57, 107, 165, 166], however whether this occurs in T cells 
from the autoimmune prone NOD mouse remains unknown [57, 59, 60, 95, 107, 165, 166]. To 
assess this, we measured functional parameters of CD4+ T cell activation using the in vitro PFK15 
± ConA stimulation described in the previous section. After 72 hours in culture, we assessed early 
(CD69) and late (CD25) activation marker expression on CD4+ T cells, as well as IFNγ secretion 
and CD4+ T cell proliferation (Figure 7). Consistent with the literature, inhibiting glycolysis with 
PFK15 led to reduced expression of CD69 (Figure 7A) and CD25 (Figure 7B), diminished effector 
cytokine (IFNγ secretion) production (Figure 7C), and greatly inhibited CD4+ T cell proliferation 
(Figure 7D), with 5-10 µM of PFK15 having the most optimal effect. These data indicate that 
CD4+ T cells from the NOD mouse are susceptible to metabolic modulation, and provide evidence 










Figure 7. Inhibition of glycolysis suppresses CD4+ T cell activation and effector functions in vitro. 
Assessing the impact of glycolysis inhibition on diabetogenic CD4+ T cell responses in vitro. A. Frequency of CD4+ 
CD69+ T cells (n = 3).  B. Frequency of CD4+ CD25+ T cells (n = 3). C. ELISA analysis of IFN in cell culture 
supernatants 72 hrs post stimulation (n = 3). D. Representative histogram of CD4+ T cell proliferation assessed by cell 
proliferation dye violet (CPDV) dilution (n = 3). All data are presented as the mean ± SEM. (* = p < 0.05, ** = p < 
















Previous literature has demonstrated an ability for PFK15 treatment to induce apoptosis in 
transformed cells [112, 152]. To determine whether PFK15 reduced CD4+ T cell responses to 
ConA stimulation due to induction of apoptosis, and to better define a therapeutic dose, we 
assessed cell death in 48-hour cultures via Annexin V/propidium iodide (PI) staining by flow 
cytometry.  We observed a dose dependent reduction in viability of CD4+ T cells with PFK15 
treatment, with 10 µM demonstrating overt toxicity with a majority of cells not- viable at the 
indicated timepoint (Figure 8). Further, 5 µM PFK15 treatment reduced T cell viability compared 
to ConA stimulated cells only, however cell viability remained similar to cells in media alone, 
indicating an optimal therapeutic dose. Based on these data, 5 µM of PFK15 was used for the 
remainder of our studies with PFK15, as it demonstrated an ability to dampen CD4+ T cell 















Figure 8 PFK15 induces cell death in a dose dependent manner 
NOD splenocytes were stimulated 2.5 ug/mL ConA ± a dose titration of PFK15 for 48 hrs. Apoptosis was measured 














2.4.3 PFK15 MPs recapitulate soluble drug treatment in vitro, and dampen CD4+ T cell 
responses to ConA stimulation  
Systemic delivery of immunotherapies can have detrimental consequences, either through non- 
specific targeting, depletion of lymphocytes, and/ or suppression of global immunity; thereby 
altering treated patients’ ability to fend off possible infections [14, 156]. As glycolysis is an 
evolutionarily conserved pathway utilized not only by immune cells, but also by other cell types 
in the body, we aimed to determine whether controlled release of PFK15 near the pancreas would 
limit the activation of autoreactive CD4+ T cells, while limiting any associated systemic toxicities 
associated with PFK15 treatment. We developed porous PFK15 PLGA MPs to promote fast and 
sustained release of PFK15 in a specific microenvironment. To test the ability of these MPs to 
suppress T cell responses, we employed the same ConA stimulation protocol utilized in our soluble 
drug experiments using transwell plates, to allow for MPs to sit in an upper chamber, and release 
PFK15 into the bottom chamber where splenocytes were plated and stimulated (Figure 9A). Blank 
MPs loaded without drug were used as a vehicle control for PLGA MPs formulations. PFK15 MPs 
demonstrated fast release kinetics, with a majority of PFK15 released within 4 days of culture 
(Figure 9B). Scanning electron microscopy (SEM) of PFK15 MPs confirmed the porous nature of 
MP formulations (Figure 9C). For all in vitro studies, PFK15 MPs were administered to release 5 
µM of PFK15, the optimal dose determined from our dose titration studies (Figures 6-8).  
To confirm glycolysis inhibition, we measured lactate secretion in cell culture supernatants, 
and observed significant knockdown with PFK15 MP treatment, while blank MP treated cells were 
left unaffected (Figure 9D). In our assessment of T cell activation, PFK15 MPs had no impact on 
early activation (CD69 expression), but led to a significant reduction in the ability for CD4+ T cells 
to transition to late activation status (CD25 expression) (Figure 9E-F). Further, as with soluble 
drug, PFK15 MPs led to significant reductions in IFNγ secretion and T cell proliferation (Figure 
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9G-H). Blank MPs had no impact on T cell function, indicating the phenotypes we observed with 
PFK15 MP administration were due to release of PFK15 and not due to any effect of PLGA MPs 
in general. All in all, these data confirm that PFK15 MP treatment recapitulates our experiments 








































Figure 9. PFK15 MPs display quick kinetic release, and reduces T cell responses to ConA stimulation similarly 
to soluble drug. 
Assessing the impact of PFK15 MPs on diabetogenic CD4+ T cell responses in vitro. A. Schematic diagram detailing 
our experimental design.  B. Release kinetics of PFK15 MPs. C. Scanning electron micrograph of PFK15 MPs. D. 
Lactate measurements in cell culture supernatants (n = 3). E. Frequency of CD4+ CD69+ T cells (n = 3).  F. Frequency 
of CD4+ CD25+ T cells (n = 3). G. ELISA analysis of IFN in cell culture supernatants 72 hrs post stimulation (n = 
3). H. Representative histogram of CD4+ T cell proliferation assessed by cell proliferation dye violet (CPDV) dilution 












2.4.4 PFK15 MPs inhibit antigen- specific T cell responses in vivo, with no impact on global 
immune function  
Administration of PFK15 MPs to in vitro ConA stimulated NOD splenocytes decreased the 
activation, proliferation, and effector function of CD4+ T cells, however whether they are able to 
dampen responses to nominal antigens in vivo remained unknown (Figure 9). To test the use of 
PFK15 MPs in an in vivo model of T cell activation, non- diabetic NOD animals were immunized 
with hen egg lysozyme (HEL) emulsified in Complete Freund’s Adjuvant (CFA). On the same 
day, PFK15 or blank MPs were injected subcutaneously at sites near each of the inguinal draining 
lymph nodes (dLN). HEL- specific T cell responses were measured 1 week post immunization, 
when dLNs and spleens were harvested from blank MP and PFK15 MP treated animals. Cells from 
the dLNs and spleens were plated and stimulated with HEL in an in vitro recall assay for 72 hours 
to measure activation and effector cytokine (IFNγ) production (Figures 10-11).  
In the dLN, we observed no differences in the number of cells recovered from blank or PFK15 
MP treated animals, indicating that PFK15 treatment had no impact on T cell numbers and did not 
cause lymphopenia (Figure 10A). We also assessed expansion of HEL-specific CD4+ T cells by 
tetramer staining, and observed reduced frequencies of antigen specific T cells in response to 
stimulation with HEL from PFK15 treated animals, indicating decreased expansion (Figure 10B). 
Consistent with in vitro studies (Figure 7 and 9), HEL specific T cells failed to upregulate CD69 
upon encounter with their antigen, as evidenced by reduced activation marker expression 
compared to T cells from control blank MP treated animals (Figure 10C). Finally, T cells from the 
dLN of PFK15 MP treated animals secreted less IFNγ than dLN cells from blank MP treated 
animals, confirming that glycolysis inhibition reduces T cell responses to HEL immunization in 
vivo (Figure 10D).  
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Figure 10. PFK15 MPs inhibit antigen- specific T cell responses in the dLN. 
NOD animals were immunized with HEL emulsified in CFA, with animals receiving either blank or PFK15 MP 
treatment. 1 week post immunization, dLN cells were stimulated with HEL in an in vitro recall assay for 72 hours. A. 
Total number of cells isolated from the inguinal dLNs. B. Frequency of HEL specific T cells in the dLN. C. Frequency 
of HEL specific T cells expressing CD69. D. ELISA analysis of IFN in cell culture supernatants 72 hrs post 























We also assessed HEL- specific T cell responses from the spleens of blank and PFK15 MP 
treated animals, as a measurement of the impact MP delivery has on T cells at a site that’s not in 
close proximity to the local micromilieu where MPs were subcutaneously implanted. Similar to 
results obtained from the dLN, PFK15 MPs failed to cause a lymphopenia, as there were equal 
numbers of cells recovered from the spleens of blank and PFK15 MP treated animals (Figure 11A). 
In contrast to the reduced T cell responses caused by glycolysis inhibition in the dLN with PFK15 
MP treatment, we saw no differences in the frequency of HEL- specific T cells (Figure 11B), CD69 
expression on HEL- specific T cells (Figure 11C), or in the ability of splenocytes from PFK15 MP 
treated animals to secrete IFNγ in recall responses to HEL antigen in vitro compared to splenocytes 
from blank MP treated animals (Figure 11D). Together, these data, along with the data presented 
in Figure 10, demonstrate an ability to specifically reduce T cell responses to nominal antigen 
immunization in vivo, and more importantly provide evidence that delivery of PFK15 MPs have 
no impact on global immunity, as T cell responses in the spleen, at a site away from where PFK15 












Figure 11. PFK15 MPs do not affect T cell responses to HEL immunization in the spleen. 
NOD animals were immunized with HEL emulsified in CFA, with animals receiving either blank or PFK15 MP 
treatment. 1 week post immunization, splenocytes were stimulated with HEL in an in vitro recall assay for 72 hours. 
A. Total number of cells isolated from the spleens. B. Frequency of HEL specific T cells. C. Frequency of HEL 
specific T cells expressing CD69. D. ELISA analysis of IFN in cell culture supernatants 72 hrs post stimulation.  (n 





















2.4.5 Soluble PFK15 prevents, while PFK15 MP formulations delay T1D onset in vivo  
Glycolysis inhibition via PFK15 treatment reduced T cell responses to ConA stimulation in vitro, 
and to HEL immunization in vivo, indicating that PFK15 treatment may have therapeutic benefit 
in preclinical models of T1D, an autoimmune disorder whereby autoreactive T cells are aberrantly 
activated and target β cells for destruction. To test the preventative capabilities of PFK15 in a 
mouse model of T1D, we utilized an adoptive transfer model. Briefly, splenocytes from 
NOD.BDC2.5.TCR.Tg animals, a mouse model derived from the diabetogenic CD4+ specific 
BDC2.5 T cell clone, were adoptively transferred into immunodeficient NOD.scid recipients as 
previously described [121, 123]. This model leads to fulminant CD4+ T cell mediated diabetes in 
approximately 14 days. Recipient animals were divided into three cohorts: 1) control animals 
treated with blank MPs; 2) PFK15 MP treatment; 3) Soluble PFK15 treatment. MPs were 
administered subcutaneously near the spleen, as the pancreas in an effort to release PFK15 near 
the pancreas (Figure 12A). As expected, a majority (80%) of animals in the control group were 
hyperglycemic by the end of the study period. While 100% of animals remained diabetes free in 
the soluble PFK15 treatment group, 50% remained diabetes free in the PFK15 MP group (Figure 
12B). Although a portion of animals in the PFK15 MP treated group succumbed to diabetes, onset 
of disease was delayed compared to blank MP treated animals. Further, it’s not entirely surprising 
that soluble PFK15 treatment led to more robust protection from disease in comparison to PFK15 
MPs, as animals receiving MPs were administered 1/4th the total dose of animals receiving 
systemic delivery of soluble drug. Interestingly, PFK15 treatment in any form had no impact on 
body weights and did not cause lymphopenia, indicating that even systemic delivery did not cause 





Figure 12. PFK15 MPs delay T1D onset in an adoptive transfer model. 
The effect glycolysis inhibition has on Type 1 Diabetes onset was assessed using an adoptive transfer model. A. 
Schematic diagram of experimental design for adoptive transfer studies. B. Survival analysis of diabetes incidence in 
blank MP, PFK15 MP, and PFK15 treated groups. Kaplan-Meier survival analysis test was performed for statistical 
significance. C. Body weight measurements. D. Total cells isolated from spleens in mice from all three treatment 











2.4.6 Investigating the mechanisms leading to tolerance in PFK15 treated animals  
To determine the mechanisms leading to tolerance due to glycolysis inhibition in PFK15 treated 
animals, we performed a global histological assessment to assess changes in islet infiltration by 
H&E staining for gross histology, as well as immunofluorescent staining for insulin, TUNEL 
(indicator of apoptosis), and FoxP3 (Treg marker). Control animals displayed invasive insulitis 
and a loss in insulin staining, correlating with disease status. In contrast PFK15 soluble drug and 
MP treated animals had reduced islet infiltration with peri- islet insulitis observed, indicating an 
ability for immune cells to make it to pancreatic islets, albeit without the ability to completely 
penetrate and cause disease (Figure 13A-F). Further, PFK15 treatment was not associated with 
induction of apoptosis, as indicated by no appreciable differences observed by TUNEL staining of 
pancreatic tissue sections (Figure 12G-I). Finally, glucose restriction in the TME, and glycolysis 
inhibition during CD4+ T cell differentiation in vitro, have been shown to drive T cell exhaustion 
and/ or induce Treg generation, respectively [155]. To assess this, we measured FoxP3 expression 
in pancreatic tissue sections, and assessed T cell exhaustion markers CTLA-4, PD-1, and LAG-3 
on CD4+ T cells from the peripheral blood of a subset of protected animals who received PFK15 
soluble drug, and donor BDC2.5 animals to compare baseline levels. Interestingly, we observed 
increased FoxP3 expression in pancreatic islets of PFK15 treated animals compared to controls 
(Figure 13J-L), and an increased frequency of CD4+ T cells expressing immune inhibitory 
receptors CTLA-4, PD-1, and LAG-3 (Figure 13M). Together, these data demonstrate that the 
protective benefits associated with PFK15 treatment are due to induction of Tregs that reside in 
the islets and mediate protection against effector T cells. Moreover, increased IR expression could 
indicate the induction of T cell exhaustion, however, further studies are required to confirm these 
































































A-C. Representative H&E staining to assess islet infiltration in pancreatic sections. D-F. Representative 
pancreatic tissue immunostaining for insulin co-stained with DAPI. G-I. Representative pancreatic tissue 
TUNEL staining for apoptosis co-stained with DAPI. J-L. Representative pancreatic tissue immunostaining 
for FoxP3 co-stained with DAPI. M. Frequency of CD4+ T cells expressing CTLA-4, LAG-3, and PD-1 in the 
peripheral blood compared to control BDC2.5 animals at baseline. All data are presented as the mean ± SEM. 




In this study, we provide evidence that T cells from the autoimmune prone NOD mouse are 
susceptible to metabolic modulation with the glycolysis inhibitor PFK15 when stimulated in vitro 
with global T cell activator ConA and immunized with nominal antigen HEL in vivo. Moreover, 
PFK15 treatment had beneficial therapeutic capabilities, as we have demonstrated an ability to 
restrain autoreactive CD4+ T cell mediated damage of pancreatic β cells in an adoptive transfer 
model of T1D. Although the benefits associated with glycolysis inhibition of T cell proliferation 
and IFNγ secretion are not entirely novel, this is the first study testing the use of the inhibitor 
PFK15 to suppress T cell mediated autoimmunity in T1D [155]. Further, use of MPs delivering 
glycolysis inhibitors have never been reported or used in settings of autoimmunity, and underlies 
another novel aspect of this study.  
A limitation of the current study lies in the lack of an antigen- specific stimulus for T cell 
activation. Instead, we used the global T cell activator ConA, as it is more realistic to the other 
non- antigen specific alternative αCD3/αCD28 due to its reliance on APC and T cell interaction 
[163, 164]. However, these data provided proof of principle evidence suggesting that use of PFK15 
could have a therapeutic benefit in modulating aberrant T cell activation that occurs during the 
pathogenesis of T1D. Further, we performed an in vivo prevention study where PFK15 was able 
to prevent adoptive transfer of diabetes, indicating the results we obtained in our in vitro studies 
translated well to in vivo experiments. In light of this limitation and to expand on this study, we 
investigated the ability to modulate T cell glycolysis during activation with specific antigen in 
chapter 3, where we stimulated diabetogenic T cells from the NOD.BDC2.5 mouse with their 
peptide mimotope; thus allowing for an investigation into how glycolysis inhibition alters T cells 
responses to diabetes relevant antigens.  
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Use of PFK15 MPs were able to recapitulate soluble drug administration in vitro, and prevent 
diabetes onset in 50% of animals in adoptive transfer studies. These finding are important as 
treatment with 1/4th the total dose of PFK15 administered via MPs compared to the dose delivered 
systemically had therapeutic benefits. Although beneficial, we decided to focus the remainder of 
our studies for this work using soluble drug. However, MP therapies have shown great promise in 
the treatment of T1D in mouse models, and we plan to further optimize the dose and delivery of 
PFK15 to reduce systemic delivery and allow for a more targeted approach to use of glycolysis 
inhibitors [167].  
In an adoptive transfer study, PFK15 soluble drug and MP formulations were capable of 
delaying and in some cases completely prevent the onset of T1D, suggesting an ability to modulate 
autoreactive T cell responses. Specifically, we observed increased expression of FoxP3 within 
pancreatic islets of treated animals, indicating increased Tregs. Further, T cells in the peripheral 
blood of treated animals had increased expression of the checkpoint molecules CTLA-4, PD-1, 
and LAG-3, potentially indicative of possible T cell exhaustion [17, 29, 154, 155, 168]. Regarding 
Tregs, glycolysis inhibition has been shown to promote the differentiation of Tregs [71]. However, 
it remains unknown whether we actually induced the differentiation of Tregs, or whether reduced 
effector T cell responses due to PFK15 treatment selected for Tregs, allowing them to maintain 
their stability and mediate their suppressive function. Further studies are needed to confirm 
whether PFK15 mediated tolerance is dependent on Tregs, or whether an increased frequency of 
Tregs was observed due to selective targeting of effector T cells, thus leaving Treg frequency and 
function intact.  
In the TME, nutrient competition between tumors and T cells drives T cell exhaustion, 
indicating that reduced glycolytic flux may contribute to T cell hyporesponsiveness [108, 155]. 
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We observed increased expression of checkpoint molecules on T cells in the peripheral blood of 
PFK15 treated animals. This, along with the hyporesponsive phenotype of transferred T cells based 
on their inability to cause disease as efficiently as T cells in control animals indicates the induction 
of possible T cell exhaustion. However, the expression of IRs alone is not enough to mark 
exhausted T cell subsets, effector T cells transiently upregulate these molecules upon activation 
[155, 169]. Further experiments are required to fully understand the extent to which PFK15 
treatment induces T cell exhaustion. These studies were performed and are a part of the studies 
detailed in chapter 3.  
In conclusion, we demonstrated for the first time an ability to modulate autoreactive T cell 
effector function by specifically targeting the glycolysis pathway in T1D. Although the therapeutic 
benefits associated with glycolysis inhibition have been extensively reported in the literature, and 
have proven effective at controlling T cell responses during autoimmunity, targeting this pathway 
in T1D have remained largely unexplored. Moreover, our findings indicating an ability to 
prematurely exhaust CD4+ T cells by modulating their ability to utilize glycolysis is novel, and has 
never been reported in the literature. Although future experiments are required to further our 
understanding of the impact PFK15 has on T cell responses in T1D, these data suggest that use of 
metabolic inhibitors may be efficient in controlling autoreactive T cell responses and preventing 
disease onset in those genetically predisposed to autoimmunity.  
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3.0 GLYCOLYSIS INHIBITION INDUCES FUNCTIONAL AND METABOLIC 
EXHAUSTION OF CD4+ T CELLS IN TYPE 1 DIABETES 
This is an adaptation of the author’s version of the work. The definitive version is published in 
Frontiers in Immunology.  
 
“Glycolysis Inhibition induces Functional and Metabolic Exhaustion of CD4+ T cells in 
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In Type 1 Diabetes (T1D), CD4+ T cells initiate autoimmune attack of pancreatic islet β cells. 
Importantly, bioenergetic programs dictate T cell function, with specific pathways required for 
progression through the T cell lifecycle. During activation, CD4+ T cells undergo metabolic 
reprogramming to the less efficient aerobic glycolysis, similarly to highly proliferative cancer 
cells. In an effort to limit tumor growth in cancer, use of glycolytic inhibitors have been 
successfully employed in preclinical and clinical studies. This strategy has also been utilized to 
suppress T cell responses in autoimmune diseases like Systemic Lupus Erythematosus (SLE), 
Multiple Sclerosis (MS), and Rheumatoid Arthritis (RA). However, modulating T cell metabolism 
in the context of T1D has remained an understudied therapeutic opportunity. In this study, we 
utilized the small molecule PFK15, a competitive inhibitor of the rate limiting glycolysis 
enzyme 6-phosphofructo-2-kinase/fructose-2,6- biphosphatase 3 (PFKFB3). Our results 
confirmed PFK15 inhibited glycolysis utilization by diabetogenic CD4+ T cells and reduced T cell 
responses to β cell antigen in vitro. In an adoptive transfer model of T1D, PFK15 treatment 
delayed diabetes onset, with 57% of animals remaining euglycemic at the end of the study period. 
Protection was due to induction of a hyporesponsive T cell phenotype, characterized by increased 
and sustained expression of the checkpoint molecules PD-1 and LAG-3 and downstream 
functional and metabolic exhaustion. Glycolysis inhibition terminally exhausted diabetogenic 
CD4+ T cells, which was irreversible through restimulation or checkpoint blockade in vitro and in 
vivo. In sum, our results demonstrate a novel therapeutic strategy to control aberrant T cell 
responses by exploiting the metabolic reprogramming of these cells during T1D. Moreover, the 
data presented here highlight a key role for nutrient availability in fueling T cell function and has 
implications in our understanding of T cell biology in chronic infection, cancer, and autoimmunity. 
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3.2 INTRODUCTION 
Invasion of pancreatic islets by immune cells is a hallmark of Type 1 Diabetes (T1D), where the 
innate and adaptive immune systems work cooperatively to mediate damage of insulin- secreting 
β cells [33, 45]. This attack is largely orchestrated by self-reactive CD4+  T cells, which are 
fundamental drivers of disease pathology [45]. During their life cycle, CD4+ T cells rely on specific 
metabolic pathways to generate energy in the form of adenosine triphosphate (ATP) [59, 60]. 
However, it has become abundantly clear that these programs are not merely for energy production, 
but rather are necessary for the ability of T cells to carry out specialized effector capabilities, 
including interferon gamma (IFNγ) secretion [107]. During homeostasis, naïve CD4+ T cells utilize 
oxidative phosphorylation (OXPHOS) to support surveillance efforts and migration in the 
periphery. Upon encounter with antigen (i.e., islet β cells in T1D), activated T cells undergo robust 
metabolic reprogramming marked by a transition to the less efficient aerobic glycolysis [59, 60]. 
Although net energy obtained through the glycolysis pathway is far less than what is generated via 
OXPHOS (net gain of 2 versus approximately 36 ATP molecules, respectively), glycolysis is 
required to generate ATP quickly to support T cell activation, clonal expansion, and effector 
cytokine production [107].  
While distinct metabolic programs dictate T cell differentiation and function, a number of 
studies have also implicated nutrient availability as an important determinant of T cell fitness. This 
is especially evident in the tumor microenvironment (TME), where reports have demonstrated that 
cancer cells outcompete T cells for key nutrients like glucose and amino acids, which are required 
for acquisition of specialized effector functions [108]. This battle for metabolic substrates, along 
with persistent antigen exposure, has been implicated in suppressing immune responses and 
driving T cell exhaustion. Exhaustion is defined as a state of dysfunction characterized by 
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increased expression of immune inhibitory receptors (IRs) like programmed cell death protein- 1 
(PD-1) and lymphocyte Activation Gene-3 (LAG-3), and a marked decrease in T cell effector 
functions that allow tumors to go unabated by the immune system [108, 169]. Although metabolic 
insufficiencies demonstrate a major hurdle in reinvigorating tumor-specific T cell responses, the 
opposite is plausible in settings of autoimmunity, where enforcing T cell exhaustion by targeting 
metabolism may be a novel mechanism by which tolerance to self-antigens is restored [129].  
Efforts to target the glycolysis pathway have been successfully employed to limit tumor growth 
and metastasis in cancer, with a number of these inhibitors undergoing FDA clinical trials [15, 
152, 159, 170]. One such inhibitor, PFK15, is a small molecule inhibitor of 6-phosphofructo-2-
kinase/fructose-2,6- biphosphatase 3 (PFKFB3), an enzyme involved in a cells commitment to 
metabolize glucose via glycolysis [152, 159, 160]. Regarding autoimmunity, researchers have 
successfully targeted metabolism as a means to control T cell responses in models of Systemic 
Lupus Erythematosus (SLE), Multiple Sclerosis (MS), and Rheumatoid Arthritis (RA), however 
the ability to target metabolic pathways to control T1D have been largely unstudied [84, 86, 87, 
115] . Previously, our laboratory demonstrated that redox modulation via disruption of third signal 
reactive oxygen species (ROS) impeded T cell metabolic reprogramming to glycolysis, and altered 
the diabetogenic potential of autoreactive CD4+  T cells [123]. However, whether specifically 
modulating the glycolysis pathway could be used to limit the activation of autoreactive CD4+ T 
cells and prevent attack of pancreatic β cells deserves further exploration. Based on these previous 
studies, we hypothesized that use of the glycolysis inhibitor PFK15 would inhibit the activation, 
proliferation, and effector capabilities of autoreactive CD4+ T cells, thereby delaying the onset of 
T1D. Herein, we demonstrate that PFK15 treatment interrupts metabolic reprogramming to 
glycolysis upon activation with β cell antigen, and reduces T cell responses in vitro, while delaying 
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the onset of T1D in vivo. These results were, in part, due to increased and sustained expression of 
checkpoint molecules PD-1 and LAG-3 and downstream functional and metabolic exhaustion of 
diabetogenic T cell clones. These findings support that inhibition of glycolysis drives T cell 
exhaustion, and that metabolic modulation may serve as a novel therapeutic target to control T cell 
metabolism and restore tolerance in autoimmunity.  
3.3 MATERIALS AND METHODS 
3.3.1 Animals 
Non-obese diabetic (NOD), NOD.BDC2.5.TCR.Tg (BDC2.5) and NOD.scid mice were 
maintained under specific pathogen free conditions in the animal facility located at the Rangos 
Research Center within UPMC Children’s Hospital of Pittsburgh. All animal experiments were 
approved by the University of Pittsburgh’s Institutional Animal Care and Use Committee (IACUC; 
Assurance Number: D16-00118). Male and female mice aged 6-12 weeks old were used in all 
experiments.  
3.3.2 Splenocyte isolation and in vitro stimulation 
BDC2.5 animals were sacrificed, and spleens harvested and homogenized into single cell 
suspensions as described [123]. Red blood cells were lysed using RBC lysis buffer (Sigma 
Aldrich). For in vitro experiments, 2.5 x 106 splenocytes were plated per well in 24 well plates and 
stimulated with 0.05 M of their peptide mimotope ± 5 M PFK15 soluble drug (Selleck), 0.2-1 
mM 2-DG (Sigma Aldrich), 25-50 M YN1 (Millipore Sigma), or 2.5-5 M PFK158 (Selleck) for 
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24-72 hours. Cells and culture supernatants were collected for downstream flow cytometry, 
western blotting, ELISA, and lactate measurement analyses.  
3.3.3 Flow Cytometry 
5x105 – 1x106 cells were harvested at indicated timepoints and surface stained for flow cytometric 
analysis as described [123]. Briefly, cells were incubated with Fc block (CD16/CD32; BD 
Biosciences) for 15 minutes prior to staining for flow cytometry. Surface staining was performed 
at 4°C using CD4-PE, PerCP-Cy5.5, or APC (Clone RM4-5), CD69-PeCy7 (Clone H1.2F3), 
CD25-APC (Clone PC61), CD223-PE (LAG-3; Clone C9B7W), CD279-BV480 (PD-1; Clone 
J43) antibodies (BD Biosciences) in FACS buffer (1% BSA in PBS). For proliferation 
measurements, splenocytes were labeled with Cell Proliferation Dye Violet (BD Bioscience) per 
manufacturer’s instructions prior to stimulation. After indicated timepoints, cells were harvested, 
and surface stained as described above. In some instances, cells were fixed in 2% PFA for 15 
minutes at 4°C (Thermo Fisher Scientific). Cells were stored at 4°C until time of analysis.  
To measure glucose uptake, splenocytes were incubated with 100 μM of the fluorescent 
glucose analog 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl) Amino)-2-Deoxyglucose (2-NBDG; 
Cayman Chemical) for 10 minutes at 37°C prior to harvest as described [110, 123]. Cells were 
washed with PBS and surface stained for CD4 expression and analyzed live by flow cytometry. 
To measure fatty acid uptake, cells were harvested, surface stained for CD4 expression, and 
incubated with the fluorescent fatty acid BODIPY FL C16 (4,4-Difluoro-5,7-Dimethyl-4-
Bora-3a,4a-Diaza-s-Indacene-3-Hexadecanoic Acid; Invitrogen) in serum-free warm PBS 
for 30 minutes at 37°C. Cells were washed with PBS and analyzed live by flow cytometry. 
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To assess mitochondrial function, Day 14 BDC2.5 T cell clones were harvested, surface 
stained for CD4 expression, and incubated with MitoTracker green, MitoSOX red, or TMRE 
(tetramethylrhodamine, ethyl ester, perchlorate; Invitrogen) in warm PBS at 37°C for 15-30 
minutes. Cells were washed with PBS and analyzed live by flow cytometry as described previously 
[110]. For all flow cytometry studies, fluorescence was measured using a FACS Aria II flow 
cytometer (BD Biosciences). All data were analyzed using FlowJo software (v10.5.3) and samples 
were gated on CD4+ cells. Forward scatter of CD4+ T cells was also determined by flow cytometry. 
3.3.4 Preparation of Protein Lysates and Western Blotting 
Cells were lysed by sonication in anti-pY lysis buffer (50 mM Tris pH 8.0, 137 mM NaCl, 10% 
glycerol, 1% NP-40, 1 mM NaF, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 2 mM Na3VO4, and 1 
mM PMSF). Protein concentration was determined by Bicinchoninic acid protein (BCA) assay 
(Thermo Fisher Scientific). 25 μg of protein per sample were boiled in 6x Lammaeli buffer 
(BIORAD) for 5 minutes and separated on 4-20% gradient SDS-PAGE gels (BIORAD). Samples 
were then transferred to PVDF membranes for 2 hours in 3% MeOH Tris-Glycine Transfer buffer 
(BIORAD). Western blots were blocked in 5% non-fat dry milk in Tris-buffered Saline with 1% 
Tween-20 (TBST). Blots were probed with the following antibodies in 5% BSA/TBST overnight 
at 4°C: Glut-1, CPT1α (1:1000; Abcam), HK2, PFKFB3, LDHA (1:1000; Cell Signaling), and β-
actin as a loading control (1: 10,000; Sigma- Aldrich). Membranes were washed with TBST and 
incubated with HRP-conjugated goat anti-rabbit or rabbit anti-mouse (Jackson ImmunoResearch 
1:10,000) secondary antibodies for 2 hrs in 5% non- fat milk/TBST at room temperature. 
Chemiluminescence was detected using SuperSignal West Pico PLUS Chemiluminescence 
solution (Thermo Fisher Scientific) and the iBright FL1500 imaging system (Invitrogen).  
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3.3.5 Lactate and Cytokine Measurements 
Cell culture supernatants from in vitro experiments were harvested and used to measure IL-2, 
IFNγ, and TNFα by ELISA. Antibody pairs for IFNγ and IL-2 ELISAs were purchased from BD 
Biosciences, and TNFα ELISA kits were purchased from R&D according to the manufacturer’s 
instructions. ELISAs were read on a SpectraMax M2 microplate reader (Molecular Devices) and 
data analyzed using SoftMax Pro version 7.0.2 software (Molecular Devices). Lactate, a byproduct 
of aerobic glycolysis, was measured using the Lactate Plus meter and test strips per manufacturer’s 
instructions (Novus Biologics).  
3.3.6 CD4+ T cell Isolation and ex vivo Activation and Expansion 
Spleens from BDC2.5 animals were harvested and homogenized into single cell suspensions as 
described above. CD4+ T cells were isolated by magnetic bead separation using the EasySep CD4+ 
T cell Negative Selection isolation kit (StemCell) per the manufacturer’s instructions. For ex vivo 
activation, 6 well plates were coated with plate bound αCD3 (BD Biosciences; 1 ug/mL) in PBS 
for at least 3 hours in a cell culture incubator (37 C, 5% CO2). The antibody solution was decanted, 
and 5x106 isolated cells were plated with 100 U/mL IL-2 and 1 ug/mL soluble αCD28 (BD 
Biosciences) for 3 days in a cell culture incubator. After 3 days in culture, cells were harvested 
and transferred to T75 flasks with an additional 100 U/mL IL-2 for expansion. At the end of the 
3-day expansion in IL-2, cells were isolated, counted, and washed with sterile PBS for adoptive 
transfer experiments.  
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3.3.7 Adoptive Transfer Model of T1D 
1 x 107 ex vivo activated CD4+ T cells from BDC2.5 mice (described above) were injected i.p. into 
NOD.scid recipients. For initial prevention studies, recipient animals were split into two groups. 
One cohort of recipients received 25 mg/kg PFK15 (Selleck) dissolved in 5% DMSO + 45% 
PEG300 + 1% Tween80 + 49% ddH2O prepared fresh; the other cohort received vehicle control 
every other day for 2 weeks. In reversibility studies, recipient animals were placed into one of the 
following treatment groups: 1) Vehicle Control, 2) PFK15 + IgG (Isotype controls for PD-1 and 
LAG-3 blocking antibodies; 200 μg each per treatment), or 3) PFK15 + 200 μg PD-1 (clone 
J43; BioXCell), + 200 μg  LAG-3 (clone C9B7W; BioXCell) as previously described [30, 110]. 
Animals were treated every other day for two weeks, with checkpoint blockade or IgG treatment 
initiated during the second week. Body weights and blood glucose (BG) levels were monitored 
over the course of the experiments. Animals were deemed diabetic after two consecutive BG 
readings  350 mg/dL. Diabetic animals were sacrificed at indicated timepoints and peripheral 
blood, pancreata, and spleens were harvested for downstream analyses. 
3.3.8 Tissue Collection and Histological Assessment 
Pancreatic tissue was collected and fixed in 4% paraformaldehyde (PFA; Thermo Fisher 
Scientific) overnight at 4 C. Fixed tissue was processed and embedded in paraffin by the 
Histology Core Laboratory located at UPMC Children’s Hospital of Pittsburgh’s Rangos Research 
Center [161].  Embedded tissue was sectioned at 4 μm thickness and stained with hematoxylin and 
eosin (H&E) for histological examination of immune infiltration in pancreatic islets. Samples were 
imaged using a Nikon Eclipse E800 microscope (Nikon) and associated software.  
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3.3.9 Immunofluorescent Staining 
Immunofluorescent staining was performed on paraffin embedded samples prepared as described 
above. Antigen retrieval was performed in either sodium citrate or Tris-EDTA buffers followed 
by overnight incubation with primary antibodies against insulin (1:100; Santa Cruz), CD3 (1:100; 
Abcam), and PD-1 (1:50; Abcam) all co-stained with DAPI (1:3000; Thermo Fisher Scientific). 
The following day, slides were incubated with Alexa Fluor 488 conjugated donkey anti- rabbit 
secondary antibody (Invitrogen). Samples were imaged using a Leica DMi8 inverted microscope 
(Leica) and LAS X Navigator software (Leica).  
3.3.10 Maintenance of BDC2.5 T cell Clones 
CD4+ MHC-II restricted BDC2.5 T cells, a generous gift from Dr. Kathryn Haskins (University of 
Colorado), were maintained in supplemented DMEM as previously described [38, 122, 171, 172]. 
Briefly, BDC2.5 T cells were cultured in T-25 flasks with  membrane (antigen), irradiated NOD 
splenocytes (antigen presenting cells: APC), and EL-4 supernatant (source of IL-2) for 2 weeks in 
a cell culture incubator. For mechanistic studies, a subset of flasks were treated with 5 M PFK15 
every third day over the course of the restimulation period. Day 8 and 14 T cells and culture 
supernatants were harvested for downstream analyses. Similarly, for reinvigoration studies, 
untreated and PFK15 treated T cells were put into restimulation flasks ± 5g/mL PD-1 (clone 
J43; BioXCell), LAG-3 (clone C9B7W; BioXCell), or PD-1 + LAG-3. Cells were treated 
every third day for 2 weeks.  
92 
3.3.11 ADP/ATP Ratio Measurements 
Day 14 control and PFK15 treated T cell clones were harvested and assayed for the ADP/ATP 
ratio per the manufacturer’s instructions (Millipore Sigma).  
3.3.12 Statistical Analyses 
All data are presented as mean values ± standard error of the mean (SEM), with n indicating the 
number of independent experiments or animals. Student’s t-test, One- way ANOVA, or Two-way 
ANOVA were used where appropriate. For survival studies, Kaplan-Meier analysis was used to 
measure significance of diabetes incidence. A p-value of p < 0.05 was considered significant for 
all statistical analyses. Histology and immunofluorescent images were generated using Photoshop. 
All statistics and graphs were generated using GraphPad Prism software.  
3.4 RESULTS 
3.4.1 PFK15 interrupts metabolic reprogramming to glycolysis and reduces T cell effector 
functions during activation  
To determine the effect of glycolysis inhibition on the activation and subsequent metabolic 
reprogramming of autoreactive CD4+  T cells in T1D, we stimulated splenocytes from 
NOD.BDC2.5.TCR.Tg animals in vitro with their cognate peptide mimotope (MM) ± PFK15 (a 
PFKFB3 inhibitor; Figure 14A), as previously described [123]. PFK15 treated BDC2.5 
splenocytes failed to upregulate glycolysis-associated proteins glucose transporter-1 (Glut-1), 
hexokinase 2 (HK2), PFKFB3, and lactate dehydrogenase A (LDHA) in response to MM 
stimulation compared to T cells stimulated without treatment (Figure 14B). Additionally, PFK15 
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treatment decreased glucose (2-NBDG) uptake by CD4+ T cells upon stimulation to levels similar 
to T cells in media alone (Figure 14C-D). A significant reduction in 2-NBDG fluorescence from 
treated CD4+ T cells was most likely due to reduced expression of Glut-1 (Figure 14B), indicating 
decreased capacity to engage in aerobic glycolysis [37, 123]. Utilization of the glycolysis pathway 
by CD4+ T cells is accompanied by increased secretion of the by-product lactate [59, 60, 121, 123]. 
Splenocytes stimulated with MM alone displayed a significant increase in lactate secretion in cell 
culture supernatants as expected, indicating increased glycolytic flux (Figure 14E). In comparison, 
PFK15 treated splenocytes secreted less lactate compared to MM stimulated T cells, further 
confirming an inability to metabolically transition to glycolysis upon encounter with β cell 






























Figure 14. PFK15 treatment inhibits metabolic reprogramming to glycolysis during T cell activation. 
NOD.BDC2.5 splenocytes were stimulated with their cognate peptide MM ± PFK15 for 24-72 hrs. A. Schematic 
diagram displaying the mechanism of action of PFK15. B. Representative western blot analysis of glycolysis proteins 
in untreated, MM stimulated, and MM+ PFK15 treated splenocytes after 48 hrs in culture. C, D. Representative 
histogram and statistical analysis showing 2-NBDG fluorescence and MFI of CD4+ T cells, indicative of glucose 
uptake 48 hrs post stimulation (n = 3). E. Lactate measurements in cell culture supernatants (n = 6). All data are 








As bioenergetics and T cell function are intricately linked, we next determined the impact of 
glycolysis inhibition on the activation, proliferation, and effector capabilities of BDC2.5 T cells. 
While activated CD4+ T cells displayed increased forward scatter (FSC) compared to unstimulated 
controls, indicative of increased cell growth, PFK15 treatment resulted in reduced FSC compared 
to stimulated T cells, indicating inhibited growth (Figure 15A). We then assessed proliferative 
capacity by measuring cell proliferation dye violet (CPDV) dilution by CD4+ T cells in all three 
treatment groups. MM stimulated T cells displayed robust proliferation in response to antigen; 
however, PFK15 treatment significantly reduced this response (Figure 15B-C). 
To interrogate the activation status of PFK15 treated T cells, expression of the early activation 
marker CD69, and the late activation marker and high- affinity interleukin-2 (IL-2) receptor CD25, 
was measured 48-72 hours post stimulation on CD4+ T cells by flow cytometry (Figure 15D-E). 
There were no appreciable differences in the expression of CD69 in stimulated or PFK15 treated 
groups indicating that PFK15 treatment does not interfere with early activation (Figure 15D). 
Conversely, CD25 expression was significantly decreased with PFK15 treatment, suggesting an 
inability to fully transition to late activation status when glycolysis is inhibited (Figure 15E). Since 
glycolysis is required for acquisition of effector functions [107], we interrogated this ability by 
kinetically measuring IL-2, tumor necrosis factor alpha (TNFα), and IFNγ in cell culture 
supernatants (15F-H). ELISA analysis revealed a reduced ability to secrete all three cytokines. The 
phenotype we observed was due to specific targeting of PFKFB3, as treatment of BDC2.5 
splenocytes with the prototypical glycolysis inhibitor 2-Deoxy-D-glucose (2-DG), a non- 
metabolizable glucose analog, was only capable of dampening IFNγ secretion, but not IL-2 or 
TNFα (Figure 26; Appendix A). However, activation of BDC2.5 splenocytes with two other 
known PFKFB3 inhibitors YN1 and PFK158 recapitulated our data with PFK15 (Figure 26; 
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Appendix A), further implicating glycolysis, and more specifically PFKFB3, as a vital metabolic 













































Figure 15. Inhibiting glycolysis suppresses CD4+ T cell responses to  cell antigen in vitro. 
Assessing the impact of glycolysis inhibition on diabetogenic CD4+ T cell responses in vitro. A. Representative 
histogram measuring forward scatter (FSC). B, C. Representative histogram and statistical analysis of CD4+ T cell 
proliferation assessed by cell proliferation dye violet (CPDV) dilution (n = 3). D. Frequency of CD4+ CD69+ T cells 
(n = 5). E. Frequency of CD4+ CD25+ T cells (n = 6). F, G, H. ELISA analysis of IL-2, TNF, and IFN in cell culture 
supernatants 24-72 hrs post stimulation (n = 3-4). All data are presented as the mean ± SEM. (* = p < 0.05, ** = p < 









3.4.2 Targeting glycolysis delays the onset of T1D in an adoptive transfer model  
Based on the ability of PFK15 treatment to reduce BDC2.5 T cell responses, we examined the 
impact of glycolysis inhibition on the onset of diabetes using an adoptive transfer model (Figure 
16A). Here, isolated CD4+  T cells from the spleens of NOD.BDC2.5.TCR.Tg animals were 
activated and expanded ex vivo with plate- bound ɑCD3/ɑCD28 and EL-4 supernatant as a source 
of IL-2 as previously described [173]. We confirmed activation by measuring proinflammatory 
cytokine secretion in culture supernatants 3 days post activation, and observed significant levels 
of TNFα and IFNγ in BDC2.5 T cell cultures prior to adoptive transfer (Figure 27). Activated T 
cells were transferred via intraperitoneal (i.p.) injection into immunodeficient NOD.scid 
recipients. A cohort of animals received 25 mg/kg of PFK15 treatment beginning on the day of the 
adoptive transfer. Animals were treated every other day for two weeks, and monitored for drug 
related toxicity (body weight) and diabetes onset (BG ≥ 350 mg/dl). 100% of control animals 
exhibited diabetes 7 days post-transfer, however PFK15 treatment delayed disease onset, with 57% 
of animals remaining diabetes free for the duration of the study, with no appreciable weight loss 
observed (Figure 16B-C). Pancreases from control animals exhibited invasive insulitis, while 
protected animals treated with PFK15 displayed peri- islet insulitis as observed via H&E staining 
(Figure 16D-E). In agreement with this, immunofluorescent (IF) staining for the T cell marker 
CD3 revealed reduced T cell infiltration into the islets of PFK15 treated animals corresponding to 
an inability for T cells to completely penetrate the islets (Figure 16F-G). As expected, loss of 
insulin staining was observed in diabetic controls, with retention of insulin staining observed in 
PFK15 treated animals, correlating with disease status (Figure 16H-I). Lastly, PFK15 treatment 
had no impact on circulating CD4+ T cell frequencies in the peripheral blood, however reduced 
CD4+ T cell percentages were observed in the spleens of treated animals, indicating reduced 
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expansion of PFK15 treated T cells (Figure 16J). Analysis of CD25 on CD4+ T cells in control and 
PFK15 treated animals revealed a significant decrease in the percentage of CD4+ CD25+ T cells in 
the periphery, however a higher percentage of CD4+ T cells expressed CD25 in the spleens of 
treated animals compared to controls (Figure 16K). Although a larger percentage of CD4+ T cells 
in the spleens of treated animals expressed CD25, treated animals had less CD4+ T cell percentages 
in the spleens, indicating possible sequestration of effector- like T cells in the spleen compared to 
control animals, as glycolysis is required for proper T cell migration to sites of inflammation [174]. 
Together, these data indicate that metabolic modulation by PFK15 treatment alters the 
diabetogenic potential of activated CD4+ T cells, thereby reducing the immunopathological 





























Figure 16. PFK15 treatment alters the diabetogenic potential of autoreactive CD4+ T cells and delays adoptive 
transfer of Type 1 Diabetes. 
The effect glycolysis inhibition has on Type 1 Diabetes onset was assessed using an adoptive transfer model. A. 
Schematic diagram of experimental design for adoptive transfer studies. B. Survival analysis of diabetes incidence in 
vehicle control and PFK15 treated groups. Kaplan-Meier survival analysis test was performed for statistical 
significance. C. Body weight measurements. D, E. Representative H&E staining to assess islet infiltration in 
pancreatic sections. F, G. Representative pancreatic tissue immunostaining for the T cell marker CD3 co-stained with 
DAPI. H, I. Representative pancreatic tissue immunostaining for insulin co-stained with DAPI. J. Frequency of CD4+ 
T cells in the peripheral blood and spleens of PFK15 treated and control animals. K. Frequency of CD4+ CD25+ T 
cells in the peripheral blood and spleens. All data are presented as the mean ± SEM. (n = 6-7 animals/ group; ** = p 




3.4.3 PFK15 Treatment increases Expression of Checkpoint Molecules PD-1 and LAG-3 on 
CD4+ T cells  
In the tumor microenvironment (TME), metabolic restriction leads to increased IR expression and 
subsequent T cell exhaustion [108]. To investigate the mechanisms leading to T cell 
hyporesponsiveness and protection in PFK15 treated animals, we measured known markers of 
exhaustion, PD-1 and LAG-3, in the peripheral blood and spleens from control and PFK15 treated 
animals. Consistent with a hyporesponsive phenotype, PFK15 treatment led to significantly 
increased frequencies and expression of PD-1+ (Figure 17A-C) and LAG-3+ CD4+ T cells (Figure 
17D-F) in the peripheral blood and spleens. Since T cell exhaustion is associated with increased 
expression of multiple immune inhibitory receptors (IRs), we assessed co-expression of PD-1 and 
LAG-3 and found that T cells from PFK15 treated animals retained high expression of both PD-1 
and LAG-3 on circulating CD4+ T cells and T cells in the spleens (Figure 17G-H). Effector T cells 
transiently upregulate checkpoint molecules early during activation to temper their initial response 
and clonal burst [169, 175]. To phenotypically characterize differences between PD-1+ LAG-3+ T 
cells in control and PFK15 treated animals, we measured the percentage of PD-1+ LAG-3+ T cells 
expressing the activation marker, CD25. Strikingly, we observed a higher percentage of PD-1+ 
LAG-3+ T cells in the peripheral blood of control animals expressing CD25, indicative of an 
effector phenotype, while PD-1+ LAG-3+ T cells in PFK15 treated animals had decreased CD25 
expression, consistent with an exhaustion phenotype (Figure 17I). Similar to our analysis of CD25 
on CD4+ T cells in Figure 16K, no differences in CD25 expression were observed in the spleen of 
control and PFK15 treated animals, providing further evidence for sequestration of effector like T 
cells due to the importance of both glycolysis and PD-1 signaling in T cell trafficking [167, 174]. 
Finally, to determine the impact glycolysis inhibition had on T cell responses in the pancreas, we 
stained pancreatic sections for PD-1. Indeed, PFK15 treated animals displayed increased PD-1 
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staining in the pancreatic islets compared to diabetic control animals (Figure 17J-K). These results 
demonstrate that PFK15 treatment results in increased frequency of CD4+ T cells expressing 
checkpoint molecules PD-1 and LAG-3 in vivo, suggesting that inhibition of glycolysis induces 






































Figure 17. Inhibition of glycolysis results in increased expression of PD-1 and LAG-3 on CD4+ T cells. 
PD-1 and LAG-3 expression were assessed on CD4+ T cells in PFK15 treated and control animals. A, B. 
Representative histogram and statistical analysis measuring the frequency of PD-1+ CD4+ T cells in the peripheral 
blood and spleen of PFK15 treated and control animals. C. Statistical analysis of PD-1 expression (MFI) on CD4+ T 
cells in the peripheral blood and spleens. D-E. Representative histogram and statistical analysis measuring the 
frequency of LAG-3+ CD4+ T cells in the peripheral blood and spleen of PFK15 treated and control animals. F. 
Statistical analysis of LAG-3 expression (MFI) on CD4+ T cells in the peripheral blood and spleens of PFK15 and 
control animals. G, H. Representative flow plots and statistical analysis measuring PD-1 and LAG-3 co-expression 
on CD4+ T cells in the peripheral blood and spleen of PFK15 treated and control animals. I. Statistical analysis of the 
frequency of PD-1+ LAG-3+ CD4+ T cells expressing CD25. J, K.  Representative pancreatic tissue immunostaining 
for PD-1 co-stained with DAPI. All data are presented as the mean ± SEM.  (n = 6-7 animals/ group; * = p < 0.05, ** 






3.4.4 Modulating glycolysis leads to functional and metabolic exhaustion of diabetogenic 
CD4+ T cell Clones 
To further substantiate evidence of T cell exhaustion induction by PFK15 treatment, we performed 
mechanistic studies in vitro using the BDC2.5 T cell clone maintained on a 2-week restimulation 
schedule [38, 122, 171, 172]. This 2- week period allows for the treatment of T cells with PFK15 
on a similar regimen to our in vivo study. Consistent with our in vivo data, sustained PFK15 
treatment of BDC2.5 T cell clones significantly increased the expression of PD-1 and LAG-3 alone 
on CD4+ T cells (Figure 18A-C). However, while a hallmark of T cell exhaustion is the expression 
of checkpoint molecules, expression of these proteins alone is not indicative of exhaustion, as these 
molecules are upregulated transiently on the surface of newly activated T cells [169]. We 
confirmed this by kinetically measuring PD-1 and LAG-3 co-expression on days 4, 8, and 14 post 
stimulation on CD4+ T cells from untreated and PFK15 treated flasks (Figure 18D), and quantified 
the percentage of CD4+ T cells co-expressing both PD-1 and LAG-3 on day 14 (Figure 18E). 
BDC2.5 T cells upregulated both PD-1 and LAG-3 early (day 4) after activation, however by Day 
8 most untreated CD4+ T cells began to downregulate expression of the checkpoint molecules as 
predicted, with an even further downregulation evident by Day 14 (Figure 18D-E) [175]. 
Interestingly, PFK15 treated T cells displayed increased and sustained expression of PD-1 and 
LAG-3 over the course of the 14-day restimulation, with a majority of T cells expressing both PD-
1 and LAG-3 on Day 14 (Figure 18D-E). Concomitant with this, PFK15 treated T cell clones had 
decreased expression of CD25 compared to control flasks, confirming that PD-1 and LAG-3 
expression on PFK15 treated T cells occurred independently of late T cell activation (Figure 18F-
G). 
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During exhaustion, progressive loss of function occurs in a hierarchical manner, with high 
proliferative capacity and IL-2 production lost first, followed by a reduced ability to produce TNFα 
and IFNγ [169, 175, 176]. We assessed these parameters in order to link PD-1 and LAG-3 
expression with functional measures of T cell fitness. While control BDC2.5 T cells expanded 9-
fold, treated T cells proliferated significantly less, with a mean 5-fold expansion (Figure 18H). 
Coinciding with this, we measured IL-2 production in culture supernatants on days 8 and 14 post 
stimulation by ELISA and found significantly more IL-2 accumulated in cultures treated with 
PFK15 (Figure 18I), indicating a reduced ability to consume IL-2 as a growth factor compared to 
control T cell cultures. Reduced consumption of IL-2 was likely due to the significantly decreased 
expression of the high affinity IL-2 receptor CD25 observed in PFK15 treated T cell cultures 
(Figure 18F-G). Further, the levels of IL-2 in PFK15 treated BDC2.5 cultures were similar to the 
amount of IL-2 supplemented into restimulation cultures from EL-4 supernatant (gray dotted line 
on the graph). We also measured the effector cytokines TNFα and IFNγ in cell culture supernatants 
on days 8 and 14 post stimulation, both of which were significantly reduced upon treatment with 
PFK15 (Figure 18J-K). In sum, these data indicate that targeting glycolysis leads to severe 
exhaustion of diabetogenic CD4+ T cell clones, and suggest this as the mechanism by which PFK15 















Figure 18. PFK15 treated T cell clones are functionally exhausted. 
BDC2.5 T cell clones were treated with PFK15 over the course of a 2- week restimulation period to perform mechanistic studies investigating whether glycolysis 
inhibition induces functional exhaustion of CD4+ T cells. A, B, C. Representative histograms and statistical analysis assessing PD-1 and LAG-3 expression on 
control and PFK15 treated BDC2.5 T cell clones (n = 4). Cells were gated on CD4+ T cells. D. Representative flow plots measuring PD-1 and LAG-3 co-expression 
on PFK15 treated and control BDC2.5 T cell clones on days 4, 8, and 14 post stimulation. Cells were gated on CD4+ T cells. E. Statistical analysis of the percentage 
of BDC2.5 T cells co-expressing PD-1 and LAG-3 in control and treated flasks on day 14 (n = 4). F, G. Representative histogram and statistical analysis of the 
frequency of control and PFK15 treated BDC2.5 T cells expressing CD25 (n = 3). Cells were gated on CD4+ T cells. H. Fold expansion of treated and control 
BDC2.5 T cells (n = 5). I, J, K. ELISA analysis of IL-2, TNF, and IFN in culture supernatants on days 8 and 14 post stimulation (n = 4). All data are presented 
as the mean ± SEM. (** = p < 0.01, *** = p < 0.005, **** = p < 0.0001). 
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Functional exhaustion of T cells is associated with downstream metabolic consequences. 
Generally speaking, exhausted T cells are thought to be metabolically deficient, with a majority of 
metabolic flux supporting cell survival, and limited reserve for fueling effector functions [154].  As 
PFK15 treated T cell clones were functionally exhausted, we wanted to determine whether this 
phenotype correlated with decreased metabolic fitness as has been reported in the literature [141, 
154, 177]. To begin our investigation, we measured relative adenosine diphosphate (ADP) and 
ATP levels, and calculated the ADP/ATP ratio from Day 14 control and PFK15 treated T cell 
clones. While there was no difference in the relative levels of ADP, relative ATP levels were 
significantly reduced upon PFK15 treatment, indicating decreased metabolic flux (Figure 19A-B). 
While control T cells had a low ADP/ATP ratio, indicative of cell proliferation, PFK15 treated T 
cell clones had a significantly higher ADP/ATP ratio, indicating an inability to generate ATP 
efficiently and metabolic insufficiency (Figure 19C). To characterize the reduced metabolic 
capacity of PFK15 treated T cells, we measured indicators of glycolysis, fatty acid oxidation 
(FAO), and mitochondrial metabolism. As expected, PFK15 treated T cells had downregulated 
levels of the key glycolysis proteins Glut-1, HK2, PFKFB3, and LDHA and reduced supernatant 
lactate levels as compared to control BDC2.5 T cell clones, confirming an inability to engage in 
glycolysis upon encounter with β cell antigen (Figure 19D-E). 
PD-1 signaling has been reported to promote FAO, with early exhausted T cells having 
increased carnitine palmitoyltransferase 1α (CPT1α) expression, a rate limiting enzyme that 
regulates mitochondrial fatty acid transport [109]. To investigate FAO, we first measured fatty 
acid uptake utilizing a BODIPY C16 fluorescent analog, and found no significant difference in 
uptake of fatty acids in Day 14 control or PFK15 treated T cells (Figure 19F). CPT1α expression 
was measured by western blot analysis, and revealed increased expression of CPT1α in Day 8 
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PFK15 treated T cells, but decreased levels in treated Day 14 clones compared to untreated control 
T cells (Figure 19G). Together, these results indicate that by Day 8 control T cell clones are 
engaging in glycolysis in response to presentation of β cell antigen (Figure 19D) while PFK15 
treated T cells are utilizing FAO. Although fatty acid uptake was unaltered, reduced CPT1α 
expression was observed in PFK15 treated clones compared to controls on Day 14, demonstrating 
a reduced ability to efficiently transport fatty acids into the mitochondria (Figure 19F-G), and 
likely contributing to the inefficient ATP generation we observed (Figure 19B).  
A number of reports demonstrate that exhausted T cells have reduced mitochondrial fitness 
[141, 168, 177-180].  To investigate the mitochondrial health of PFK15 treated T cells, we 
measured mitochondrial mass, reactive oxygen species (ROS), and mitochondrial membrane 
potential. Indeed, PFK15 treated T cell clones exhibited mitochondrial dysfunction as 
demonstrated by reduced mitochondrial mass (Figure 19H), decreased mitochondrial membrane 
potential (Figure 19I), and increased generation of mitochondrial ROS when compared to control 
T cells (Figure 19J). The mitochondrial dysfunction supports the reduced ATP levels measured in 
PFK15 treated T cells when uptake of fatty acids was unaffected (Figure 19F-G), further pointing 
to inefficient utilization of nutrients and overall metabolic insufficiency. All in all, these data 
indicate that inhibition of glycolysis during the activation of autoreactive CD4+ T cell clones 
enforces an exhausted phenotype that mediates protection from T1D onset in vivo
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Figure 19. Glycolysis inhibition during activation renders CD4+ T cells metabolically insufficient. 
Assessing metabolic consequences of PFK15 treatment on BDC2.5 T cell clones. All analyses were performed 14 days post stimulation (Day 14), unless otherwise 
noted. A, B, C. Relative ADP, ATP levels, and the ADP/ATP ratio were measured from Day 14 control and treated BDC2.5 T cells (n = 3). D. Representative 
western blots for glycolysis proteins in control and PFK15 treated BDC2.5 T cell clones on days 8 and 14 post stimulation. E. Lactate measurements in cell culture 
supernatants (n = 5). F. Statistical significance of BODIPY fatty acid uptake of Day 14 control and PFK15 treated BDC2.5 T cells (n = 4). Cells were gated on 
CD4+ T cells. G. Representative western blot analysis of CPT1 expression in control and PFK15 treated BDC2.5 T cell clones on days 8 and 14 post stimulation. 
Cells were gated on CD4+ T cells. H. Statistical analysis of mitochondrial mass by MitoTracker green staining on day 14 control and PFK15 treated T cell clones 
(n = 3). Cells were gated on CD4+ T cells. I. Statistical analysis of mitochondrial membrane potential by TMRE staining on day 14 control and PFK15 treated T 
cell clones (n = 3). Cells were gated on CD4+ T cells. J. Statistical analysis of mitochondrial ROS by MitoSOX staining on day 14 control and PFK15 treated T 
cell clones (n = 3). Cells were gated on CD4+ T cells. All data are presented as the mean ± SEM.  (* = p < 0.05, ** = p < 0.01, *** = p < 0.005, **** = p < 0.0001). 
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3.4.5 PFK15 treated CD4+ T cells are terminally exhausted 
Exhausted T cell lineages display heterogeneity amongst subsets with unique characteristics and 
varying abilities to become reinvigorated [181, 182]. To determine the state of exhaustion observed 
in PFK15 treated T cells, we performed reinvigoration experiments where a subset of BDC2.5 T 
cell clones were treated with PFK15 every third day for two weeks to induce exhaustion. Then, T 
cells from control or PFK15 treated flasks (PFK15 treated T cells put into restimulation cultures 
termed PFK15 TEX) were restimulated for another two weeks without further PFK15 treatment 
(Figure 20A). We first measured PD-1 and LAG-3 expression on PFK15 TEX cells after 
restimulation and found that PFK15 TEX sustained high expression of both PD-1 and LAG-3 
compared to control cultures (Figure 20B), consistent with retention of an exhausted phenotype. 
Notably, PFK15 TEX were unresponsive to IL-2 present in restimulation cultures, further 
confirming exhaustion and ruling out anergy [154]. We also measured lactate and IFNγ in cell 
culture supernatants on days 8 and 14 post restimulation as indicators of re-engagement in the 
glycolysis pathway upon activation and effector function. We observed reduced lactate production 
and little secretion of IFNγ by PFK15 TEX in response to restimulation, suggesting that treated T 
cell clones are terminally exhausted (Figure 20C-D). 
Reports have demonstrated that terminally exhausted T cells are refractory to checkpoint 
blockade [154, 168, 177]. To determine whether PFK15 TEX cells were responsive to checkpoint 
blockade, a subset of restimulation cultures were treated with αPD-1, αLAG-3, or a combination 
of both αPD-1/αLAG-3 blocking antibodies as described in the methods. We measured lactate and 
IFNγ in cell culture supernatants to determine whether checkpoint blockade treatment would 
rescue PFK15 TEX cell’s ability to utilize glycolysis and exert their effector function (Figure 20C-
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D). Neither αPD-1, αLAG-3, nor a combination of αPD-1 and αLAG-3 blocking antibody 
treatments were capable of rescuing PFK15 TEX ability to respond to self- antigen, evidenced by 
significantly less lactate and IFNγ secretion measured in culture supernatants of PFK15 TEX ± PD-
1 and/or LAG-3 blockade compared to control T cells (Figure 20C-D). To confirm the induction 
of terminal exhaustion in vivo, we performed reversibility experiments using our adoptive transfer 
model, described in Figure 16A. Briefly, ex vivo activated BDC2.5 T cells were adoptively 
transferred into NOD.scid recipients, with recipient animals being separated into one of three 
treatment cohorts: 1) vehicle control, 2) PFK15 + IgG, and 3) PFK15 + αPD-1 + αLAG-3 (Figure 
20E). Animals in the PFK15 treatment groups were treated every other day for two weeks, with 
IgG or checkpoint blockade treatment initiated in the second week. Notably, the dose of αPD-1 
and αLAG-3 blocking antibodies administered have been previously shown to accelerate diabetes 
onset in NOD animals, therefore any delay or protection achieved with PFK15 treatment would be 
considered durable if irreversible with checkpoint blockade [30]. As expected, 100% of control 
animals displayed fulminant diabetes by day 7 post- transfer, with significant delays associated 
with PFK15 treatment (Figure 20F). While 70% of animals receiving PFK15 + IgG remained 
diabetes free through the end of the study period, 42% receiving PFK15 + αPD-1 + αLAG-3 
treatment were protected from disease (Figure 20F). Although more animals receiving checkpoint 
blockade succumbed to diabetes than PFK15 + IgG treated animals, diabetes incidence between 
these two groups were not statistically significant (p = 0.348), indicating an inability to reverse 
PFK15 induced T cell exhaustion. Finally, regardless of αPD-1 and αLAG-3 blockade, CD4+ T 
cells in PFK15 treated animals retained high expression of PD-1 and LAG-3 in the periphery and 
spleens compared to control animals, consistent with an exhausted phenotype (Figure 20G). 
Together, these data support the findings that inhibition of glycolysis in diabetogenic CD4+ T cells 
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leads to terminal exhaustion, characterized by functional and metabolic dysfunction that is 
irreversible by restimulation or checkpoint blockade therapy in vitro and in vivo. This work 
demonstrates that the rate- limiting glycolysis enzyme PFKFB3 is a novel target for controlling 
autoreactive T cell activation as a means to protect against the onset of T1D by enforcing 








































Figure 20. Inhibition of glycolysis leads to terminal exhaustion of CD4+ T cells that are refractory to 
checkpoint blockade 
To determine the degree of exhaustion induced by PFK15 treatment, PFK15 treated T cell clones were restimulated ± 
checkpoint blockade. A. Schematic diagram of experimental design for reinvigoration studies. B. Representative flow 
plots of PD-1 and LAG-3 expression on CD4+ T cells on control and PFK15 TEX. C. Statistical analysis of lactate 
secretion in Day 8 and 14 restimulation culture supernatants (n = 3). D. ELISA analysis of IFN in culture supernatants 
on days 8 and 14 post stimulation (n = 3). E. Schematic diagram of experimental design for in vivo reversibility studies. 
F. Survival analysis of diabetes incidence in vehicle control and PFK15 treated groups. Kaplan-Meier survival analysis 
test was performed for statistical significance. G. Statistical analysis measuring PD-1 and LAG-3 co-expression on 
CD4+ T cells in the peripheral blood and spleen of vehicle control (n = 4), PFK15 + IgG (n = 7), and PFK15 + αPD-1 
+ αLAG-3 (n = 7) treatment.  All data are presented as the mean ± SEM. (* = p < 0.05, ** = p < 0.01, *** = p < 0.005, 
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3.5 DISCUSSION 
In the present study, we evaluated the ability of the anti- glycolytic PFK15 to control the activation 
of diabetogenic CD4+ T cells in T1D. To our knowledge, this is the first study testing the ability 
of a PFKFB3 inhibitor to prevent the onset of autoimmune diabetes. Our findings confirmed 
PFK15 inhibited glycolysis upon activation of CD4+ T cells (Figure 14), dampened autoreactive 
CD4+ T cell responses in vitro (Figure 15), and delayed disease onset in vivo (Figure 16-17). The 
protective benefits associated with PFK15 treatment are not entirely surprising as glycolysis is 
required for CD4+ T cell activation and IFNγ secretion. In fact, targeting T cell metabolism has 
been successfully used to prevent and reverse disease in other autoimmune diseases, albeit without 
mediating durable tolerance [84-87, 115]. However, our findings demonstrate an induction of 
terminal exhaustion by glycolysis inhibition, which to our knowledge, has not been previously 
reported in the literature. 
 Previously, use of the prototypical glycolysis inhibitor 2-DG in SLE, RA, and MS failed to 
generate a long- lasting benefit, as cessation of treatment was associated with disease flare-ups 
[84, 86, 87, 115]. Dissimilarities in the observed outcomes between our study and others is likely 
due to differences in the mechanisms of inhibition. 2-DG is a glucose analog that indirectly targets 
the action of HK2 through competition with endogenous glucose levels [183]. For this reason, an 
effective reduction in glycolytic flux requires high dose treatments, which are associated with 
adverse effects and non- specific targeting [183]. In comparison, PFK15 is highly selective for a 
defined intracellular enzyme, thus requiring a much lower concentration for effective inhibition 
[183]. These key differences appear to have drastically different outcomes on the T cell response, 
and the data included in Figure 26 confirm this as treatment of BDC2.5 splenocytes with 2-DG in 
vitro was only able to reduce IFNγ secretion, and failed to recapitulate PFK15’s ability to dampen 
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IL-2 and TNFα (Figure 26). Strikingly, our data demonstrate an ability for PFK15 treated T cells 
to become early activated (Figure 15D). 2-DG treatment, however, leads to reduced CD69 
expression upon activation, indicating maintenance of a quiescent phenotype that is reversible 
when treatment is stopped [84]. The early activation observed in our model supports the need for 
T cells to lineage commit to effector subsets in order to induce a terminal phenotype. Finally, PD-
1 and LAG-3 expression are induced upon TCR signaling, therefore early activation is required to 
upregulate IRs that ultimately render PFK15 treated T cells exhausted (Figure 17-18)  [169, 175].  
Although often overlooked, availability of nutrients is vital to maintaining T cell fitness. As 
described herein, T cells and cancer cells have a shared reliance on aerobic glycolysis, which 
becomes problematic in the TME when tumor cells metabolically restrict T cells, thus eliciting 
poor anti- tumor immunity [108, 177]. Analogously, our data supports the idea that reduced 
glycolytic flux promotes T cell exhaustion, as PFK15 treatment induced defective effector 
responses upon activation (Figure 15 and 18). Glycolysis restriction, however, is not the only 
metabolic pathway dysregulated by TILs.  Notably, TILs demonstrate a progressive loss of 
mitochondrial mass and function [141, 168, 177, 180]. This, along with a low glucose 
environment, promote a state of metabolic insufficiency due to an inability to meet nutrient 
requirements, leading to a permanent hyporesponsive state [108, 141, 168, 177, 180]. 
Unexpectedly, we too observed mitochondrial dysfunction when glycolysis was inhibited (Figure 
19). Although other factors in the TME contribute to repressed mitochondrial function, particularly 
hypoxia, our data strengthens the link between nutrient restriction and T cell exhaustion since 
glycolysis inhibition led to the development of metabolic insufficiency [184].  
While the development of T cell exhaustion is detrimental in cancer and chronic infection, the 
opposite is true in autoimmunity, where induction of a hyporesponsive phenotype protects the host 
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from attack [129]. The onset of autoimmunity in T1D occurs due in large part to defective central 
and peripheral tolerance mechanisms that fail to control pathogenic T cells. This defect is due to 
dysregulated IR expression in T1D [31, 134, 185]. In healthy individuals, binding of IR proteins 
to their associated ligand and subsequent downstream signaling act as a metaphorical “brake” that 
impedes T cell activation and protects against autoimmunity [129, 169, 175]. Evidence of the 
importance of IRs is underscored by the accelerated diabetes observed in the absence or blockade 
of PD-1 or LAG-3 in NOD mice [30-32]. Clinically speaking, polymorphisms in the PD-1 gene 
have been identified and associated with disease susceptibility [185]. Concomitantly, T1D patients 
fail to upregulate PD-1 on T cells compared to control subjects, correlating to aberrant T cell 
activation and effector function [134, 136]. In our study, PFK15 treatment led to increased PD-1 
and LAG-3 expression on CD4+ T cells that correlated with protection from diabetes onset (Figure 
16). Importantly, expression of IRs alone is not sufficient to induce T cell exhaustion, since 
activated T cells transiently upregulate both PD-1 and LAG-3 upon early activation [169, 175]. In 
fact, exhaustion can occur even in the absence of checkpoint molecules, further complicating the 
role these molecules play in enforcing and maintaining functional exhaustion [177]. While IRs 
may play a lesser role in driving exhaustion in other disease settings, our data reveal a pivotal role 
for PD-1 and LAG-3 in maintaining tolerance against autoimmune responses. In conclusion, we 
demonstrated a unique ability to correct defects in peripheral tolerance mechanisms in T1D by 
inducing PD-1 and LAG-3 expression on CD4+ T cells. Increased IR expression and glycolysis 
restriction led to the functional and metabolic exhaustion of diabetogenic T cells independent of 
PD-1 and LAG-3 signaling, as checkpoint blockade failed to reverse this phenotype (Figure 20).  
Therapeutic strategies for T1D have focused on two specific areas:  1) β cell replacement via 
regeneration of endogenous β cell mass or 2) immunomodulation [143, 146]. Although innovative 
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efforts have been made to restore β cell mass, these strategies ultimately fail due to reemergence 
of the autoimmune response [143]. Moreover, although immunomodulation has yielded positive 
results in preclinical studies, success in the clinic has remained limited. Unfortunately, present 
clinical studies have only administered immunotherapies to patients with diagnosed T1D. By 
diagnosis, T1D patients have endured longstanding autoimmunity, with significant β cell loss, thus 
highlighting a need to intervene prior to symptomatic disease [33]. Interestingly, the presence of 
autoantibodies is known to be a strong predictor for disease onset [186, 187]. In fact, the first in 
man prevention study was published recently, where the αCD3 antibody teplizumab was utilized 
in patients at risk for diabetes development [146]. Teplizumab delayed T1D onset by 2 years, and 
similarly to our study, protection was associated with increased expression of IRs and induction 
of a T cell hyporesponsive state [146]. However broad immunosuppression was observed in 
teplizumab treated patients, which is an adverse effect of most immunotherapies due to non- 
specific targeting. A potential benefit of modulating glycolysis is the ability to specifically target 
activated T cells, while leaving established memory T cells and regulatory T cell populations 
unaffected based on their reliance on alternative metabolic pathways [57, 59, 71, 95]. Clinically 
speaking, we would anticipate glycolysis inhibition to delay or prevent disease onset, while use of 
PFK15 in conjunction with methods to restore β cell mass may be a novel way to reverse T1D.  
In summary, these findings demonstrate an ability to induce terminal exhaustion of 
autoreactive T cells in T1D by modulating the glycolysis pathway via targeting of PFKFB3 (Figure 
21). On a broader note, these data support a key role for glucose utilization in T cell activation and 
function, since an inability to efficiently metabolize glucose enforces a hyporesponsive phenotype. 
In our study, this phenotype was associated with expression of PD-1 and LAG-3, which are known 
to be dysregulated in T1D patients. This study remains focused on the ability to restrain 
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diabetogenic CD4+ T cells due to their importance in the initiation of autoimmunity. While we 
would anticipate an overall benefit to other mediators of autoimmunity in T1D, like CD8+ T cells, 
further investigations are required to fully understand the impact glycolysis inhibition would have 
on other immune cell subsets. However, with the ability to restore tolerance in preclinical studies, 
we anticipate the use of metabolic modulators, like PFK15, may have a beneficial impact in both 































Figure 21. Mechanism for the effect of glycolysis inhibition on CD4+ T cell activation and Type 1 Diabetes 
Pathogenesis. 
Upon encounter with antigen via TCR: MHC-II interaction, CD4+ T cells become activated. Under conditions of 
sufficient nutrient availability, effector CD4+ T cells are metabolically active and transition to aerobic glycolysis to 
fuel their clonal expansion and effector function (i.e. IFN secretion). In the case of T1D, the activation of autoreactive 
CD4+ T cells ultimately leads to  cell attack, hyperglycemia, and T1D onset. Treatment with PFK15, an inhibitor of 
a rate- limiting enzyme of the glycolysis pathway, reduces glycolytic flux, and results in the induction of terminal 
exhaustion, characterized by high PD-1 and LAG-3 expression, decreased proliferative capacity, reduced effector 







4.0 INVESTIGATING THE IMPACT GLYCOLYSIS INHIBITION HAS ON ANTIGEN 
PRESENTING CELL FUNCTION 
This chapter is an ongoing study and more experimentation is required before it can be 
considered for publication.  
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The activation of autoreactive T cells that target β cells in the pancreas during T1D is dependent 
on the presentation of self- antigen by professional antigen presenting cells (APCs), like 
macrophages and dendritic cells (DCs). Further, their role in the immunopathology of T1D 
supersedes their ability to present antigen, as macrophages and DCs are the first immune cells to 
invade the islets, and also mediate β cell death over the course of the autoimmune response. Similar 
to what has been described for T cells, cellular metabolic programs dictate APC activation and 
function, where a metabolic transition to aerobic glycolysis accompanies activation. In chapters 2 
and 3, we have demonstrated an ability to the glycolysis inhibitor PFK15 to control autoreactive 
T cells responses in T1D by inducing T cell exhaustion, however due to the shared reliance of T 
cells and APCs on the glycolysis pathway, we wanted to determine the impact glycolysis inhibition 
had on APC function. Our data presented herein demonstrate that the therapeutic benefits 
associated with PFK15 administration are due to direct modulation of CD4+ T cells, as both 
macrophage and DC function remained intact with PFK15 treatment. The observed outcomes on 
APC function were independent of the defects associated with macrophages and DCs in the NOD 
mouse, as APCs from healthy control C57BL/6J animals were also unaffected by PFK15 
treatment. In sum, these data confirm that the protective benefits of PFK15 treatment occur 
independently of any effects on APCs. These data highlight a need to better characterize the 
metabolic phenotype and flexibility of APCs in T1D, as understanding these pathways are vital to 







Professional APCs, such as macrophages and DCs, are important mediators of inflammation. Not 
only can APCs mount innate immune responses against invading pathogens, they also play a 
pivotal role in initiating an adaptive immune response, via engagement of peptide-MHC 
complexes with the TCR [1]. Upon antigen recognition via pattern recognition receptors (PRRs), 
APCs become activated, increase their expression of MHC-peptide complexes and costimulatory 
molecules (i.e. CD80/CD86, CD40), and secrete proinflammatory cytokines such as IL-6, TNF, 
IL-1, IL-12, and type 1 IFNs [1]. Synthesis of proinflammatory cytokines act to promote 
inflammation and initiate the differentiation and effector function of naïve T cells that mediate 
antigen- specific responses, and are vital for the maturation of adaptive immunity and IFN 
synthesis by effector T cells.   
Similarly to T cells, macrophages and DCs too, undergo metabolic transitions over the course 
of their lifespan with specific pathways utilized to promote anti- inflammatory or immunogenic 
processes. Generally speaking, tolerogenic DCs or anti- inflammatory M2 macrophages that 
promote the resolution of inflammation are oxidative while proinflammatory immunogenic 
dendritic cells and classically activated M1 macrophages are considered more glycolytic, however 
these cells display plasticity and adaptability in regard to the nutrients required for their function 
and survival [59, 75, 76, 78, 80, 188]. Upon activation to pro- inflammatory phenotypes, 
macrophages and DCs increase their glucose consumption and lactate production as a result of a 
rapid increase in glycolytic flux [59, 75, 76, 78, 80, 188]. While T cells rely on glycolysis to 
produce biosynthetic intermediates to fuel their high proliferative capacity and clonal expansion, 
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macrophages and DCs do not proliferate and instead use this pathway both as a survival 
mechanism and to exert their effector function [189].  
Regarding Type 1 Diabetes (T1D), macrophages and DCs have an often-unappreciated role in 
perpetuating autoimmunity against islet  cells. T -cell mediated destruction of pancreatic  cells 
during T1D is secondary to islet- infiltrating macrophages and DCs, which are some of the first 
cells to invade the islets [3, 4]. Notably, resident macrophages are present within the pancreas at 
all times, however it is not until acquisition of antigen that tissue- resident APCs become activated 
and secrete inflammatory cytokines. As described in the introduction, environmental triggers like 
viral infection or chemical exposure in genetically predisposed individuals leads to  cell 
destruction and the release of  cell antigens within the pancreas. Resident macrophages and DCs 
within the pancreatic microenvironment become activated, phagocytose  cell antigens and dying 
 cells, and traffic to the pancreatic draining lymph node to present processed antigenic peptides 
to autoreactive T cells. Importantly, TNF, IL-1, IL-6, and reactive oxygen species (ROS) 
secreted by activated APCs can damage  cells, with IL-1 specifically able to cause direct  cell 
lysis and cell death [36, 121, 189]. Therefore, APCs are instrumental in both the initial insult 
against islet  cells, as well as in the maturation of the adaptive immune response that ultimately 
leads to complete destruction of  cells, and the onset of hyperglycemia in afflicted individuals.  
Our previous work described in chapters 2 and 3 demonstrated an ability to inhibit T cell 
responses to nominal and  cell antigens in vitro and delay T1D onset in vivo via administration 
of the glycolysis inhibitor PFK15. Previous literature has demonstrated that treatment of bone 
marrow derived macrophages (BMDMs) or dendritic cells (BMDCs) activated with the TLR4 
agonist lipopolysaccharide (LPS) in the presence of the glycolysis inhibitor 2-DG reduced 
costimulatory molecule expression and proinflammatory cytokine production [75, 76, 78, 188, 
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190, 191]. However, whether specific targeting of PFKFB3 via PFK15 treatment has not been 
studied, especially in the context of T1D. Due to the importance of APCs in T1D pathogenesis and 
the reliance of macrophages and DCs on the glycolysis pathway, we sought to determine whether 
PFK15 treatment would also affect APC function. In contrast to use of other metabolic modulators 
of the glycolysis pathway, treatment of LPS- activated BMDMs or BMDCs from T1D prone NOD 
animals with PFK15 in vitro failed to reduce their activation and effector functions, as 
costimulatory molecules and proinflammatory cytokine production remained intact despite PFK15 
treatment. Ultimately, these data are interesting and demonstrate that use of other 
immunomodulatory agents in conjunction with PFK15 may be required to suppress both APC and 
T cell mediated autoimmunity against islet  cells in T1D.   
4.3 MATERIALS AND METHODS 
4.3.1 Mouse Strains 
Non- Obese Diabetic (NOD), NOD.BDC2.5.TCR.Tg (BDC2.5), NOD.scid, and C57BL/6J 
animals were bred and maintained under specific pathogen free conditions in the animal facility 
located at the Rangos Research Center within UPMC Children’s Hospital of Pittsburgh. All animal 
experiments were approved by the University of Pittsburgh’s Institutional Animal Care and Use 
Committee (IACUC; Assurance Number: D16-00118). Male and female mice aged 6-12 weeks 
old were used in all experiments. 
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4.3.2 Differentiation of Bone Marrow Derived Dendritic Cells and Macrophages 
Bone marrow derived macrophages and dendritic cells were differentiated as previously described 
[3, 192]. Bone marrow cells were flushed from the bones using a 26 g needle. Bone marrow cells 
were then centrifuged and filtered through a cell strainer. For differentiation of BMDMs to the 
classical M1 proinflammatory phenotype, 2×106 cells/well cells were plated on 24-well tissue 
culture plates. Cells were cultured in macrophage colony- stimulating factor 1 (mCSF1) 
conditioned RPMI 1640 media, with a media change every two days. After 7 days of 
differentiation, BMDMs were stimulated with 100 ng/mL or 1 ug/mL lipopolysaccharide (LPS) 
from Escherichia coli (055:B5) (Sigma Aldrich) ± 2.5- 10 µM PFK15. Cell culture supernatants 
were collected 24-72 hours post- stimulation to assess effector cytokine secretion. For 
differentiation of BMDCs, 2×106 cells/well cells were plated on 24-well tissue culture plates. Cells 
were cultured in IL-4 and GM-CSF (8 ng/mL) conditioned RPMI-1640 media, with a media 
change after 2 days, followed by an additional 3-day incubation. After 5 days of differentiation, 
BMDCs were stimulated with 100 ng/mL LPS ± 5 µM PFK15. Cells and cell culture supernatants 
were collected 24-48 hours post- stimulation to assess the expression of costimulatory molecules 
by flow cytometry and effector cytokine secretion by ELISA. 
4.3.3 Flow Cytometry 
1x106 BMDCs cells were harvested at indicated timepoints and surface stained for flow cytometric 
analysis as described [123]. Briefly, cells were incubated with Fc block (CD16/CD32; BD 
Biosciences) for 15 minutes prior to staining for flow cytometry. Surface staining was performed 
at 4°C using CD11b, CD11c, MHC-II, CD80, and CD86 antibodies (BD Biosciences) in FACS 
126 
buffer (1% BSA in PBS). Cells were then fixed in 2% PFA for 15 minutes at 4°C (Thermo Fisher 
Scientific), and stored at 4°C until time of analysis.  
4.3.4 ELISA and Lactate Measurements 
Supernatants were collected from LPS ± PFK15 stimulated BMDMs or BMDCs after 24-48 hours 
in culture. IL-6 and TNF cytokines secreted by BMDMs or BMDCs were measured by ELISA 
using purified IL-6 capture and biotinylated antibody pairs (BD Biosciences) or TNFα ELISA kits 
(R&D) according to the manufacturer’s instructions. ELISAs were read on a SpectraMax M2 
microplate reader (Molecular Devices) and data analyzed using SoftMax Pro version 7.0.2 
software (Molecular Devices). Lactate, a byproduct of aerobic glycolysis, was measured using the 
Lactate Plus meter and test strips per manufacturer’s instructions (Novus Biologics).  
4.3.5 Adoptive Transfer Model of T1D 
1 x 107 ex vivo activated CD4+ T cells from BDC2.5 mice were injected i.p. into NOD.scid 
recipients as described previously by our laboratory [155]. One cohort of recipients received 25 
mg/kg PFK15 (Selleck) dissolved in 5% DMSO + 45% PEG300 + 1% Tween80 + 49% ddH2O 
prepared fresh; the other cohort received vehicle control every other day for 2 weeks. Body weights 
and blood glucose (BG) levels were monitored over the course of the experiments. Animals were 
deemed diabetic after two consecutive BG readings  350 mg/dL. Diabetic animals were sacrificed 
at indicated timepoints and Pancreata were harvested for downstream analyses. 
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4.3.6 Tissue Collection and Histological Assessment 
Pancreatic tissue was collected and fixed in 4% paraformaldehyde (PFA; Thermo Fisher 
Scientific) overnight at 4 C. Fixed tissue was processed and embedded in paraffin by the 
Histology Core Laboratory located at UPMC Children’s Hospital of Pittsburgh’s Rangos Research 
Center [161].  Embedded tissue was sectioned at 4 μm. Samples were imaged using a Nikon 
Eclipse E800 microscope (Nikon) and associated software.  
4.3.7 Immunofluorescent Staining 
Immunofluorescent staining was performed on paraffin embedded samples prepared as described 
above. Antigen retrieval was performed in sodium citrate buffer followed by overnight incubation 
with primary antibodies against F4/80 (1:100; BD Biosciences). The following day, slides were 
incubated with Alexa Fluor 594 conjugated donkey anti- rat secondary antibody (Invitrogen). 
Samples were imaged using a Leica DMi8 inverted microscope (Leica) and LAS X Navigator 
software (Leica).  
4.3.8 Statistical Analysis 
All data are presented as mean values ± standard error of the mean (SEM), with n indicating the 
number of independent experiments or animals. Some data were collected from preliminary 
experiments, and therefore only one representative experimental data point is shown. Student’s t-
test or One- way ANOVA were used where appropriate. A p-value of p < 0.05 was considered 
significant for all statistical analyses. All statistics and graphs were generated using GraphPad 
Prism software.  
128 
4.4 RESULTS 
4.4.1 BMDCs and BMDMs fail to secrete aerobic glycolysis byproduct, lactate, in response 
to LPS stimulation  
Macrophages and DCs transition from a resting state to an activated state in response to TLR 
agonists [59]. Activation is an energetically demanding process, and therefore leads to metabolic 
transitions that ultimately increase the glycolytic rate [59, 76, 188, 193-195]. Similarly to both 
tumor cells and T cells, this phenotype is reminiscent of the Warburg effect, where cells 
preferentially metabolize glucose to lactate despite the presence or availability of oxygen. Further, 
glucose restriction and treatment of APCs derived from bone marrow progenitors with inhibitors 
of the glycolysis pathway, such as 2-DG, severely inhibits the lifespan and activation of both 
macrophages and DCs [59, 76, 188, 195]. To determine the effect PFK15 treatment had on LPS 
induced metabolic reprogramming of BMDMs and BMDCs, we measured extracellular lactate in 
cell culture supernatants from BMDC (Figure 22A) and BMDMs (Figure 22B-C) stimulated with 
LPS ± PFK15 as previously described [110, 123, 155]. In contrast to published literature, we did 
not observe a significant increase in lactate secretion by LPS stimulated BMDMs or BMDCs 
(Figure 22A-B). Interestingly, BMDCs secreted more lactate than BMDM cultures, even when 
unstimulated. This could be due to intrinsic effects of GM-CSF, which has been reported to 
increase glycolytic capacity [77, 191].  Further, unlike the data obtained in chapters 2 and 3, PFK15 
treatment had no impact on lactate secretion and did not reduce lactate levels in 24-hour culture 
supernatants, indicating 1) that NOD BMDCs and BMDMs do not utilize aerobic glycolysis upon 
LPS stimulation, and 2) treatment with PFK15 has no impact on APC lactate secretion. Further 
experimentation is required to fully assess the metabolic changes that occur during APC activation 
and confirm these data.  
129 
It has been well established that APCs from the NOD mouse, and in T1D patients, are defective 
in their maturation and function [124, 196-200]. To determine whether the phenotypes observed 
were due to inherent dysfunctionality of NOD APCs, we differentiated bone marrow cells from 
control C57BL/6J (B6) animals into BMDMs and stimulated them with LPS ± PFK15 (Figure 
22C). Similarly to NOD BMDCs and BMDMs, mCSF1 derived BMDMs from B6 animals failed 
to upregulate aerobic glycolysis upon stimulation with LPS, and were unaffected by PFK15 





























Figure 22. LPS stimulated BMDCs and BMDMs fail to secrete lactate, the byproduct of aerobic glycolysis 






















A-C. BMDCs and BMDMs were differentiated from bone marrow cells isolated from NOD and C57BL/6J animals. After 
differentiation, cells were stimulated with 100 ng/mL (BMDMs; n = 1) or 1 µg/mL (BMDCs; n = 3) LPS ± 5 µM PFK15. After 24 
hours in culture, lactate in cell culture supernatants was measured.  
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4.4.2 PFK15 treatment does not alter BMDC function  
LPS stimulation of BMDCs leads to increased expression of MHC-II and costimulatory molecules, 
and subsequent synthesis of proinflammatory cytokines, especially IL-6 and TNF; all of which 
are required for efficient priming of T cell responses [60, 76, 188]. To determine whether targeting 
the glycolysis pathway alters BMDC function upon TLR4 ligation with LPS, we first measured 
expression of MHC-II, and the costimulatory molecules CD80 and CD86 (Figure 23A-C) 24-48 
hours post stimulation with LPS ± PFK15. Again, we saw no appreciable increases in MHC-II 
(Figure 23A), CD80 (Figure 23B), or CD86 (Figure 23C) expression upon LPS stimulation 
compared to unstimulated controls, although CD80 appeared to be slightly increased (Figure 23B). 
Moreover, PFK15 did not reduce the expression of either MHC-II, CD80, or CD86 (Figure 23A-
C) compared to LPS stimulated only BMDCs. Next, we measured IL-6 and TNF production as 
indicators of BMDC effector function (Figure 23D-E) by ELISA. While LPS stimulation led to 
increased IL-6 and TNF production 24 – 48 hours post- stimulation compared to unstimulated 
control BMDCs, PFK15 treatment did not reduce the production of either cytokine, providing 










Figure 23. Glycolysis inhibition via PFK15 treatment does not alter BMDC function. 
BMDCs were differentiated from bone marrow cells isolated from NOD mice. After differentiation, cells were 
stimulated with 1 µg/mL (BMDCs; n = 3) LPS ± 5 µM PFK15. After 24-48 hours in culture, A. MHC-II, B. CD80, 
C. CD86 expression were analyzed by flow cytometry. D-E. 24-48 hour supernatants were harvested and utilized to 
measure D. IL-6 and E. TNF secretion by LPS ± PFK15 BMDCs. All data are presented as the mean ± SEM. (* = p 











4.4.3 TNF secretion by C57BL/6J and NOD BMDMs remain intact with PFK15 treatment  
PFK15 treatment of LPS stimulated BMDCs from NOD animals did not reduce their effector 
functions (Figure 23). To determine whether this was specific for BMDCs, or whether PFK15 
would fail to regulate other APC subsets, we performed similar experiments using BMDMs 
derived from NOD animals. We also differentiated BMDMs from C57BL/6J mice as a control, to 
ensure the phenotypes we observed were not due to inherent defects associated with APC function 
and maturity that have been extensively reported in the literature for NOD mice [124, 196-200]. 
After 24 hours in culture, we measured TNF secretion in cell culture supernatants from BMDMs 
treated with LPS ± PFK15. While our BMDC studies were performed using 5 µM PFK15, which 
we found to be the optimal dose in our T cell studies in Chapters 2 and 3, we performed a PFK15 
dose titration for our BMDM studies to ensure we were not seeing inefficient downregulation of 
BMDM function due to insufficient dosing.  Similarly to the results obtained with PFK15 treated 
BMDCs, PFK15 treatment failed to reduce LPS stimulated BMDM secretion of TNF, a key 
mediator in the pathogenesis of T1D (Figure 24). Further, an inability to therapeutically target 
PFKFB3 in NOD BMDMs was not due to defective function associated with the NOD mouse, as 
PFK15 treatment failed to reduce TNF secretion by both non- autoimmune prone C57BL/6J 
(Figure 24A) and autoimmune prone NOD BMDMs (Figure 24B). Cumulatively, these data 













Figure 24. PFK15 treated BMDMs retain their ability to secrete the effector cytokine TNF. 
BMDMs were differentiated from bone marrow cells isolated from C57BL/6J or NOD mice. After differentiation, 
cells were stimulated with 100 ng/mL LPS ± 1.25 - 10 µM PFK15. After 24 hours in culture, supernatants were 
harvested and utilized to measure TNF secretion from A. C57BL/6J BMDMs or B. NOD BMDMs. Data are 




















4.4.4 PFK15 treatment in vivo does not alter macrophage migration and infiltration into 
pancreatic islets in an adoptive transfer model of CD4+ T cell mediated T1D  
Induction of autoimmune diabetes by diabetogenic BDC2.5 T cells is dependent on macrophages, 
as they are the final effectors that mediate  cell killing in adoptive transfer models using CD4+ T 
cells only [201]. Since PFK15 treatment delayed diabetes onset in in vivo adoptive transfer studies 
and reduced CD4+ T cell invasion in pancreatic islets, we wanted to assess the ability of 
macrophage populations to migrate and infiltrate the islets [155]. To assess this, we stained 
pancreatic sections from control and PFK15 treated animals from previous adoptive transfer 
studies (Chapter 3) with the macrophage marker F4/80. No significant differences in islet 
infiltration of macrophages were observed between vehicle control and PFK15 treated animals, 
indicating that protection from disease was due to specific targeting and inhibition of autoreactive 



























Representative immunofluorescence staining of macrophage infiltration by F4/80 staining in pancreatic sections from 




Macrophages and DCs are important mediators of immunity, and are crucial for initiating 
autoreactive T cell responses against  cells during the pathogenesis of T1D [1, 33-35, 45, 201]. 
Recently, interest in the field of immunometabolism has demonstrated that bioenergetic pathways 
are important for proper immune cell function, both during the initiation and resolution of 
inflammation [59, 60]. Specifically, macrophages and dendritic cells metabolically transition to 
the less efficient aerobic glycolysis during their activation, similarly to both T cells and cancer 
cells. Notably, while T cells and cancer cells shared reliance on the glycolysis pathway occurs as 
a means to generate nucleotides and biosynthetic intermediates required for proliferation and in 
the case of T cells, effector functions, macrophages and DCs resort to this pathway as a survival 
mechanism [75, 76, 78, 188, 190, 191]. Upon stimulation, APCs increase the expression of  
inducible nitric oxide synthase (iNOS), which produces nitric oxide (NO) from arginine, a toxic 
gas with microbicidal, antiviral, and antitumoral properties [202]. NO inhibits mitochondrial 
electron transport and reduces oxygen consumption and coupled ATP production, ultimately 
leading to a collapse in mitochondrial respiration [59]  
Adoption of glycolysis, however, is not the only reason APCs rely on this pathway, as it’s 
required for initiating activation early following stimulation. Evidence of this is supported by 
studies treating BMDC and BMDM macrophage cultures with the glycolysis inhibitor 2-DG 
prevented their activation, costimulatory molecule expression, and ability to secrete 
proinflammatory cytokines [75, 76, 78, 188]. In contrast to previously published literature, 
glycolysis inhibition via PFK15 treatment of BMDM and BMDCs from the autoimmune prone 
NOD mouse did not alter their activation or effector function. Further, this was not due to the 
inherent defects associated with APCs in the NOD mouse and T1D patients, as BMDMs from 
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control C57BL/6J were also unaffected by PFK15 treatment. The differences in the observed 
outcomes of our study with previously reported literature may be due to differences in the 
glycolysis inhibitor used in each study. As discussed in chapter 3, 2-DG is often the glycolysis 
inhibitor of choice for immunometabolism based studies. However, 2-DG is not a specific inhibitor 
of a glycolysis enzyme like PFK15 is, but rather is a non- metabolizable glucose analog that must 
be administered in often toxic doses to outcompete endogenous glucose levels in cell culture 
supernatants or in in vivo models [155]. As we demonstrated in chapter 3 with the differential 
effects of 2-DG and PFK15 on T cell responses, it appears this is also true with BMDC and BMDM 
responses to stimulation. These data provide further evidence to support that treatment with PFK15 
selectively targets autoreactive T cells, while leading other mediators of T1D unaffected.  
Another possibility contributing to the inability for PFK15 to dampen APC function could be 
due to an ability for macrophages and DCs to be metabolically adaptable. While T cells appear 
unable to utilize other forms of energy to fuel effector functions, APCs demonstrate metabolic 
plasticity to fulfill their ability to fend off foreign invaders. In a study by Raulien et al., monocytes 
stimulated with LPS under conditions of glucose starvation were capable of shifting their 
metabolism toward OXPHOS fueled by FAO, thus allowing them to maintain activation and 
proinflammatory cytokine secretion [80]. However, the expression of iNOS and the production of 
NO was not tested in this model, and would be important to measure given its role in collapse of 
the ETC and oxidative metabolism. It would be interesting to know whether glycolysis is required 
for NO production, and what specific pathways mediate the various aspects of APC biology and 
function. It is also important to consider that use of BMDCs and BMDMs differentiated from bone 
marrow progenitors, while useful model systems, are not entirely representative of tissue resident 
APCs. Further studies assessing immunometabolism of APCs isolated from within the pancreas 
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and pancreatic draining lymph nodes during the course of T1D would provide diabetes relevant 
data, and ensure the phenotypes observed were specific to macrophages and DCs resident in the 
pancreatic microenvironment. Cumulatively, our data demonstrate that macrophages and DC 
function are unaltered by PFK15 treatment in vitro and in vivo, and suggest that the therapeutic 
benefits associated with PFK15 treatment are due to a direct effect on CD4+ T cells (chapter 3). 
Due to their importance in the immunopathology of T1D, use of PFK15 in conjunction with 
therapeutics that also suppress macrophage and DC functions may prove to be beneficial. 
However, it will be important to know whether functional APCs are required for PFK15 mediated 
induction of T cell exhaustion, as the expression of PD-1 and LAG-3 on CD4+ T cells occurs as a 









5.0 FUTURE DIRECTIONS 
5.1 IMMUNOMETABOLISM IN TYPE 1 DIABETES 
5.1.1 Metabolic characterization of β cell reactive CD4+ T cells 
While the data presented in chapters 2 and 3 demonstrate that T cells from the NOD mouse are 
susceptible to modulation with the glycolysis inhibitor PFK15, the metabolic profile of 
autoreactive T cells in T1D remains unknown. There is mounting evidence to suggest that 
autoreactive T cells do not play by the same rules metabolically [86, 115, 155]. As described in 
great detail in the introduction, studies in SLE, MS, and RA have provided robust evidence that 
autoreactive T cells display altered metabolic dependencies and programs [55, 81, 82]. Generally 
speaking, autoreactive T cells demonstrated enhanced bioenergetics characterized elevated 
glycolysis and mitochondrial oxidative metabolism, as well as mTOR activity compared to control 
animals [84, 86, 101]. 
In T1D, although specific evidence is lacking in regard to the metabolic preferences of 
diabetogenic T cells, recent studies have provided insight into the bioenergetic profiles of β cell 
reactive T cells. Firstly, Chen et al. observed that T cells from human T1D patients displayed 
increased mitochondrial hyperpolarization (MHP) compared to control subjects, which correlated 
with increased activation induced IFNγ secretion and ROS production [117]. Typically, enhanced 
MHP is associated with an activated phenotype characterized by increased bioenergetics [110]. In 
line with these data, work by our laboratory demonstrated that ROS are required for metabolic 
reprogramming to glycolysis during the activation of diabetogenic CD4+ T cells [123]. As 
glycolysis is required for ROS and IFNγ production, and with T cells from T1D patients displaying 
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increased MHP, it’s likely that autoreactive T cells in T1D are more metabolically active than 
control T cells, however further exploration is required to validate these hypotheses. Interrogating 
the metabolic preferences of autoreactive T cells would allow for an ability to potentially utilize 
multiple metabolic inhibitors as a means to control their activation and effector functions during 
the course of T1D. Combinatorial approaches have been tested in other autoimmune disorders, 
where treatment of lupus prone mice with 2-DG and Metformin (inhibitor of mitochondrial 
metabolism) was proven beneficial in reducing autoreactive T cell effector functions [15]. 
However, use of Metformin in T1D is somewhat controversial due to its anti- hyperglycemic 
properties, with a high risk of the development of hypoglycemia in T1D patients [203].  
To begin to explore these questions, we are planning future experiments to assess the metabolic 
phenotypes of autoreactive T cells from the NOD mouse. As female NOD mice spontaneously go 
diabetic, we would be able to follow the progression of T1D and take T cells at different timepoints 
to assess metabolic characteristics via Seahorse Extracellular Flux Analysis to assess glycolytic 
and oxidative metabolisms. We will also activate these T cells ex vivo and determine whether 
bioenergetics relay autoreactive T cells enhanced effector functions. The MHC-II matched non- 
obese diabetes resistant (NOR), and non- autoimmune prone C57BL/6J animals will be used to 
isolate T cells from control animals. One caveat of this study is the use of bulk T cell populations, 
as only a small percentage of the T cell repertoire are autoreactive, with an even smaller frequency 
in control strains. However, studies in other autoimmune diseases used bulk T cell populations and 
were still able to capture differences metabolically between control and diseases animals [86, 115, 
155]. If needed, we can specifically isolate insulin or BDC2.5 reactive T cells via tetramer staining 
to assess the metabolic preferences of autoreactive T cells specifically. Another limitation of these 
studies is that autoreactive T cells in the NOD mouse may be inherently more “active” even in 
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younger mice prior to onset of disease, as they develop in and have likely encountered their antigen 
(pancreatic β cells). Moreover, increased activation phenotypes of autoreactive T cells encounter 
their antigen in the thymus during negative selection, as insulin is expressed there. However, in 
T1D, autoreactive T cells are able to escape deletion through unknown mechanisms. Therefore, 
it’s possible that β cell reactive T cells leave the thymus already in an activated state, thus allowing 
for their persistence and resistance to tolerance inducing mechanisms in the periphery [15].  
A major focus of our study, and the future directions proposed here remained focused on 
interrogating the metabolic requirements and vulnerabilities of CD4+ T cells in T1D. However, 
translating our work to human studies would be another future direction of this project. As has 
been done in SLE, it would be interesting to determine the metabolic profile of T cells from T1D 
patients [84-87, 115]. We currently have collaborations with Drs. Eddie James and Sally Kent, two 
experts in the isolation of autoreactive T cells from the PBMCs, as well as in the isolation of 
infiltrating T cells from the pancreata of T1D patients. In fact, a major focus of a recent R21 
submission from our laboratory is focused on understanding whether PFK15 can induce T cell 
exhaustion in primary human T cell clones from type 1 diabetics, and would allow for translational 
potential of PFK15 to reduce human CD4+ T cell effector functions in those genetically 
predisposed to autoimmunity.  
5.1.2 Effects of metabolic modulation on CD8+ T cells, macrophages, and dendritic cells 
Our work presented here was primarily focused on modulating CD4+ T cell metabolism as a means 
to prevent autoimmune targeting of pancreatic β cells, due to their importance in mediating the 
pathogenesis of T1D. However, as mentioned previously, a number of immune cells target 
pancreatic β cells for destruction, including APCs and CD8+ T cells.  
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In chapter 4, we performed preliminary in vitro studies to determine whether APCs were 
affected by PFK15 treatment, as they too transition to aerobic glycolysis upon activation [75, 78]. 
In contrast to what has been reported in the literature, glycolysis inhibition had no impact on 
BMDC and BMDM activation or effector functions. This is in line with the data in chapter 3, 
where PFK15 treatment did not alter expression of early activation marker CD69, indicating an 
ability to become activated. One reason for the stark results obtained in our study versus others 
may be due to the choice of inhibitor. As we demonstrated in chapter 2 when treating BDC2.5 
splenocytes with 2-DG, PFK15, YN1, and PFK158 to confirm the phenotypes we observed were 
due to targeting glycolysis, we observed vastly different outcomes on the T cell responses when 
treating with 2-DG versus specific inhibitors of the glycolysis enzyme PFKFB3. In the literature, 
2-DG has been the glycolysis inhibitor of choice in studies examining the immunometabolism of 
APCs. Therefore, future studies should be aimed at expanding the studies we performed with 
PFK15 using other metabolic inhibitors like 2-DG to compare the therapeutic benefits associated 
with each inhibitor. Other parameters associated with APC function, such as antigen processing 
and presentation should also be tested to fully appreciate the impact glycolysis inhibition has on 
APC function. Another reason for the different outcomes we observed in modulating glycolysis 
utilization by APCs beyond use of different inhibitors could be due to potential metabolic 
adaptability. Raulien et al. demonstrated that monocytes are sufficiently metabolically flexible, as 
LPS stimulation of monocytes under conditions of glucose deprivation did not alter their migration 
and phagocytosis abilities, nor their ability to secrete effector cytokines like TNFα, IL-6, or IL-1β 
[80]. Instead, metabolic assessment revealed that glucose deprived monocytes shifted their 
metabolism towards OXPHOS fueled in large part by FAO [80]. Although CD4+ T cells were 
unable to metabolically transition to a different energy source upon PFK15 treatment, metabolic 
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plasticity of APCs allows them to utilize alternative fuel sources to maintain important effector 
functions. It would be interesting to know whether similarly to the study by Raulien et al., if PFK15 
treated APCs stimulated with LPS are able to metabolically revert back to OXPHOS to generate 
ATP for effector capabilities. Lastly, the NOD mouse and human patients with T1D suffer from 
severe maturation defects in their APCs, likely due to associated MHC-II haplotypes (I-Ag7 in the 
NOD mouse, or HLA class II alleles DR4, DQ8, and DQ2, which confer the highest genetic risk 
of T1D in human patients) [124, 197-200, 204]. As maturation of APC responses relies on the 
metabolic transition to glycolysis upon activation, its likely macrophages and DCs in mouse model 
and humans with T1D may have metabolic defects that correlate with their dysfunctionality. 
Further studies fully characterizing the metabolic profile of APCs in the NOD mouse and human 
patients would be interesting to pursue to have a better understanding of the mechanisms mediating 
immaturity and dysfunction of APCs that may contribute to the pathogenesis of T1D.  
CD8+ T cells typically attract the most attention in the pathogenesis of T1D, as they are able 
to directly cause β cell death through their cytolytic capabilities [45]. However, their ability to 
target pancreatic β cells relies on CD4+ T cell help, as secretion of IFNγ by autoreactive CD4+ T 
cells aids in the activation and maturation of CTL responses [45, 121, 155, 189]. Further, in mouse 
models of autoimmune diabetes CD4+ T cells are able to cause diabetes on their own, while 
adoptive transfer of CD8+ T cells alone fail to cause diabetes when transferred into 
immunodeficient recipients, with the exception of the A14 CD8+ T cell clone [205].  Studies in 
T1D have demonstrated that CD8+ T cells require glycolysis for their cytolytic activity, and are 
susceptible to regulation by 2-DG [151, 206]. Therefore, it’s likely that PFK15 too would have 
similar effects on the activation and effector functions of diabetogenic CD8+ T cells. However, 
even if PFK15 did not directly affect CD8+ T cell function, we would hypothesize that PFK15 
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induced exhaustion of CD4+ T cells would have downstream consequences on CD8+ T cells, as 
they would not be as able to provide help to efficiently activate CTL responses. We are currently 
in the process of acquiring the diabetogenic A14 CD8+ T cell clone to perform in vitro studies 
testing the ability of PFK15 treatment to induce exhaustion in the CD8+ T cell compartment 
similarly to CD4+ T cells.  
Ultimately, while the isolation and characterization of the metabolic profiles of specific 
immune cell subsets would be interesting, these studies are unrealistic. T1D is a result of the innate 
and adaptive immune systems working cooperatively to mediate β cell death. Therefore, studies 
taking this into account would provide the most beneficial results with translational potential. To 
do this, we propose performing prevention studies in female NOD mice. Prior to the onset of 
diabetes, NOD mice would be treated with PFK15 to determine the impact glycolysis inhibition 
has on the pathogenesis of T1D over the natural course of disease. Then, we could look at the 
phenotypes of CD4+ and CD8+ T cells, as well as APCs both in the periphery and within the 
pancreatic islets to characterize changes in islet infiltration. Differences in the kinetics of disease 
onset in NOD mice may be difficulty in assessing the best time to initiate treatment. In those 
instances, synchronization with cyclophosphamide or checkpoint blockade, as has been previously 
reported, could be used to circumvent this [30].  
5.1.3 Resisting Tolerance: Linking metabolism, checkpoint molecules, and TCR signal 
strength to autoreactive T cell persistence 
As discussed in great detail in chapter 3, treatment of CD4+ T cells with PFK15 in vitro and in vivo 
induced the expression of the checkpoint molecules PD-1 and LAG-3 and led to downstream 
functional and metabolic exhaustion. While T cell exhaustion is associated with negative 
consequences in the immune response to cancer, this phenotype is protective in settings of 
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autoimmunity. This is especially true in T1D, as T cells from human patients display a reduced 
ability to upregulate PD-1 compared to T cells from healthy subjects [134], suggesting an inability 
to be regulated by IR signaling in the periphery due to reduced expression of checkpoint molecules. 
Interestingly in the NOD mouse, expression of PD-1 on CD4+ T cells has been implicated in 
suppressing islet infiltration during autoimmune diabetes, indicating a protective role for PD-1 in 
mediating protection of β cells [135].  Further, polymorphisms in the PD-1 have been identified in 
T1D patients, and are associated with susceptibility to disease [185]. However, IR expression alone 
is not sufficient to induce T cell exhaustion, as activated T cells upregulate both PD-1 and LAG-3 
upon activation and TCR signaling. In fact, exhaustion can occur even in the absence of checkpoint 
molecules, further questioning the exact role these molecules play in enforcing or maintaining 
functional exhaustion [177].  
While IRs may play a lesser role in driving exhaustion in cancer, they appear to be pivotal in 
restoring tolerance against autoimmune responses. For example, in the absence of PD-1 or LAG-
3, and during PD-1 or LAG-3 blockade, NOD mice demonstrate accelerated diabetes [30, 32, 131]. 
In contrast, PD-1 or LAG-3 deletion in non- autoimmune prone mouse strains results in minor 
phenotypes without spontaneous disease development [155]. This divergence in the phenotypes of 
PD-1 and LAG-3 KO animals on the C57BL/6 versus NOD backgrounds could come down to 
faulty antigen presentation by APCs in T1D. Piganelli et al. demonstrated that splenic 
macrophages in the NOD mouse are defective in their ability to present antigen, leading to less-
than-optimal T cell activation [124]. This reduced strength of signal during autoreactive T cell 
activation, while enough to promote differentiation to effector subsets, may be insufficient to 
upregulate IRs, leading to uncontrolled and persistent pathogenic responses to self-antigen. 
Finally, decreased TCR:MHC signal strength may explain why autoreactive T cells escape deletion 
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in the thymus, as binding affinity to self- peptides controls what T cell clones are positively 
selected for or deleted.   
Reduced TCR signal strength could also explain why Tregs fail to control diabetogenic effector 
T cell subsets during T1D, as strong TCR signals are required for selection of self- reactive Tregs 
in the thymus [207]. Regarding the role of signal strength and Treg suppressive function, 
stimulation of Tregs by peptide- MHC complexes determines strength of Treg mediated 
suppression capabilities [208]. Therefore, weak engagement of self- reactive Tregs with peptide- 
MHC complexes may permanently imprint reduced suppressive capabilities, rendering them 
unable to control effector T cells in the periphery.  
Tregs utilize a number of methods to suppress conventional T cells, including cell contact 
dependent or independent mechanisms. One cell contact dependent mechanism of Treg 
suppression is the expression of immune inhibitory receptors and their ligands by Tregs, with 
evidence supporting a critical role of IRs in mediating Treg function [209]. Specifically, the PD-
1/PD-L1 axis is vital to both Treg development and function [209]. Francisco et al. reported that 
PD-L1 signaling can induce FoxP3 expression and enhance their immunosuppressive function 
[210]. PD-L1 signaling was also capable of converting naïve Th1 T cells into Tregs via 
downregulation of the AKT and mTOR pathways [210, 211]. Importantly, reduced expression of 
IRs would be detrimental, as an inability for IRs to engage their ligands could lead to a breakdown 
in self- tolerance. Similarly to as has been described in conventional T cells in T1D where IR 
expression is dysregulated [134], Tregs from T1D patients are defective in their ability to 
upregulate PD-1 as well [212, 213]. Cumulatively, these data provide evidence that defective IR 
expression affects the ability of effector T cells to be suppressed, and also leads to dysfunctional 
Treg suppressive function, therefore contributing to the ability of autoreactive T cells to become 
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activated and mediate T1D pathogenesis. Garnering a better understanding of the mechanisms 
leading to IR defects associated with T1D will allow for targeted therapeutic approaches.  
The expression, or lack thereof, of IRs on T cells ultimately have the ability to influence 
metabolism. Especially given the role bioenergetics and IRs have in modulating T cell function. 
IRs themselves can control T cell metabolic programs. For example, PD-1 has been implicated in 
suppressing glycolysis and promoting lipolysis and FAO, thereby maintaining tolerance and 
inhibiting effector T cell differentiation [83, 109]. LAG-3 has also been implicated in controlling 
T cell metabolic programs, and has been a major focus within out laboratory. Previte et al. 
demonstrated that LAG-3 deficiency enhanced the metabolic profile of CD4+ T cells, characterized 
by increased aerobic glycolysis and effector functions following activation [110]. Although a 
characterization of LAG-3 expression has not been performed in T1D patients to, we would 
hypothesize that dysfunctional IR expression encompasses LAG-3 as well, especially due to the 
synergistic nature of PD-1 and LAG-3, as well as the redundant nature that exists amongst IRs 
[110]. Based on this assumption, we would expect that autoreactive T cells would have metabolic 
profiles similar to LAG-3-/- T cells, characterized by increased glycolysis and oxidative 
metabolisms. Further work is required to understand the role LAG-3 plays in the pathogenesis of 
T1D. 
Regarding Tregs, who primarily utilize FAO and OXPHOS via the mitochondria, reduced 
expression of IRs in setting of autoimmunity may promote Tregs to commit to a glycolytic 
program. Although Tregs do utilize glycolysis to fuel their proliferation, with some evidence 
supporting use of this pathway by human Tregs as well [67, 74], increased glycolysis may allow 
Tregs to adopt a proinflammatory phenotype that has been documented in T1D patients, where 
Tregs lose their suppressive capabilities and begin to secrete IFNγ [9, 10].  
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In sum, a plethora of defects affecting patients with T1D ultimately lead to the escape and 
activation of self- reactive T cells that mediate attack of β cells. These defects, including aberrant 
T cell activation and excessive effector cytokine production, Treg dysfunction, and reduced IR 
expression, likely contribute to metabolic abnormalities that deserve and require further 
exploration [15]. The work presented here, however, demonstrates an ability to modulate the 
glycolysis pathway as a means to induce T cell exhaustion, a protective phenotype with the ability 
to prevent or significantly delay the onset of autoimmunity in T1D. Our work demonstrates a novel 
ability to correct a number of defects associated with autoreactive T cells in T1D, and should be 
expanded to interrogate how metabolic modulation impacts all mediators involved in the 
pathogenesis of autoimmune diabetes.  
5.2 THERAPEUTIC OPPORTUNITIES FOR MODULATING IMMUNE CELL 
METABOLISM IN TYPE 1 DIABETES 
Insulin replacement has been the front- line therapy for type 1 diabetics since the early 1920’s, 
with a number of adverse complications associated with its long- term use [34]. Although the 
administration of exogenous insulin is vital to the health and wellness of T1D patients, it acts as 
somewhat of a band aid, covering up the problem rather than managing the underlying problem: 
self- reactivity. A number of immune mechanisms and pathways have been targeted in T1D [214], 
however a large portion of these studies have been performed in patients with new- onset or 
established T1D. As only 10-20% of β cell mass remains at the time of diagnosis, 
immunomodulatory therapies would be better suited if they could be administered to patients prior 
to the onset of clinical disease. As discussed in chapter 3, predicting patients most at risk for 
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progressing to T1D is possible, as the presence of 2 or more autoantibodies predicts a lifetime risk 
of almost 100% [187]. Proof of principle of this concept is highlighted by the Teplizumab 
prevention study, where use of an anti- CD3 antibody delayed T1D onset by 2 years, and was 
associated with partial exhaustion of CD8+ T cells in responding patients [146, 215]. Importantly, 
while prevention could be possible, determining the time of intervention can be difficult, as it can 
be challenging to pinpoint exactly when autoreactive T cells are activated. On the other hand, 
reversal strategies for T1D, including islet transplantation and gene therapy approaches to restore 
endogenous β cell mass have been tested as well. However again, these therapies while beneficial 
initially ultimately fail due to a reoccurrence of autoimmunity [143]. These studies beg the 
question, when should metabolic inhibitors like PFK15 be administered in a clinical setting? 
While prevention may be the ideal way of handling autoimmunity in T1D, it’s certainly not 
the easiest to determine the exact kinetics of a patient’s path to T1D onset. Even the presence of 
autoantibodies, while effective at determining lifetime risk of disease development does not 
provide a specific timeframe for disease onset to occur. One benefit to targeting the glycolysis 
pathway that is largely lacking from other immunotherapies, including Teplizumab, is lack of 
specificity. Although PFK15 is not specific for autoreactive T cell populations itself, it’s inherently 
specific for activated T cells, due to their reliance on glycolysis to fuel effector functions, and 
theoretically would not have an effect on other immune cells such as Tregs or established memory 
T cells. This specificity would allow for specific targeting of effector T cells, as long as treatment 
was administered at a time when these cells were activated. Second, there have been reports 
indicating that metabolic inhibitors display cellular selectivity based on demand, with only the 
most activated cells being susceptible to modulation, and therefore leaving less metabolically 
active cells unscathed [17, 29, 154, 155, 168]. Further, although there’s a possibility that an 
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individual experiencing autoimmunity could also be fighting off an infection and have active 
immune responses against multiple targets, there is evidence to support that autoreactive T cells 
are more metabolically active than non- autoreactive counterparts. This has been demonstrated in 
one study, where lupus prone mice receiving metabolic modulators were still capable of mounting 
a response to nominal antigen immunization., suggesting global immunity remained intact during 
this type of treatment [84]. Although our studies did not test the ability of PFK15 treated animals 
to respond to foreign antigen immunization, there is precedence in the literature that metabolic 
inhibitors could have a therapeutic benefit without global immune consequences, and therefore 
deserve further exploration. While we have demonstrated prevention is possible in mouse models 
of autoimmune diabetes with PFK15, we would need to ensure an active immune response was 
occurring for these types of therapies to be initiated in a clinical setting. Testing for autoantibodies 
is a start, as their presence is heavily suggestive of an ongoing immune response, however it would 
also be helpful to phenotype T cells from patients at risk to determine their activation status. 
Further assessment of biomarkers for at risk patients would greatly advance the ability to predict 
T1D onset, and provide better therapeutic windows for modulation of the glycolysis pathway to 
obtain beneficial outcomes.    
Use of PFK15 in conjunction with therapeutic approaches to reverse disease and restore β cell 
mass could be even more promising, and would likely benefit a larger percentage of patients. One 
study by Xiao et al. demonstrated an ability for an AAV viral vector gene therapy approach to 
reprogram α cells within pancreatic islets into functional, insulin secreting β cells, capable of 
restoring euglycemia in diabetic animals durably for 4 months [143]. This delay in the 
reoccurrence of autoimmunity and diabetes onset was significant, however again, this type of 
therapy failed to cure self- reactivity. However, this could be a setting where PFK15 would be 
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beneficial as a combinatorial approach to 1) restore β cell mass endogenously in the patient and 2) 
induce exhaustion of autoreactive T cells that will eventually target the neogenic β cells. We are 
currently in collaboration with Dr. Xiangwei Xiao of Dr. George Gittes’s group here at the 
University of Pittsburgh to determine the ability of PFK15 to maintain protection of these neogenic 
β cells by inducing exhaustion of autoreactive T cells that ultimately target them without further 
intervention. These studies are ongoing and are a future direction of the concepts and ideas 
demonstrated here. Ultimately, we believe modulating T cell metabolism is a viable therapeutic 
opportunity for the clinical prevention or reversal of T1D, and deserves further exploration in both 
aspects with the goal of finding a cure for those affected. Especially given the terminal exhaustion 
phenotype we observed when treating diabetogenic T cells, as this suggests only a short- term 
treatment would be required to provide lasting tolerance to β cells.  
5.2.1 Optimization of Controlled Release Microparticle Systems for Delivery of Metabolic 
Modulators in conjunction with Antigen- Specific approaches 
In chapter 2, we explored use of PLGA microparticles encapsulated with PFK15 to specifically 
target autoreactive T cells by administering them in close proximity to the pancreas. While PFK15 
MPs were able to inhibit T cell responses to ConA stimulation in vitro similarly to soluble drug, 
we did not observe a statistically significant delay in diabetes onset in adoptive transfer prevention 
studies. One future direction for this project would be to further optimize the dose and delivery 
kinetics required to obtain therapeutically beneficial results, as we had observed with systemic 
PFK15 treatment. It is possible that a high systemic dose of PFK15 treatment is required for the 
induction of T cell exhaustion that correlated with disease prevention in our studies, therefore it 
may not be possible to efficiently deliver an equivalent dose locally to obtain the desired outcome. 
In one study (data not shown), we treated recipient animals in adoptive transfer studies with 12.5 
153 
mg/kg and 25 mg/kg of PFK15. Animals receiving the lower dose all succumbed to diabetes, with 
the higher 25 mg/kg required for therapeutic benefit, suggesting that optimally deriving 
microparticles able to deliver a lower therapeutic amount locally could be difficult to achieve. 
Further, delivery near the pancreas is challenging. Although the pancreas is in close proximity to 
the spleen, exact delivery at the site is difficult and requires further optimization. Further, delivery 
near the pancreatic draining lymph node would be more beneficial, however its lack of 
accessibility for subcutaneous delivery of MPs would be another hurdle to overcome.  
An alternative approach to use of PFK15 MPs alone would be to utilize them in conjunction 
with antigen- specific approaches. One idea being pursued to expand this project currently is the 
generation of multiple antigenic peptides, or MAPs [216]. MAPs are peptides that are branched 
artificially to a lysine backbone able to support up to 8 different peptide branches. These systems 
can be used to present antigens to the immune system, and are immunogenic [216]. This approach 
would allow for the presentation of multiple autoantigens, that could be used to attract autoreactive 
T cells responding to a panel of antigenic peptides. These MAPs could then be encapsulated into 
MPs to allow for local delivery, and could act as “bait” to attract autoreactive T cells to the site 
administered. At the same time, PFK15 MPs could be administered at the sight, released in the 
local area, and therefore specifically target the autoreactive T cells responding to the antigenic 
peptides presented on the MAPs. Often, antigen specific solutions do not take into account the 
breadth of the autoreactive T cell repertoire and focus on one of multiple known autoantigens, with 
insulin being an ideal candidate in T1D. However, autoreactive T cells respond to a number of 
different β cell specific proteins, not just insulin, therefore highlighting the need to provide 
solutions to target a broader range of autoreactive T cell clones. Ultimately, we know that PFK15 
is capable of suppressing T cell responses when delivered systemically in vivo. However, we 
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believe that optimization of controlled release systems to better modulate T cell responses locally 
without potential toxic effects could be beneficial when translating these therapies into the clinic. 
We plan to continue our collaboration with Dr. Abhinav Acharya and Dr. Steven Little to continue 
our investigation to optimize our drug delivery systems with the ultimate goal of delivering PFK15 
therapeutically without global consequences.  
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6.0 SIGNIFICANCE TO PUBLIC HEALTH 
A portion of this section was adapted from the author’s version of a review paper. The definitive 
version of this work was published in Immunometabolism. 
 
“Targeting T cell Metabolism to Combat Autoimmunity: Implications for the Future of 




Christina P. Martins1 and Jon D. Piganelli 1,* 
 
1 Department of Surgery, Children’s Hospital of Pittsburgh, University of Pittsburgh Medical 












In 2020, diabetes was the 8th leading cause of death in the United States, with a health care cost 
estimated to be approximately $327 billion USD [217]. While a majority of diabetes cases are 
related to Type 2 Diabetes (T2D), T1D patients make up approximately 10% of total cases. 
Regarding T1D specifically, 1.25 million Americans are living with T1D, including 200,000 youth 
and over a million adults [217]. If current trends continue, 5 million people in the U.S. are expected 
to have T1D by 2050, including 600,000 people under the age of 20 years old [217]. Since the 
1920’s, patients with T1D have been treated by the daily administration of exogenous insulin in 
order to maintain euglycemia; however, insulin is not a cure for these individuals [40, 51]. 
Complications still arise from exogenous insulin use, as a number of patients experience low blood 
sugar unawareness and increased susceptibility to infections, further impacting their day-to-day 
activities [33-35, 217]. As a result, less than one-third of people with T1D are achieving target 
blood glucose levels. Furthermore, while the life expectancy of patients with T1D continues to 
improve, it remains reduced by approximately 20 years compared to the general population [33-
35, 217]. For these reasons, new and innovative preventative measures are needed to combat T1D.  
As is the case in several autoimmune diseases, the activation of autoreactive CD4+ T cells that 
escape central tolerance and bypass tolerogenic mechanisms in the periphery drive T1D 
pathogenesis [40, 51]. Therefore, understanding the mechanisms governing T cell activation and 
aberrant immune- mediated responses are vital for finding druggable therapeutic targets for disease 
prevention or treatment. An emerging concept in immunology is that metabolic reprogramming 
and lymphocyte activation are intricately linked, as both T cell fate and function are dependent on 
cellular metabolism [54, 56, 58-62, 64, 66]. Consequently, cellular metabolism has the ability to 
influence the final outcome of the innate and adaptive immune responses, further impacting health 
and disease outcome [54]. Studies interrogating T cell activation and function in animal models 
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and human patients with T1D have indicated autoreactive T cells may have a heightened activation 
status [55, 81, 82]. This altered status, along with functionally defective Tregs, leads to T cell 
activation, enhanced effector capabilities, and excessive proinflammatory cytokine secretion, 
especially interferon- (IFN). 
In the studies presented here, we took advantage of the metabolic changes that occur over the 
course of the T cell lifecycle, and selectively targeted the glycolysis pathway as a means to 
suppress the activation and effector function of autoreactive CD4+ T cells in preclinical models of 
T1D. Not only did treatment with the glycolysis inhibitor PFK15 significantly delay the onset of 
autoimmune diabetes in adoptive transfer models, but inhibition of glycolysis led to the induction 
of terminal exhaustion of diabetogenic T cell clones characterized by increased expression PD-1 
and LAG-3. This phenotype was permanent, as treatment with checkpoint blockade 
immunotherapy failed to reverse T cell exhaustion phenotypes in vitro and in vivo, indicating 
formation of durable tolerance.  
While T cell exhaustion is detrimental in cancer and chronic infection, as this phenotype leads 
to an inability to efficiently clear tumors or pathogens, induction of T cell exhaustion in settings 
of autoimmunity has protective benefits and thus safe host tissues from autoimmune targeting [15, 
155]. Exhausted T cell subsets not only have functional defects, but also suffer from metabolic 
insufficiency and a reduced capacity to generate ATP. We too observed this phenotype in PFK15 
induced exhausted T cells. Metabolic dysfunction has been implicated in the formation of 
terminally exhausted cells, which are refractory to reinvigoration by restimulation or checkpoint 
blockade [15, 155]. This has broad implications in chronic infection and cancer, as restoring 
metabolic sufficiency to exhausted T cell subsets is vital to reinvigorating exhausted T cell 
responses. Ultimately, the link we have established between immunometabolism and T cell 
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exhaustion are vastly applicable to a number of areas including autoimmunity, cancer 
immunology, and chronic infection. Lastly, the lessons learned here offer valuable insight into 
both the promotion and reversal of T cell hyporesponsiveness, with the glycolysis pathway at the 
center of proper T cell function.  
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Appendix A Supplementary Data for “Glycolysis Inhibition induces Functional and 




Figure 26. Specific targeting of PFKFB3, not glycolysis inhibition alone, reduces BDC2.5 T cell effector functions in vitro. 
Comparing the impact of glycolysis inhibition with 2-DG or PFKFB3 inhibition (via administration of YN1 or PFK158) on diabetogenic CD4+ T cell 
responses in vitro. NOD.BDC2.5 splenocytes were stimulated with their cognate peptide MM ± 200 M, 500 M, and 1 mM 2-DG; 25-50 M YN1, or 
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2.5-5 M PFK158 for 24-72 hrs. A-C. Lactate measurements in 24- 72 hr cell culture supernatants from 2-DG (A), YN1 (B), and PFK158 (C) treated 
cultures. D-F. ELISA analysis of IL-2 in 2-DG (D), YN1 (E), and PFK158 (F) treated T cell culture supernatants 24-72 hrs post stimulation. G-I. ELISA 
analysis of TNF in 2-DG (G), YN1 (H), and PFK158 (I) treated T cell culture supernatants 24-72 hrs post stimulation. J-L. ELISA analysis of IFN in 
2-DG (J), YN1 (K), and PFK158 (L) treated T cell culture supernatants 24-72 hrs post stimulation. All data are presented as the mean ± SEM. (n = 3-5; * 












Figure 27. ex vivo activated BDC2.5 T cells produce proinflammatory cytokines TNF and IFN  prior to adoptive transfer. 
Confirming the effector phenotype of ex vivo activated BDC2.5 T cells prior to adoptive transfer studies. Isolated CD4+ T cells from the spleens of 
NOD.BDC2.5.TCR.Tg animals were activated and expanded ex vivo with plate- bound ɑCD3/ɑCD28 and EL-4 supernatant as a source of IL-2. A. Schematic 
diagram of experimental design and timepoints for analysis. Cells in media alone served as controls. B. ELISA analysis of TNF in BDC2.5 T cell culture 
supernatants 3 days post stimulation. C. ELISA analysis of IFN in BDC2.5 T cell culture supernatants 3 days post stimulation. All data are presented as the mean 
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